Annual Report 2006 - Boehringer Ingelheim
Annual Report 2006 - Boehringer Ingelheim
Annual Report 2006 - Boehringer Ingelheim
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Value through Innovation<br />
<strong>Annual</strong> <strong>Report</strong> <strong>2006</strong><br />
nopq
Financial Highlights<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> group of companies<br />
Amounts in millions of EUR, unless otherwise indicated <strong>2006</strong> 2005 change<br />
Net sales 10,574 9,535 11 %<br />
by region<br />
Europe 31 % 33 %<br />
Americas 51 % 48 %<br />
Asia, Australasia, Africa 18 % 19 %<br />
by business area<br />
Human Pharmaceuticals 96 % 96 %<br />
Animal Health 4 % 4 %<br />
Research and development 1,574 1,360 16 %<br />
Personnel costs 2,836 2,671 6 %<br />
Average number of employees 38,428 37,406 3 %<br />
Operating income 2,140 1,923 11 %<br />
Operating income as % of sales 20.2 % 20.2 %<br />
Income after taxes 1,729 1,514 14 %<br />
Income after taxes as % of sales 16.4 % 15.9 %<br />
Shareholders’ equity 5,175 4,609 12 %<br />
Return on shareholders’ equity 37.4 % 34.2 %<br />
Cash flow 2,317 2,069 12 %<br />
Investments in tangible assets 596 532 12 %<br />
Depreciation of tangible assets 419 439 -5 %<br />
Top 5 products — Prescription Medicines<br />
Net sales <strong>2006</strong> in millions of EUR change<br />
spiriva® 1,381 45.2 %<br />
micardis® 967 33.6 %<br />
flomax® 922 27.8 %<br />
combivent® 671 19.6 %<br />
mobic® 579 -31.8 %<br />
Top 5 products — Consumer Health Care<br />
Net sales <strong>2006</strong> in millions of EUR change<br />
dulcolax® 122.0 6.2 %<br />
mucosolvan® 108.3 18.6 %<br />
pharmaton® 95.6 8.2 %<br />
buscopan® 71.2 19.6 %<br />
bisolvon® 67.1 0.4 %
Contents<br />
1 Value Through Innovation<br />
2 The Shareholders’ Perspective<br />
4 Key Aspects of <strong>2006</strong><br />
9 Our Caring Culture<br />
10 “There is help”<br />
14 Our People<br />
18 Caring for our Neighbours<br />
22 Our Environment & Employee Safety<br />
27 Our R & D Drive<br />
28 Targeting tomorrow’s therapies<br />
32 Our R & D Strategy<br />
38 Our Expertise in Landmark Studies<br />
40 From Mind to Man – The R & D Process<br />
42 New Biological Entities (NBE)<br />
43 Biomarker & Pharmacogenetics<br />
45 Serving Patients *<br />
46 “I wake up refreshed ...”<br />
49 Human Pharmaceuticals<br />
60 “My recovery came fast”<br />
78 “Now I know how to keep them under control”<br />
80 From Plant to the Pharmacy – The buscopan® Story<br />
81 Consumer Health Care<br />
84 Our friend Tom<br />
87 Animal Health<br />
91 Our Customer Orientation<br />
92 Biopharmaceuticals – How Innovations are Made<br />
95 Pharmaceuticals Production and Pharma Chemicals<br />
97 Counterfeits – A Real Threat for Patients<br />
99 Group Management <strong>Report</strong><br />
115 Consolidated Financial Statements <strong>2006</strong><br />
116 Overview of the Major Consolidated Companies<br />
118 Consolidated Balance Sheet<br />
119 Consolidated Profit and Loss Statement<br />
120 Cash Flow Statement<br />
121 Statement of Changes in Group Equity<br />
122 Notes to the Consolidated Financial Statements <strong>2006</strong><br />
140 Auditor’s <strong>Report</strong><br />
142 Glossary<br />
Flap Comparison of Balance Sheet / Financial Data 1997–<strong>2006</strong><br />
Our friend Tom<br />
Every year, about 10 % of<br />
all horses suffer from<br />
equine colic, a disease that<br />
can prove life-threatening.<br />
[page 84]<br />
“Now I know<br />
how to keep<br />
them under<br />
control”<br />
Abdominal pains and cramps,<br />
a widespread ailment, is<br />
more common in women<br />
than in men and can affect<br />
people still in their teens.<br />
[page 78]<br />
* The patient reports are authentic reports which refer to personal<br />
experience only. Please acknowledge that other patients may experience<br />
different treatment results. Individual treatment schemes have always to<br />
be discussed between patient and physician case by case.<br />
“There is help“<br />
In Kenya, about 50,000 newborn babies a year are<br />
estimated to acquire HIV from their infected mothers.<br />
Worldwide UNAIDS talks of 2.3 million cases of<br />
AIDS-diseased children. [page 10]<br />
Targeting tomorrow’s<br />
therapies<br />
Focusing on both biopharmaceutical and<br />
small molecule drugs, <strong>Boehringer</strong> <strong>Ingelheim</strong><br />
has embarked on a major drive to discover<br />
and develop new cancer drugs. [page 28]<br />
“My recovery<br />
came fast”<br />
Stroke is a serious disease.<br />
It is the third leading cause<br />
of death after heart disease<br />
and cancer and the most<br />
important reason for<br />
medical disability. [page 60]<br />
“I wake up<br />
refreshed ...”<br />
Hypertension is not only an<br />
unpleasant condition that<br />
keeps people from doing<br />
what the things they like.<br />
It is also a serious cardiovascular<br />
risk that can be<br />
the precursor to stroke and<br />
heart attack. [page 46]<br />
please turn over
Value through Innovation<br />
Our vision drives us forward. It helps us to<br />
foster value creation through innovation<br />
throughout our company and to look to the<br />
future with constantly renewed commitment<br />
and ambition.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> is a research-driven group of companies<br />
dedicated to researching, developing, manufacturing and marketing<br />
pharmaceuticals that improve health and quality of life.<br />
Our business consists largely of Prescription Medicines, Consumer<br />
Health Care, Biopharmaceuticals and Animal Health. We focus on the<br />
production of innovative drugs and treatments that represent major<br />
therapeutic advances.<br />
Excellence in innovation and technology guides our actions in all<br />
areas. Our products have long been highly successful in the treatment<br />
of respiratory, cardiovascular, central nervous system, urological and<br />
virological disorders. In addition we have intensified our research<br />
into the immune system, metabolic diseases and oncology.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>, which currently has more than 38,400<br />
employees, has 137 affiliated companies spread around the globe.<br />
We have research and development facilities in ten countries and<br />
production plants in more than 20.<br />
Our Human Pharmaceuticals research and development in our<br />
Prescription Medicine spending corresponds to about 18 % of net<br />
sales in this business.<br />
Our headquarters is at <strong>Ingelheim</strong>, the German town where the<br />
company was founded in 1885.
The Shareholders’ Perspective<br />
Dear Reader,<br />
Family-owned companies such as <strong>Boehringer</strong><br />
<strong>Ingelheim</strong> are attracting considerable interest<br />
these days. As their strategy and investments are<br />
often directed towards ensuring the continuation<br />
of the company in the long term, family-owned<br />
companies have often proved to be particularly<br />
stable and crisis-resistant, especially in the<br />
volatile market conditions of recent years.<br />
The success of value-based family-owned companies<br />
is also confirmed by various surveys and<br />
indices comparing family-owned companies<br />
with listed ones. It is borne out by our own<br />
success as well. <strong>Boehringer</strong> <strong>Ingelheim</strong>’s sales<br />
growth this past financial year exceeded the<br />
market average for the seventh year in a row,<br />
allowing us to improve our world market share<br />
yet again. Benchmarking operating margins<br />
also show <strong>Boehringer</strong> <strong>Ingelheim</strong> to be well<br />
positioned. That our commercial success has<br />
also allowed the corporation to take on more<br />
employees is particularly gratifying. Over<br />
the past ten years, <strong>Boehringer</strong> <strong>Ingelheim</strong> has<br />
increased its personnel capacity by 5 % per<br />
annum on average.<br />
We are a research-driven pharmaceutical com-<br />
pany. The guiding principles in our Leitbild give<br />
top priority to the development of innovative<br />
medicines for the benefit of patients worldwide.<br />
The same applies to our endeavours in animal<br />
health as well. Innovation and the quality of our<br />
products drive our success and materialise many<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
years of research and development. The development<br />
of innovative substances with an efficacy<br />
superior to those already available will be crucial<br />
to our success in the future.<br />
The market demands that productivity be<br />
constantly raised throughout the value chain.<br />
Our employees are the driving force behind<br />
the innovations required at any one stage of our<br />
complex processes. We rely on their integrity<br />
and commitment. It is also important for us<br />
to remain an employer of choice for our own<br />
employees and for people outside the company.<br />
That <strong>Boehringer</strong> <strong>Ingelheim</strong>, as numerous<br />
external comparisons have shown, is one of<br />
the most interesting and desirable employers<br />
in many countries is a source of great pride.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> certainly has the corporate<br />
culture, the size and the structure to enable us<br />
to identify with a common strategy and to help<br />
shape it, too. Such an environment is essential<br />
to innovation and excellence. We believe that<br />
our corporate culture, with its focus on how we<br />
work together in a ‘great team’, is a significant<br />
prerequisite for motivating our employees<br />
to achieve still more innovative solutions for<br />
patients, progress and economic success.<br />
The year <strong>2006</strong> was again one of market consoli-<br />
dation in the pharmaceutical industry. And this<br />
trend with mergers and acquisitions is most<br />
likely to continue. The main reason for this is a<br />
very simple one: lack of productivity in R&D.
<strong>Boehringer</strong> <strong>Ingelheim</strong>’s shareholders have set the<br />
course for the future in such a way that we can<br />
continue to build on the successful development<br />
of recent years as an independent company. This<br />
applies not only to the corporate strategy decided<br />
jointly with the Board of Managing Directors,<br />
but also to the make-up of both the Board and<br />
the Shareholders’ Committee. After 32 years of<br />
highly successful commitment to <strong>Boehringer</strong><br />
<strong>Ingelheim</strong>, as Chairman of the Board of<br />
Managing Directors, and since 2001 as Chairman<br />
of the Shareholders’ Committee too, Dr Heribert<br />
Johann took well deserved retirement as of<br />
31 December <strong>2006</strong>. Dr Johann played a key role<br />
in shaping our company’s strategic development<br />
over the past 15 years and we are profoundly<br />
grateful to him for his unflagging commitment<br />
to <strong>Boehringer</strong> <strong>Ingelheim</strong>.<br />
The commitment of the owner-family to<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>, meanwhile, has been<br />
further strengthened by two important decisions<br />
taken in <strong>2006</strong>: the move of family member<br />
Hubertus von Baumbach to the Board of<br />
Managing Directors at the beginning of 2009<br />
and the increased involvement of other family<br />
members in the Shareholders’ Committee,<br />
which is now chaired again by a family member<br />
representing the increased commitment of the<br />
fourth generation of shareholders.<br />
Christian <strong>Boehringer</strong>,<br />
Chairman of the<br />
Shareholders’ Committee<br />
We are confident of the continued motivation<br />
and loyalty of our employees, the expertise and<br />
experience of the Board and constructive commitment<br />
of our Advisory Board in the future. On<br />
behalf of the shareholders of <strong>Boehringer</strong> <strong>Ingelheim</strong>,<br />
allow me to congratulate all those I have<br />
mentioned on the very successful financial year<br />
<strong>2006</strong>. Thank you all for your tremendous efforts.<br />
We look forward to continuing to work closely<br />
with our employees, the Board of Managing<br />
Directors and the Advisory Board for the good<br />
of <strong>Boehringer</strong> <strong>Ingelheim</strong> as a whole. Despite what<br />
is sometimes a difficult economic and political<br />
environment, and some highly competitive<br />
markets, we are confident that we are set to<br />
remain one of the world’s leading pharmaceutical<br />
companies.<br />
Christian <strong>Boehringer</strong><br />
Chairman of the Shareholders’ Committee<br />
The Shareholders’ Perspective
Key Aspects of <strong>2006</strong><br />
<strong>2006</strong> was again a rewarding year for <strong>Boehringer</strong><br />
<strong>Ingelheim</strong>. We grew faster than the market<br />
average for the seventh year in succession.<br />
While the global pharmaceutical markets are<br />
changing and mergers and consolidation efforts<br />
continue, we again maintained our successful<br />
course as an independent and dynamically<br />
growing pharmaceutical company. We are proud<br />
that we once again achieved our overall goal<br />
of helping people by making our medications<br />
available to patients through researching and<br />
developing new and innovative drugs. Our<br />
economic success in recent years mirrors the<br />
value of our medications for patients.<br />
Market analyses by the healthcare information<br />
provider IMS confirm that our +8.4 % growth<br />
rate was appreciably healthier than that of the<br />
pharmaceutical market in general (+6.1 %).<br />
Although our growth curve flattened out as a<br />
result of the generic competition that our antirheumatic<br />
drug mobic® has been facing in the<br />
USA since summer <strong>2006</strong>, we increased our<br />
market share in <strong>2006</strong> worldwide and in the<br />
USA to about 2 %. Overall, we are happy<br />
with our <strong>2006</strong> results.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
Success in serving patients<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> is a pharmaceutical<br />
company that generates almost 80 % of its net<br />
sales with prescription medicines. Yet we do<br />
not measure our success in financial key figures<br />
alone, but also, and of equal importance, in<br />
terms of the acceptance of our products and<br />
programmes. For instance, in conjunction with<br />
our donation programme for the anti-AIDS<br />
product viramune®, we have so far succeeded<br />
in providing medication for almost 1 million<br />
mother-child pairs in around 60 countries for<br />
the prevention of mother-to-child transmission<br />
of HIV. About six million patients benefited from<br />
our product spiriva® for chronic obstructive<br />
pulmonary disease (COPD). The number of<br />
patients using our anti-hypertension medicine<br />
micardis® amounted to more than four million<br />
in <strong>2006</strong>.<br />
Value through Innovation<br />
Naturally, the success of our products is reflected<br />
in our business results. In <strong>2006</strong>, our net sales<br />
across all business areas grew by 11 % to<br />
almost EUR 10.6 billion. We were also pleased<br />
that we were able to increase the number of our<br />
employees by 3 % to 38,428 and so offer more<br />
than 1,000 new and qualified jobs around the<br />
world.
Members of the Board<br />
of Managing Directors:<br />
Dr Hans-Jürgen Leuchs<br />
Dr Andreas Barner<br />
Dr Alessandro Banchi<br />
Prof. Marbod Muff<br />
(from left to right)<br />
The Prescription Medicines business area, which<br />
grew by 15 % to EUR 8.3 billion (compared to<br />
2005) made the greatest contribution to sales<br />
growth. The most important products driving<br />
this growth included our leading product<br />
spiriva®, with sales up 45 % to EUR 1.4 billion,<br />
micardis® which grew by 34 % to EUR 967<br />
million, and flomax®/alna®, for benign<br />
prostatic hyperplasia, which grew by 28 %<br />
to EUR 922 million. In US dollar terms,<br />
micardis® and flomax® thus represent two<br />
more <strong>Boehringer</strong> <strong>Ingelheim</strong> blockbusters<br />
alongside spiriva®.<br />
In <strong>2006</strong>, we were granted marketing authorisation<br />
for sifrol® in the indication restless legs<br />
syndrome (RLS), both in Europe and the USA.<br />
Important and innovative clinical studies (phase<br />
I-IV) continued successfully, involving about<br />
90,000 patients worldwide. These included<br />
the ontarget study (micardis®), uplift®<br />
(spiriva®) and profess® (aggrenox®/<br />
micardis®).<br />
Well-filled pipeline<br />
Our product pipeline has further improved and<br />
is being progressively filled with substances from<br />
our research. We focus on respiratory and cardiovascular<br />
diseases, virology, central nervous<br />
system, immunology, metabolic diseases and<br />
oncology. In this last therapeutic area, for example,<br />
three anti-cancer drug candidates are now<br />
in clinical phase II development. Our projects<br />
are complemented by strategic alliances and the<br />
in-licensing of new compounds and technologies.<br />
Our late-stage pipeline also progressed well in<br />
phase III, and we were able to file the first indications<br />
of our lead anti-thrombotic compound<br />
dabigatran for registration in Europe at the<br />
beginning of 2007.<br />
Investments in research and development in<br />
our prescription medicines increased again<br />
in <strong>2006</strong>, up by 16 % to about EUR 1.5 billion;<br />
this corresponds to around 18 % of sales in<br />
this business area.<br />
Overall, our Consumer Health Care (CHC) busi-<br />
ness showed good development, in spite of an<br />
increase in sales of only 1 % to EUR 1.1 billion.<br />
Key Aspects of <strong>2006</strong>
This growth was clearly restrained by the<br />
weakness of the Japanese market, where we<br />
generate almost 30 % of our CHC business.<br />
Excluding Japan, we achieved strong growth<br />
of about 9 %.<br />
Our international core brands, in particular<br />
dulcolax®, pharmaton® and buscopan®,<br />
showed wholly positive development. As an<br />
outstanding complement to our gastrointestinal<br />
disease business, we successfully acquired<br />
zantac® (for heartburn) for the important US<br />
market. Our CHC business accounted for about<br />
10 % of our total net sales.<br />
Our Biopharmaceuticals business segment,<br />
which embraces contract manufacture and<br />
development for our international customers,<br />
declined by 8 % to EUR 503 million. This development<br />
was expected, despite plant running at<br />
full capacity, as the 2005 business year benefited<br />
from extraordinary effects caused by special<br />
projects that helped boost sales by 40 %.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> is not only strategically<br />
committed to the Human Pharmaceuticals<br />
business but also to Animal Health. Here, sales<br />
in <strong>2006</strong> rose by 4 % to about EUR 374 million,<br />
giving growth above the market average.<br />
Adjusted for extraordinary and currency effects<br />
the Animal Health business grew by 8 %. According<br />
to the market research institute Wood Mac-<br />
Kenzie, <strong>Boehringer</strong> <strong>Ingelheim</strong>, with a market<br />
share of about 3 %, ranks 10th in the international<br />
ranking of animal health companies.<br />
The most important products in this business<br />
area include the anti-inflammatory product<br />
metacam®, vetmedin®, a product for treating<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
chronic heart disease in dogs, as well as the pig<br />
vaccines enterisol® ileitis (against diarrhoea)<br />
and ingelvac® prrs (against porcine reproduc-<br />
tive and respiratory syndrome).<br />
The outlook remains good<br />
The picture seen in recent years has not changed.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>’s growth in <strong>2006</strong> was<br />
excellent across all regions of the world. The<br />
Americas region grew very well in spite of the<br />
sales decrease of mobic® due to generic competition<br />
in the USA, with sales rising by 18 % to<br />
EUR 5.4 billion. But not only the USA (+20 % to<br />
4.5 billion) performed well. Other countries, in<br />
particular Mexico, with its vigorous 27 % growth<br />
(to EUR 300 million), put in an excellent performance,<br />
too. Europe showed a rather gratifying<br />
development, growing by 6 % to EUR 3.3 billion.<br />
France (+19 % to EUR 263 million), the Regional<br />
Center Vienna with its expanding East European<br />
business (+13 % to EUR 362 million) and Spain<br />
(+10 % to EUR 349 million) developed very well.<br />
That Germany, on the other hand, stagnated<br />
in <strong>2006</strong> (+1 % to EUR 822 million) was a result<br />
of the expiry of our patent on alna® on top<br />
of the very difficult pharmapolitical impacts.<br />
In the Asia, Australasia, Africa (AAA) region,<br />
Japan is showing encouraging signs of growth<br />
(currency adjusted +6 % to EUR 1.2 billion).<br />
In Japan, we were for the second year in a row<br />
the fastest growing company among the top 25<br />
in prescription medicines; we would like to pay<br />
a special tribute to our Japanese employees.<br />
Gratifying growth and effective cost manage-<br />
ment led to increased operating income for the<br />
company, as reflected in our results. Operating<br />
income rose by 11 % to over EUR 2.1 billion.<br />
This corresponds to a return on sales of 20.2 %.
The outlook for further business development at<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> remains good. Drugs with<br />
patent protection or exclusivity will continue<br />
to be our main growth drivers. These products<br />
are expected to account for more than 60 % of<br />
net sales in 2007. We also expect to grow in line<br />
with the market in 2007 due to the generic<br />
competition of mobic® in the USA, which will<br />
put pressure on our growth rate for the first<br />
half of the year.<br />
Dr Alessandro Banchi Dr Andreas Barner<br />
Dr Hans-Jürgen Leuchs Prof. Marbod Muff<br />
However, our major products still have high<br />
growth potential. We also hope that 2007 will<br />
see registration granted in Europe for our<br />
new and, for patients, innovative device, the<br />
respimat® Soft Mist Inhaler, for our most<br />
important product spiriva®.<br />
And more importantly, we rely on top-class<br />
worldwide teams of highly committed and skilled<br />
employees. In spite of the increasing health<br />
policy restrictions in many countries, we continue<br />
to look towards the future with optimism.<br />
Key Aspects of <strong>2006</strong>
Shareholders’ Committee<br />
Dr Heribert Johann<br />
(until 31. 12. <strong>2006</strong>)<br />
Chairman of the<br />
Shareholders’ Committee<br />
Christian <strong>Boehringer</strong><br />
(from 1. 1. 2007)<br />
Chairman of the<br />
Shareholders’ Committee<br />
Albert <strong>Boehringer</strong><br />
Christoph <strong>Boehringer</strong><br />
Ferdinand von Baumbach<br />
Hubertus von Baumbach<br />
Dr Mathias <strong>Boehringer</strong><br />
Advisory Board<br />
Prof. Michael Hoffmann-Becking<br />
Attorney at Law, Düsseldorf<br />
Chairman of the Advisory Board<br />
Dr Rolf-E. Breuer<br />
Chairman of the Supervisory Board<br />
Deutsche Bank AG,<br />
Frankfurt (Main)<br />
Prof. Fredmund Malik<br />
Chairman of the Board<br />
Managementzentrum<br />
St. Gallen Holding AG<br />
Prof. Axel Ullrich<br />
(until 30. 6. <strong>2006</strong>)<br />
Director of the Max Planck Institute<br />
for Biochemistry, Martinsried<br />
Dr Heinrich Weiss<br />
Chairman of the Board<br />
SMS AG, Düsseldorf<br />
Board of Managing Directors<br />
Dr Alessandro Banchi<br />
Corporate Board Division<br />
Chairman of the Board<br />
Corporate Board Division<br />
Pharma Marketing and Sales<br />
Dr Andreas Barner<br />
Vice-Chairman of the Board<br />
Corporate Board Division<br />
Pharma Research,<br />
Development and Medicine<br />
Dr Hans-Jürgen Leuchs<br />
Corporate Board Division<br />
Operations<br />
Corporate Board Division<br />
Animal Health<br />
Prof. Marbod Muff<br />
Corporate Board Division<br />
Finance<br />
Corporate Board Division<br />
Human Resources
Our caring culture
“There is help”<br />
“The woman who came to my hospital was pregnant. Her husband accompanied her. And<br />
she had AIDS. When I asked her how she had acquired the disease she just turned to her<br />
husband and glanced at him. He lowered his head and looked at the ground.” Dr Charles<br />
Wanyonyi, Medical Director of Pumwani Maternity Hospital in Nairobi, Kenya, has seen many<br />
patients like this woman. Promiscuity, carelessness, superstition or lack of information and<br />
education contribute to the spread of the deadly disease. Stigma and discrimination also<br />
have a persistent, negative impact in many countries.<br />
In Kenya, about 50,000 newborn babies are estimated to acquire HIV from their infected<br />
mothers every year. Worldwide, UNAIDS talks of 2.3 million cases of AIDS-diseased children.<br />
Most of them will die before they are five years old. Hence the forceful call from former<br />
UN Secretary-General Kofi Annan, a man deeply committed to the struggle against AIDS:<br />
“We must prevent the cruellest, most unjust infections of all – those that pass from mother<br />
to child.”<br />
The infection does not necessarily occur only in the womb during pregnancy. The baby may<br />
also come into contact with the mother’s infected body fluids during labour and delivery.<br />
Finally, they may acquire the virus from their HIV-positive mother’s breastmilk. Without<br />
treatment, around 15–30 % of babies born to HIV-positive women will become infected with<br />
HIV during pregnancy and delivery. A further 5–20 % will become infected through breast<br />
feeding.<br />
There is help. Adelaide Moraa Ayiechad, a midwife from Dr Wanyonyi’s hospital in Kenya,<br />
says: “A baby can be protected from contracting HIV by using nevirapine, so long as the<br />
medication is given in time.” Nevirapine, marketed by <strong>Boehringer</strong> <strong>Ingelheim</strong> worldwide<br />
under the tradename viramune®, has proven to significantly reduce the transmission of the<br />
virus from mother to child. Just one tablet taken by the mother during labour and a dose<br />
of viramune® suspension given to the baby within the first 72 hours after birth can reduce<br />
the rate of transmission by about 50 %, as demonstrated in clinical studies.<br />
Saving hundreds of thousands of lives<br />
In its commitment to expanding access to antiretroviral therapy for developing countries,<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> has since 2000 been giving free access to nevirapine through<br />
the viramune® Donation Programme (VDP). The company currently donates the product<br />
to 156 programmes in 59 countries in Africa, Asia, Latin America and Eastern Europe.<br />
continued on page 12
Examination at Pumwani Maternity Hospital, Nairobi, Kenya,<br />
where HIV-infected women and their babies receive treatment<br />
with nevirapine to prevent mother-to-child transmission of HIV.
1<br />
continued from page 10<br />
A Kenyan mother, having just delivered<br />
twins, undergoes HIV counselling<br />
and testing under the prevention of<br />
mother-to-child transmission<br />
programme at Pumwani Hospital,<br />
Nairobi.<br />
So far, a total of almost one million mother-and-child pair doses have been supplied free of<br />
charge, with the greatest proportion directed to sub-Saharan Africa, epicentre of the AIDS<br />
pandemic. The VDP continues to develop and the numbers still receiving the medication are<br />
rising.<br />
The programme is open to any government, NGO, charitable organisation or other healthcare<br />
providers actively involved in the prevention of mother-to-child transmission (MTCT) based<br />
on local government approval and registration, according to World Health Organization<br />
(WHO) donation guidelines. <strong>Boehringer</strong> <strong>Ingelheim</strong> has contracted Axios International,<br />
a distributor of healthcare supplies in the developing world, to provide technical assistance<br />
to support the implementation of the VDP.<br />
“Provided free of charge by <strong>Boehringer</strong> <strong>Ingelheim</strong>, nevirapine is straightforward to use<br />
and ideally should be part of a full treatment schedule. But if this is not possible, it can also<br />
be used alone. I feel tremendously privileged to have participated in the discovery and<br />
development of a drug that is having the impact that nevirapine is having throughout the<br />
world,” says Professor John L. Sullivan from the University of Massachusetts Medical School,<br />
who has made a decisive contribution to the viramune® clinical trials.<br />
The single-dose nevirapine regimen has won the support of the public health and HIV/AIDS<br />
treatment communities as, in some countries, it may be the only therapy available for<br />
preventing HIV transmission to infants during birth. Although the most recent WHO guidelines<br />
(<strong>2006</strong>) continue to recommend single-dose nevirapine use as a practical option in<br />
resource-limited settings, there is general agreement that whenever possible single-dose<br />
nevirapine should be used in combination with short courses of other antiretroviral drugs<br />
to decrease the development of resistance.<br />
In addition to the VDP programme, <strong>Boehringer</strong> <strong>Ingelheim</strong> has granted in the past years local<br />
and internationally operating manufacturers licenses to produce and sell nevirapine for use<br />
in anti-HIV combination therapy for the sub-Saharan Africa.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> has now expanded its access policy which will make it easier for local<br />
and internationally operating manufacturers to produce and sell nevirapine for treatment<br />
in anti-HIV combination therapy for the whole of Africa and least developed countries,<br />
according to the World Bank and UNDP standard. This new access policy is made available<br />
for all producers of nevirapine containing products pre-qualified by the WHO, irrespective<br />
of local patent issues or place of production.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6
Mothers deliver healthy babies<br />
Interview with Dr Charles Wanyonyi<br />
What is the situation in your area in terms of the HIV infection<br />
rate? The rate of HIV-infected people has gone down from 13 %<br />
in 2003 to at the moment 8 - 9 % of Kenya’s population. This drop<br />
is showing that the rate is now stabilising and is being brought<br />
under control.<br />
How long have you been using nevirapine at your hospital?<br />
We introduced a prevention of mother-to-child transmission<br />
programme in 2003, the aim of which was to inform HIV-<br />
positive expectant mothers about how to protect a baby from<br />
contracting the virus. They are also told of the importance of<br />
using nevirapine and we have been using it since then.<br />
How many mother-child pairs have been treated with<br />
nevirapine so far? Since we started the programme, we have<br />
handled approximately 4,500 cases.<br />
What is your opinion of nevirapine in terms of its efficacy<br />
and safety? Nevirapine is very effective and has helped many<br />
HIV-positive mothers deliver healthy babies. I must say that there<br />
has been a drastic drop of mother-to-child transmission during<br />
delivery. I have seen the drug work in a baby whose blood had<br />
been in contact with the virus during birth and where a dose of<br />
nevirapine had been given, which had then caused the virus to<br />
be wiped out and the antibodies to disappear.<br />
our caring culture<br />
Consultant obstetrician and gynaecologist<br />
Dr Charles Wanyonyi is Medical Director of<br />
Pumwani Maternity Hospital (PMH), the largest<br />
maternity institution in the East and Central Africa<br />
region. Located in Nairobi, the Kenyan capital,<br />
it is the most active site in Kenya for preventing<br />
mother-to-child transmission (PMTCT) of HIV.<br />
Dr Wanyonyi oversees the day to day running of<br />
PMH which provides antenatal, delivery and postnatal<br />
services, midwife training, research activities<br />
and healthcare programmes, such as PMTCT.<br />
VIRAMUNE® Donation Programme<br />
1
1<br />
Our people<br />
In pursuing our vision to create “Value through Innovation”, we build on the<br />
inspiration, expertise and dedication of our more than 38,400 people around<br />
the world. Their striving for continuous innovation and discovery of novel<br />
solutions enable us to maintain our growth, to sustain high-level performance<br />
and prepare for future challenges.<br />
Supported by our Leitbild (guiding principles)<br />
and our long-term strategic direction, we continue<br />
to focus on core issues for enhancing our<br />
people’s capabilities and their passion to pursue<br />
our vision everywhere we operate. A key element<br />
of our sustained success at <strong>Boehringer</strong> <strong>Ingelheim</strong><br />
is the way we work together. Guided by fundamental<br />
questions contained in Lead & Learn,<br />
our common cultural understanding, we are<br />
individually and collectively called on to shape<br />
an environment where creativity, challenge,<br />
team-spirit, respect and fairness flourish. Interdisciplinary<br />
teams throughout our organisations<br />
continue to support this aspiration with unconventional<br />
and inspirational ways of questioning,<br />
sharing and learning from each other.<br />
Preferred employer recognition<br />
The strength of our distinctive working culture<br />
is winning wide acknowledgement from<br />
prestigious, independent workplace surveys (see<br />
page 17). We regard these awards as an affirma-<br />
tion of our success in establishing a demanding<br />
yet highly attractive working environment. The<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
surveys increasingly place us among the most<br />
preferred employers, giving us a competitive<br />
advantage in recruiting and retaining the best<br />
talent. In <strong>2006</strong>, <strong>Boehringer</strong> <strong>Ingelheim</strong> was listed<br />
No. 2 among the top 20 employers of scientists<br />
in a respected survey among researchers in the<br />
USA and Europe (see page 15).<br />
Preparing for the future<br />
To ensure our sustained, positive development, a<br />
number of our organisations devoted substantial<br />
attention in <strong>2006</strong> to capitalising on opportunities<br />
to improve business and operating efficiency<br />
beyond existing continuous improvement.<br />
Hence, processes have been launched in which<br />
our employees have contributed powerful<br />
insights into how we can reinvent ourselves,<br />
create structures and processes for better serving<br />
the marketplace, reducing costs and redundancies,<br />
as well as working more efficiently and<br />
securing breakthroughs.
As many of our country organisations will be<br />
challenged by an increasingly ageing workforce<br />
and shortage of qualified new entrants, we have<br />
set out to emphasise the options available and<br />
the opportunities to be seized in this development.<br />
While measures promoting lifelong learning<br />
for all, diversity management, enabling better<br />
work-life balance, maintaining and enhancing<br />
physical, mental and social well-being are well<br />
anchored and the scope for improvement continuously<br />
scrutinised, we have now embarked on<br />
a course designed to prompt ideas and actions<br />
00 2005 2004 2003 2002<br />
Personnel costs in millions of EUR 2,836 2,671 2,443 2,252 2,175<br />
Personnel costs as % of net sales 26.8 28.0 29.9 30.5 28.7<br />
Number of employees (incl. apprentices) 38,428 37,406 35,529 34,221 31,843<br />
The No. 2 for scientists<br />
Its clear orientation towards values makes <strong>Boehringer</strong><br />
<strong>Ingelheim</strong> a top employer in the pharmaceutical<br />
industry, according to a web-based Science survey<br />
from October <strong>2006</strong>. In particular, it found that the<br />
respectful treatment of employees, their loyalty and<br />
the social orientation of the company rank <strong>Boehringer</strong><br />
<strong>Ingelheim</strong> the second most attractive employer (from<br />
number 8 last year) to scientists in the USA and<br />
Western Europe.<br />
from everyone at <strong>Boehringer</strong> <strong>Ingelheim</strong> that will<br />
benefit all.<br />
A model of our successful adaptation to changing<br />
employment requirements is offered by<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> Germany. With kinder-<br />
gartens on two sites, educational supervision for<br />
schoolchildren during the summer holidays and<br />
interns for employee children, flexible working<br />
times, more than 100 varying part-time working<br />
models and access to elderly care services as well<br />
as emergency caring arrangements, the organi-<br />
Hans-Joachim Geppert, Head of Corporate<br />
Division Human Resources at <strong>Boehringer</strong> <strong>Ingelheim</strong><br />
says: “We try to provide a working environment for<br />
our employees where they can challenge assumptions,<br />
make decisions and where they find the freedom to<br />
implement innovations.”<br />
In other categories, such as “clear vision to the future”<br />
or “innovative leader in the industry”, <strong>Boehringer</strong><br />
<strong>Ingelheim</strong> also ranked top. The 656 respondents<br />
were mainly employed in the biopharmaceutical<br />
and biotechnology sector (67 %), where <strong>Boehringer</strong><br />
<strong>Ingelheim</strong> is one of the leading international<br />
our caring culture<br />
companies. Two thirds of the respondents held Ph.D.s.<br />
Our people<br />
1
Company childcare enters new territory<br />
In an old orchard on <strong>Boehringer</strong> <strong>Ingelheim</strong>’s sprawling US<br />
campus in Ridgefield, Connecticut, a long, one-story building<br />
fits discretely into its surroundings. This is the Apple Blossom<br />
Children’s Learning Center, an exciting new venture in company<br />
childcare provision. The building reflects the architectural<br />
language of the site, <strong>Boehringer</strong> <strong>Ingelheim</strong>’s US headquarters,<br />
where some 2,200 people are employed, many in research and<br />
development.<br />
The Apple Blossom Center, inaugurated in September <strong>2006</strong>,<br />
will take care during the week of up to 156 children from only<br />
six weeks old up to 12 years of age. It is open from 6.30 a.m.<br />
to 6.30 p.m.<br />
1<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
“We believe the center will stand out noticeably among the<br />
many other outstanding benefits we offer, such as our excellent<br />
relocation policy,” David Nurnberger, Senior Vice-President<br />
Human Resources, says. “It might even be one of the main<br />
reasons a candidate would choose to work at Ridgefield, since<br />
working people with children can readily appreciate its value<br />
and convenience.”<br />
At full capacity, the center will have about 35 teachers, all<br />
of whom must have a degree in either education or human<br />
service. The learning center is headed by Katrina Maloney,<br />
who has a degree in early childhood education and has worked<br />
with children for over 17 years. “We are an early learning<br />
center; we’re not babysitting children all day. We have very<br />
specific curricula, from infants all the way up to the oldest<br />
children at the center,” Ms Maloney says.<br />
A group has one or more rooms to itself, with the distribution<br />
dependent on the numbers enrolled in the various groups.<br />
The center, which assigns two teachers to every room, also<br />
provides private kindergarten and after-school care. It also<br />
has a drop-off programme.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> provides childcare at several of its sites,<br />
focusing primarily on the pre-school age group. In Germany,<br />
the company’s <strong>Ingelheim</strong> and Biberach sites run all-day crèches<br />
for very young children (both in cooperation with external<br />
partners), taking employees’ children and children from the<br />
surrounding community. The company’s kindergarten provision<br />
is also conducted in cooperation with the local authorities at<br />
the Italian sites, Milan and Florence. In Spain, for example,<br />
the company runs an annual summer camp in which about<br />
120 children took part in <strong>2006</strong>.
sation received highly esteemed certification for<br />
its achievements and commitment to making the<br />
employment conditions more family-friendly<br />
(see page 16). Our German operating unit furthermore<br />
had 667 apprentices in <strong>2006</strong> (+2.6 %), again<br />
exceeding the previous year’s total engaged in<br />
internal vocational programmes.<br />
Enhancing our capabilities<br />
To enhance the knowledge of our employees and<br />
support life-long learning, the <strong>Boehringer</strong><br />
<strong>Ingelheim</strong> Academy, with its many options from<br />
vocational subjects to leadership development,<br />
offers all employees a unique source of information<br />
about available qualification and updating<br />
opportunities.<br />
Awards <strong>2006</strong><br />
Country Ranking Survey<br />
Our biannual International Management<br />
Development Programme is one of our popular<br />
leadership enhancement schemes and is the<br />
object of external industry benchmarking and<br />
research. Our international and interdisciplinary<br />
development approach involves around 100<br />
potentials learning and working on stretching<br />
topics of strategic relevance over 14 months.<br />
International projects and assignments continue<br />
to be at the core of our global capability development<br />
strategy. Placements lasting up to two years<br />
have increased considerably. The aim of all these<br />
measures is to assign individuals to tasks in<br />
which their skill sets are most required and can<br />
best benefit the business, and to enable them to<br />
gain international experience in dealing successfully<br />
with different economies cultures, and<br />
business practices, while appreciating the rich<br />
diversity of our corporation.<br />
Argentina Best Employers in Argentina (Apertura Business Magazine)<br />
Austria Great Place to Work: The best companies to work for in Austria<br />
Belgium The fastest growing large companies<br />
Brazil among Top 10 Great Place to Work: The best companies to work for in Brazil<br />
Brazil Great Place to Work: The best companies to work for in Latin America<br />
Denmark Denmark’s Best Workplaces<br />
Finland Great Place to Work: The best companies to work for in Finland<br />
France 1 Great Place to Work<br />
Netherlands The 49 Preferred Employers in the Netherlands<br />
Netherlands bronze Great Place to Work<br />
United Kingdom 0 100 Best Companies to Work for (Sunday Times)<br />
USA (Ben Venue) among Top 100 North Coast 99 Award<br />
USA/Europe Science Survey<br />
“Great Place to Work”®, USA, is an international initiative that has been undertaken for many years<br />
in various countries to evaluate the world of work and employee satisfaction.<br />
our caring culture<br />
Our people<br />
1
1<br />
Caring for our neighbours<br />
We are fundamentally committed to fostering economic and social well-being<br />
in the countries and communities where we operate. Both as a company and<br />
as individuals, we seek in a people-orientated and inspirational way to deliver<br />
value through innovation in all we do. We contribute actively to communities,<br />
charitable organisations and projects in research, science, education, healthcare,<br />
culture and environmental protection.<br />
Our commitment to our neighbours was again<br />
demonstrated across the world in <strong>2006</strong> in a<br />
broad range of activities involving thousands of<br />
our employees and substantial company<br />
resources, expressing our adherence to the<br />
principles of social responsibility in both devel-<br />
oping and developed economies.<br />
Our employees’ enthusiasm for making personal<br />
contributions is noteworthy. Their contributions<br />
range from regularly giving part of their income<br />
to good causes to using their spare time to engage<br />
both at home and abroad in hands-on projects,<br />
such as building homes for the poor.<br />
Asia, Australasia, Africa<br />
Our subsidiary in Indonesia, which in 2005<br />
provided immediate support to victims of the<br />
tsunami that devastated coastal regions in South-<br />
East Asia, held its third annual healthcare programme<br />
at its Bogor plant in <strong>2006</strong>. The company<br />
gave free treatment and medicines for almost 250<br />
local people, with 20 <strong>Boehringer</strong> <strong>Ingelheim</strong><br />
employees, three doctors and two nurses dispensing<br />
healthcare.<br />
In the Philippines, we joined forces with Gawad<br />
Kalinga (GK – “To give care”) as a corporate<br />
donor to build homes for less fortunate Filipinos.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> employees will help build<br />
homes for the local community over the next<br />
three years.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
Our Australian operation supported projects in<br />
other parts of the region, participating in the<br />
Collaboration for Health in Papua New Guinea<br />
Project and in the design and implementation of<br />
a pilot scheme to train healthcare workers in the<br />
treatment of people affected by HIV/AIDS.<br />
Substantial charitable activities continued in<br />
Australia, including funds donated to the<br />
Innisfail Hospital after the area was struck by<br />
Cyclone Larry.<br />
In South Africa, where we provided the prime<br />
funding for the country’s first lung institute,<br />
the company also sponsors children in a Johannesburg<br />
childrens’ home as one of its many<br />
activities. In Botswana, the <strong>Boehringer</strong><br />
<strong>Ingelheim</strong> Training and Facilitation Centre<br />
in Gabarone continued in <strong>2006</strong> to facilitate<br />
important conferences and educational events<br />
for healthcare professionals and government<br />
officials, especially related to AIDS (“Turning<br />
the Tide” training programme). The year also<br />
saw the first pharmacy student commence<br />
studies at Rhodes University under a <strong>Boehringer</strong><br />
<strong>Ingelheim</strong>-funded programme agreed with the<br />
Botswana government. Pharmacists on the<br />
programme are bonded to take up service in the<br />
public sector after completing their studies.<br />
Americas<br />
In North and South America, our company<br />
and employees were engaged in a comprehensive<br />
range of activities. In the USA, this involved
Open Day <strong>2006</strong> in Germany<br />
draws record attention<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> holds open days for employees’ families<br />
and friends, and the general public. The <strong>2006</strong> events in mid-<br />
September at the main German sites, <strong>Ingelheim</strong> and Biberach,<br />
attracted a record number of visitors keen to find out more<br />
about the research-based company. The opportunity to take a<br />
look behind the scenes in areas normally only accessible to the<br />
workforce drew a combined total of almost 25,000 people.<br />
The visitors, many of them enthusiastic children, came to the<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> sites to spend a day meeting the staff,<br />
seeing the research and manufacturing facilities and learning<br />
about the many-sided nature of pharmaceuticals.<br />
Open Day <strong>2006</strong> was designed to provide insight into the key<br />
technologies for the discovery, development and production of<br />
innovative drugs. There were also guided tours through a range<br />
of state-of-the-art buildings, including the company’s plant for<br />
worldwide production of pharmaceutical substances and the<br />
new biopharmaceutical production unit.<br />
Broader interests were accommodated, too. Those interested<br />
familiarised themselves with the company’s own power<br />
plant, the water purification plant and the on-site firefighters.<br />
Information on the wide choice of career opportunities at<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> was naturally provided as well. The<br />
events at <strong>Ingelheim</strong> and Biberach formed part of the nation-<br />
wide initiative ‘Responsible Care®’, organised by the National<br />
Federation of the Chemical Industry.<br />
our caring culture<br />
Caring for our neighbours<br />
19
0<br />
Children from St Margaret Clitherow Primary School<br />
receiving their prizes – one first prize and two runner-up<br />
awards – in the <strong>2006</strong> Environmental Art Competition,<br />
an annual event in which children develop artwork<br />
reflecting the theme of recycling. Run by <strong>Boehringer</strong><br />
<strong>Ingelheim</strong> UK for 10 year-old pupils, the competition<br />
fosters environmental awareness and supports the<br />
national curriculum for this age group. Five schools in<br />
the county of Berkshire took part in the competition.<br />
volunteering by our employees. A “Day of Car-<br />
ing” gave employees at our site in Ridgefield,<br />
Connecticut, the opportunity to volunteer for<br />
tasks to help the aged and deprived. Our US<br />
employees also participated in many sponsored<br />
events to raise funds for good causes.<br />
The <strong>Boehringer</strong> <strong>Ingelheim</strong> Cares Foundation<br />
Patient Assistance programme makes our<br />
products, worth millions of dollars, available to<br />
US patients who are without pharmaceutical<br />
insurance coverage and who meet certain household<br />
income levels. This is geared toward helping<br />
provide medication to those who need them<br />
most, including senior citizens and families<br />
on limited incomes.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
In Latin America, our Mexican subsidiary in<br />
<strong>2006</strong> concluded its support programme for<br />
educating 6,370 poor children in schools<br />
in Xochimilco (Mexico City) by installing<br />
media rooms.<br />
Our Brazilian company was committed in the<br />
social responsibility programme, “Conectar”,<br />
designed to help disabled people to prepare for<br />
the jobs market, using our human resources<br />
professionals in cooperation with other organisations.<br />
It also supported Associação Aliança<br />
pela Vida (Alliance for Life Association (ALIVI))<br />
that provides shelter and care to adults and<br />
children living with AIDS.<br />
Europe<br />
In Germany, the scope of our community<br />
involvement is very broad, embracing kindergarten<br />
provision and assistance for the aged<br />
and disabled.<br />
The latest cooperation project between our<br />
Biberach site and the charitable organisation<br />
Heggbacher Einrichtungen provided two disabled<br />
people with much needed home improvements.<br />
Employees of the company’s health and safety<br />
section volunteered their free time to refurbish<br />
an apartment.<br />
In the United Kingdom, we have developed<br />
close partnerships with local schools. Our UK<br />
employees also donate money to charitable<br />
causes under a payroll giving scheme and get two<br />
days off a year to work on community initiatives.<br />
Our Portuguese subsidiary is engaged with an<br />
NGO to support HIV-positive people.
Modern patronage<br />
Interview with Dr Patricia Rochard<br />
For almost five decades, the Internationale Tage (International<br />
Days) in <strong>Ingelheim</strong> have offered art enthusiasts a special insight<br />
into different world cultures, the works of individual artists and<br />
important art movements. Exhibitions on specific themes, such<br />
as the art of the South Seas, Japanese woodcuts, Fauvism and<br />
Expressionism, Viennese Biedermeier or the spirit of the 50s<br />
in Paris, not only fired visitors’ enthusiasm with the displayed<br />
works, but also through their conception and educational<br />
qualities.<br />
It all started with the idea of offering people a chance to get<br />
to know the life and culture of other nations and peoples in<br />
an international company setting. The central theme of<br />
cultural openness and continuing education prompted Dr Ernst<br />
<strong>Boehringer</strong>, co-owner of the family-owned <strong>Boehringer</strong><br />
<strong>Ingelheim</strong>, to stage an annual cultural festival in 1959. The<br />
International Days team was subsequently led for almost three<br />
decades by Dr François Lachenal of Switzerland (1918–1997).<br />
Dr Patricia Rochard, a Frenchwoman who has been managing<br />
the International Days since 1988, has worked for the<br />
programme since 1975.<br />
Dr Rochard, in <strong>2006</strong> the International Days were devoted to<br />
the works of Andy Warhol. How did the exhibition handle the<br />
artist? By bringing together familiar and known dimensions<br />
in surprising contexts. This altered perspective highlighted unfamiliar<br />
and unknown aspects of his work.<br />
Your choice of subjects is extremely varied. Do you have an<br />
overall concept for the International Days? Rather than an<br />
overall concept, I’d prefer to describe it as a basic or central<br />
idea. As sponsor and patron of the International Days, the owner<br />
family was, and still is, interested in conveying humanistic and<br />
cultural values. Thus, diversity, openness, education and insight<br />
are some of the crucial elements, or main pillars, of this idea.<br />
The International Days used to be devoted to country-specific<br />
themes. Due to increased mobility in our society and the wealth<br />
of information available, the image of the International Days has<br />
changed considerably since its early days. In recent years, the<br />
focus has increasingly been on themes intrinsic to art.<br />
our caring culture<br />
What demands do you make of your exhibitions? First of all,<br />
they must be consistent with the basic idea behind the International<br />
Days. That means we can’t make arbitrary choices or<br />
play catch-up, according to events, splendour or fashion trends.<br />
On the other hand, we can’t choose subjects that are only accessible<br />
to a small circle of connoisseurs. The primary goal is to<br />
address both a wide audience interested in art and the professionals.<br />
It’s not always easy to find the right balance, but we<br />
make every effort to do so by setting a high standard of quality<br />
when preparing the concept and selecting and presenting the<br />
exhibits.<br />
Has <strong>Boehringer</strong> <strong>Ingelheim</strong> some special motivation for<br />
supporting the International Days? The history of the International<br />
Days is the history of a commitment to culture that is<br />
steeped in tradition, the purpose of which is neither to achieve<br />
short-lived impact nor economic success. This is wholly in<br />
keeping with the spirit of modern patronage which also enjoys<br />
the support of the fourth generation of company owners.<br />
What is the theme of the exhibition in 2007? Picasso – Variation<br />
& Metamorphosis. After Tinguely 2005 and Warhol, the aim<br />
here is again to highlight a known aspect of Picasso’s work while<br />
attempting to gain “new” insights into the artist’s approach to<br />
work and lifestyle post-1945 by focusing strictly and specifically<br />
on a few themes and variations on them.<br />
Caring for our neighbours<br />
1
Our environment & employee safety<br />
According to the guiding principles (Leitbild) of <strong>Boehringer</strong> <strong>Ingelheim</strong>, the<br />
health and safety of its employees and the protection of the environment has<br />
a very high priority, a fact also underlined by our “Principles on Safety, Quality<br />
and Environmental Protection.” Compliance with company-wide global<br />
standards is regularly checked in audits – a total of 13 in <strong>2006</strong> – by Corporate<br />
Headquarters. Agreed annual targets support the implementation of our<br />
environment health and safety (EHS) policy, which includes the commitment to<br />
the principles of Responsible Care®, a global initiative of the chemical industry.<br />
A corresponding management system ensures<br />
not only that legal requirements are satisfied, but<br />
also that continuous improvements in EHS are<br />
achieved at all production sites. In <strong>2006</strong>, our<br />
chemical site in Fornovo, Italy, and the pharmaceutical<br />
site in Yamagata, Japan, were certified<br />
by external institutions according to the international<br />
standard ISO 14001.<br />
For further details of our EHS management<br />
system please visit www.boehringer-ingelheim.<br />
com/ehs<br />
The following current examples show how we<br />
put our policies into practice:<br />
Responsibility for our employees<br />
Highly potent substances that represent a benefit<br />
to patients at low doses, can pose a health risk to<br />
employees in production or development when<br />
inhaled as dust. We therefore set exposure limits<br />
for all our substances in order to ensure that<br />
none of our employees are exposed to excessive<br />
concentrations. During the past year, technological<br />
solutions implemented at, for example,<br />
our sites in Biberach, Germany; Ridgefield, USA;<br />
and Kawanishi, Japan, were designed to ensure<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
that new, and often highly potent, active ingredients<br />
with very low exposure limits, can be<br />
handled safely without the need for respiratory<br />
protection.<br />
But technical measures are not the only way<br />
of protecting the health of personnel. In fact,<br />
a review of our accident statistics shows that<br />
the majority of work accidents were not related<br />
to activities specific to the chemical or pharma-<br />
ceutical industry, but that one third of the<br />
cases involved slips, trips and falls. Our sites in<br />
Germany have addressed this seemingly trivial<br />
problem by initiating a large-scale campaign –<br />
Work accidents<br />
■ Frequency rate =<br />
accidents x 1 million hours / total labour hours<br />
■ Severity rate =<br />
lost labour days x 1 million hours / total labour hours<br />
4<br />
3<br />
2<br />
1<br />
’02 ’03 ’04 ’05 ’06<br />
80<br />
70<br />
60<br />
50<br />
40
“<strong>Boehringer</strong> <strong>Ingelheim</strong> geht sicher” (<strong>Boehringer</strong><br />
<strong>Ingelheim</strong> walks safely) – that includes a<br />
physical training course. This successful model<br />
will also be introduced in other countries.<br />
Our business partners<br />
We do not just focus on <strong>Boehringer</strong> <strong>Ingelheim</strong><br />
personnel. As we have observed that the accident<br />
rate among the large number of employees from<br />
outside companies at our plants is distinctly<br />
higher than for our own employees, we have<br />
focused our attention even more closely than<br />
hitherto on the safety of this group of workers.<br />
A revised global policy specifies the ground rules<br />
for ensuring that these companies endanger<br />
neither themselves nor others. Accordingly, even<br />
before an order is placed, as well as during its<br />
execution, we scrutinise the companies to determine<br />
if they can satisfy our requirements for safe<br />
working.<br />
We have also revised our business process for<br />
the qualification of suppliers and third party<br />
manufacturers and expressed clear requirements<br />
related to EHS and social standards.<br />
Water<br />
■ Water consumption (in millions of m 3 )<br />
■ Water consumption index (in %)<br />
10<br />
8<br />
6<br />
4<br />
2<br />
’02 ’03 ’04 ’05 ’06<br />
120<br />
100<br />
80<br />
60<br />
Product responsibility<br />
One of the ways in which we fulfil our obligations<br />
in respect of product responsibility is<br />
through environmental risk assessments for our<br />
drugs. Product responsibility in the wider sense<br />
also includes the implementation of the Registration,<br />
Evaluation and Authorisation of Chemicals<br />
(REACH) regulation, a cornerstone of the future<br />
EU chemicals policy. Over the past year, we<br />
started preparing all our European sites for the<br />
implementation of REACH. The objective of the<br />
regulation is to enhance the safety of all those<br />
involved along the product chain and to protect<br />
both consumers and the environment. In future,<br />
companies will only be permitted to use or<br />
market correspondingly registered products.<br />
Minimising environmental impact<br />
The importance of reducing carbon dioxide (CO2)<br />
emissions in the future was again highlighted<br />
at the World Climate Conference in Nairobi in<br />
November <strong>2006</strong>.<br />
Since 2005, <strong>Boehringer</strong> <strong>Ingelheim</strong> has managed<br />
to improve its own CO2 balance by a quarter,<br />
Energy<br />
■ Energy consumption (in millions of gigajoules)<br />
■ Energy consumption index (in %)<br />
5<br />
4<br />
3<br />
2<br />
1<br />
’02 ’03 ’04 ’05 ’06<br />
our caring culture<br />
Our environment & employee safety<br />
120<br />
100<br />
80
thanks to the use of the wood-fired power station<br />
in <strong>Ingelheim</strong>, Germany. In addition to power<br />
generation, energy efficiency is considered in the<br />
construction of new buildings. A recent example<br />
is the new pharmaceutical development building<br />
in Biberach, which opened in <strong>2006</strong> and optimises<br />
energy efficiency through heat recovery and<br />
other measures. The latest illustration of this<br />
approach is provided by a new administration<br />
building currently under construction in <strong>Ingelheim</strong>.<br />
The building’s energy needs will be met by<br />
an environment-friendly geothermal system: the<br />
energy will be obtained by means of 32 brinefilled<br />
earth probes inserted into 100-metre-deep<br />
shafts.<br />
Crisis preparedness / incidents<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> does everything in its<br />
power to avoid incidents. Indeed, no major incidents<br />
were reported in <strong>2006</strong>. However, should<br />
a crisis occur, there are plans in place which<br />
Carbon dioxide (CO )<br />
■ CO2 by energy purchased (in 1,000 tonnes)<br />
■ CO2 by process emissions (in 1,000 tonnes)<br />
■ CO2 emissions index, direct emissions (in %)<br />
(without company car fleet)<br />
500<br />
400<br />
300<br />
200<br />
100<br />
’02 ’03 ’04 ’05 ’0<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
120<br />
100<br />
80<br />
60<br />
allow us to react quickly and appropriately to<br />
different incidents. Last year, we established<br />
an additional crisis management plan to be<br />
prepared in case of pandemics.<br />
In this report we can highlight only a proportion<br />
of the variety of our EHS activities. We constantly<br />
deal with further topics, which are<br />
described on our website at www.boehringeringelheim.com/ehs<br />
Awards<br />
Our site activities yet again received external<br />
recognition in <strong>2006</strong>: the chemical site in Malgrat<br />
was awarded by the Spanish chemical industry<br />
association for its successful accident prevention<br />
programme. The US pharmaceutical site in<br />
Bedford, Ohio, was rated among the top “Healthy<br />
50 companies” in Ohio. The Animal Health<br />
site in St. Joseph, Missouri, USA, received an<br />
award for exemplary wastewater treatment.<br />
Volatile organic carbon (VOC)<br />
■ VOC emissions, non-halogenated (in tonnes)<br />
■ VOC emissions, halogenated (in tonnes)<br />
■ VOC emissions index (in %)<br />
1,000<br />
800<br />
600<br />
400<br />
200<br />
’02 ’03 ’04 ’05 ’0<br />
120<br />
100<br />
80<br />
60
The pharmaceutical site in Shanghai, China,<br />
was presented with an award for its exemplary<br />
energy-saving efforts.<br />
Facts and figures<br />
The graphs on these pages show our performance<br />
figures for the last five years.<br />
The key parameter for our performance in<br />
occupational safety is the accident rate relative<br />
to hours worked. As the graph shows, this<br />
has remained at the same level as in previous<br />
years and is well below the average of about<br />
seven accidents/million hours worked for the<br />
European chemical industry.<br />
Our environmental impacts are shown both as<br />
absolute values and relative to production –<br />
represented in our production index. The calcu-<br />
lation of the index was slightly revised in <strong>2006</strong>.<br />
Our new baseline year is 2000. As additional<br />
Wastewater — chemical oxygen demand (COD)<br />
■ COD load before treatment (in tonnes)<br />
■ COD load after treatment (in tonnes)<br />
■ COD load (after treatment) index (in %)<br />
8,000<br />
6,000<br />
4,000<br />
2,000<br />
’02 ’03 ’04 ’05 ’0<br />
80<br />
60<br />
40<br />
20<br />
25,000<br />
20,000<br />
15,000<br />
10,000<br />
5,000<br />
information, we will show on our website the<br />
contributions made by our individual business<br />
segments – Chemicals, Biopharmaceuticals and<br />
Pharmaceuticals Production – to the respective<br />
indicators.<br />
Over the last few years, most indicators have<br />
reached a stable level because many previous<br />
technical or organisational improvements<br />
resulted in an already high performance stand-<br />
ard. Many of our ongoing efforts are no longer<br />
reflected in our performance data as clearly as<br />
during the earlier years. In <strong>2006</strong>, we observed<br />
a noticeable increase in hazardous waste and a<br />
decrease in the recycling rate. This effect can be<br />
mainly ascribed to the disposal of the slag from<br />
wood-burning in the <strong>Ingelheim</strong> power plant.<br />
While in the past the slag could be reused for<br />
filling salt deposits, it is now brought to landfill<br />
sites. For a more detailed explanation of the<br />
individual graphs, please visit www.boehringer-<br />
ingelheim.com/ehs<br />
Disposed waste<br />
■ Domestic waste (in tonnes)<br />
■ Hazardous waste (in tonnes), incl. pharmaceutical waste<br />
■ Disposed waste index (in %)<br />
■ Recycling rate (in %)<br />
’02 ’03 ’04 ’05 ’06<br />
our caring culture<br />
100<br />
90<br />
80<br />
70<br />
Our environment & employee safety
Our goals<br />
We shall continue to invest in closed systems in<br />
order to protect our employees handling highly<br />
potent substances. Corresponding modifications<br />
in the two pharmaceutical sites in the USA, as<br />
well as in <strong>Ingelheim</strong>, are planned for 2007/08.<br />
There is also potential for the reduction of emis-<br />
sions of volatile solvents (VOC) to the air. We are<br />
making changes at our chemical site in Spain,<br />
where VOCs will be eliminated in future through<br />
thermal oxidation rather than by scrubbing with<br />
aqueous media. In <strong>Ingelheim</strong>, too, additional<br />
plants are to be connected to the existing incin-<br />
erator. Our goal for 2008 is to halve our VOC<br />
emissions.<br />
In order to adapt our wastewater treatment to<br />
increasing loads, we started a major investment<br />
in our <strong>Ingelheim</strong> wastewater treatment plant.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
An additional state-of-the art treatment step will<br />
make the process more effective, will increase<br />
nitrogen removal by improving the nitrification/<br />
denitrification process, and will also target the<br />
specific halogen-containing wastewater which is<br />
difficult to treat when using only conventional<br />
technology.<br />
Energy savings represent another priority issue:<br />
the new laboratory and administration building<br />
at our production site in Bedford, Ohio, will be<br />
constructed in accordance with the Leadership<br />
in Energy and Environmental Design (LEED)<br />
standards, a recognised rating system for environment-friendly<br />
and cost-effective buildings.<br />
The goal is to obtain the LEED certification.
Our R & D drive
Targeting tomorrow’s therapies<br />
The evolution of concepts for cancer treatment into targeted therapies has changed the<br />
chances for some cancer patients drastically. New cancer treatment options may help to<br />
transform an acute, deadly disease into a chronic one. There is hope that in future more<br />
and more patients will at least be able to live with their cancer and survive into old age.<br />
“Patients and their doctors have many new opportunities and there are some excellent drugs<br />
available and even better ones under development,” says Professor Aimery de Gramont of<br />
the Hôpital Saint-Antoine, Paris, an internationally recognised centre for cancer treatment.<br />
In research, change is already taking place, with a movement away from concentrating on<br />
tumour types, such as breast, lung or colorectal cancer, towards tumour-specific targets<br />
that can be identified and treated with small molecules or monoclonal antibodies in a variety<br />
of tumour types. Additionally, the combination of cancer medicines seems to be a key to<br />
even better treatment results. Indeed, it looks as if the time for cancer drug development<br />
has never been better, as genomics, proteomics and biomedical analysis have prepared<br />
the ground for tomorrow’s therapies.<br />
By focusing on both biopharmaceuticals and small-molecule drugs, <strong>Boehringer</strong> <strong>Ingelheim</strong><br />
has embarked on a major drive to discover and develop new cancer drugs. “Particularly in<br />
the last few years, <strong>Boehringer</strong> <strong>Ingelheim</strong> has become a serious player in the area of oncology,<br />
with a whole range of interesting molecules,” Prof. de Gramont, one of the world’s leading<br />
experts in oncology, says.<br />
As one of the main international cooperation partners for oncology, the Hôpital Saint-<br />
Antoine conducts clinical studies in cancer patients for <strong>Boehringer</strong> <strong>Ingelheim</strong>’s new potential<br />
cancer treatments. The substances belong to the group of small molecules which effectively<br />
target specific enzymes (kinases) that play an important role in tumour growth. Although<br />
oncology is a highly competitive field in which no company has exclusivity for a target, and<br />
there are always several companies working on the same target, <strong>Boehringer</strong> <strong>Ingelheim</strong> has<br />
advanced three unique molecules into phase II clinical trials.<br />
BIBF 1120 is a novel triple angiokinase inhibitor. It differentiates from other compounds<br />
of this kind, as it works on three tumour growth factors simultaneously. The compound<br />
inhibits the development of new blood vessels to the tumour (tumour angiogenesis) and in<br />
consequence stops the tumour from growing.<br />
continued on page 30
Professor Aimery de Gramont, Hôpital St-Antoine, Paris, France,<br />
internationally renowned for his expertise in the field of cancer research.
0<br />
continued from page 28<br />
“<strong>Boehringer</strong> <strong>Ingelheim</strong> has become<br />
a serious player in the area of oncology,<br />
with a whole range of interesting<br />
molecules,” Professor Aimery de<br />
Gramont.<br />
BIBW 2992 is a novel dual kinase inhibitor which irreversibly blocks the activity of two<br />
growth factor receptors (EGFR and HER 2). Due to its irreversible binding, BIBW 2992 holds<br />
promise for activity against receptors that have become resistant to first-generation<br />
reversible inhibitors.<br />
BI 2536 is a novel inhibitor of the cell cycle of a cancer cell. Polo-like kinase 1 (Plk-1) is a cell<br />
cycle switch, a kinase enzyme with an important role for guiding proliferating cells through<br />
the cell cycle. BI 2536 inhibits Plk-1 and causes “polo-arrest”, interrupting cell division, thus<br />
causing cancer cell death.<br />
The cooperation between <strong>Boehringer</strong> <strong>Ingelheim</strong> and the Hôpital Saint-Antoine is aimed at<br />
optimising the process of drug development in oncology and thus to improve the speed of<br />
clinical development.<br />
“<strong>Boehringer</strong> <strong>Ingelheim</strong> is much newer to oncology than other companies we work with,<br />
but the interaction is very meaningful and effective. Decisions can be made quickly and<br />
suggestions are taken up very effectively,” Prof. de Gramont observes about the cooperation.<br />
“<strong>Boehringer</strong> <strong>Ingelheim</strong> shows strong commitment to research programmes and long-term<br />
partnerships. This commitment is beneficial for our work and – in the long run – beneficial<br />
for patients.”<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6
One key for three locks<br />
Interview with Dr Chooi Lee<br />
Oncologist Dr Chooi Lee was involved in the clinical phase<br />
I development of one of <strong>Boehringer</strong> <strong>Ingelheim</strong>’s promising<br />
potential cancer treatments, encoded as BIBF 1120, when<br />
a research fellow at the Royal Marsden Hospital in London.<br />
Dr Lee, you have worked with BIBF 1120, one of the new<br />
compounds from <strong>Boehringer</strong> <strong>Ingelheim</strong>’s research. How would<br />
you describe the effect that the molecule actually has? BIBF<br />
1120 limits nutrition provided to cancer cells by inhibiting the<br />
development of blood vessels to the tumour (tumour angiogenesis).<br />
By inhibiting this process, the tumour’s blood supply<br />
can be suppressed which stops the tumour from growing. Some<br />
studies have shown that the tumour is actually dying in the centre<br />
because of starvation due to a lack of nutrition as a result of<br />
decreased blood supply to the tumour.<br />
How exactly does BIBF 1120 work? BIBF 1120 is a so-called<br />
triple angiokinase inhibitor which means that it inhibits receptors<br />
that are relevant in angiogenesis and hence in tumour growth.<br />
BIBF 1120 inhibits not only one growth factor receptor, but three:<br />
the VEGF, FGF and PDGF receptors. The <strong>Boehringer</strong> <strong>Ingelheim</strong><br />
compound has therefore a broader range of targets compared to<br />
others in this area.<br />
What has been investigated in phase I clinical trial? It was a<br />
dose escalation phase I study to look at the maximum tolerated<br />
dose of the drug to evaluate safety and tolerability.<br />
In general, the principle of inhibiting angiogenesis is already<br />
known to be effective against cancer, so such a drug would<br />
not be the first on the market. What makes this compound<br />
BIBF 1120 so special? It is certainly very special that BIBF 1120<br />
is targeting three growth factor receptors at once, instead of<br />
just one. The data have shown that BIBF 1120 has a unique and<br />
favourable toxicity profile, which is different to the other drugs<br />
The formation of new blood vessels (angiogenesis) plays a<br />
critical role in tumour growth. Beyond a diameter of about<br />
2 mm tumours are dependent on an adequate blood supply<br />
through newly formed vessels. Inhibition of angiogenesis<br />
via specific pathways thus represents an important strategy in<br />
inhibiting cancer growth and causes the tumour to regress.<br />
out there, for example in terms of lower incidents of hypertension<br />
and bleeding complications which are common side effects of<br />
other antiangiogenic drugs.<br />
Do you think that with BIBF 1120 disease progression could<br />
actually be stopped? Yes, during Phase I, more than 50 % of the<br />
patients, who already had standard treatment for their cancer,<br />
and did not have any further treatment options left for their<br />
advanced disease, experienced stabilisation of their disease,<br />
which is very promising.<br />
BIBF 1120 is now in phase II clinical development.<br />
our r & d drive<br />
Targeting tomorrow’s therapies 1
Our R & D strategy<br />
Research and development has been the foundation of <strong>Boehringer</strong><br />
<strong>Ingelheim</strong>’s success and continues to be the major driver of innovative,<br />
new medicines. One key element of the strategy is to expand the discovery<br />
and development portfolio into new biological entities (NBEs see page 42),<br />
derived out of internal research as well as out of in-licensing efforts<br />
without neglecting to foster internal new chemical entities (NCE) R&D<br />
capabilities. These NBEs are planned to be co-developed with and produced<br />
by our Biopharmaceuticals Division. We have therefore continued to build<br />
up dedicated resources, predominantly in Vienna and Biberach.<br />
Today, we carry out drug discovery in seven<br />
major therapeutic areas allocated to four major<br />
R&D sites. Our R&D sites maintain strong<br />
responsibility and accountability for their thera-<br />
peutic areas locally and deploy their innovation<br />
and flexibility. International scientific reviews<br />
and portfolio management ensure a sustainable,<br />
competitive and risk-balanced discovery pipeline.<br />
To further strengthen our R&D organisation we<br />
have implemented international skill centres to<br />
improve efficiency and to secure equal access to<br />
state-of-the-art technologies and informatics<br />
platforms for all sites.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> recognises in-licensing<br />
and partnering as a key component of our drive<br />
to deliver novel therapeutics to the market.<br />
While our major licensing focus is in our strategic<br />
therapeutic areas, we very successfully develop<br />
and market products outside these areas as well.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
Our licensing functions along the value chain<br />
are supported by interdisciplinary, therapy-areaspecific<br />
advisory and project teams ensuring<br />
speed and diligence in objective evaluations, and<br />
seamless incorporation of partnered projects.<br />
Worldwide, we employ more than 3,300<br />
scientists, technicians and support personnel<br />
in preclinical R&D. They are complemented<br />
by about 2,300 clinical monitors, statisticians<br />
and data managers in clinical development<br />
and medical departments.
Our R & D sites<br />
Biberach and <strong>Ingelheim</strong>,<br />
Germany<br />
CNS, respiratory, metabolism,<br />
non-clinical development<br />
In our largest R&D center in Biberach, more than<br />
1,600 scientists from about 20 nations energise<br />
our research and development while nourishing<br />
the interdisciplinary scientific exchange as on a<br />
research campus. Biberach is the competence<br />
centre for several therapeutic areas: central<br />
nervous system (CNS), metabolic and respiratory<br />
diseases. Furthermore, our Human Pharmaco-<br />
logical Center, in operation since 2004, secures an<br />
important link to the clinical investigation of<br />
compounds.<br />
Projects in Biberach benefit from the open and<br />
constructive interaction among our scientists, as<br />
well as with academia and biotech companies,<br />
with whom numerous scientific collaboration<br />
agreements have been signed.<br />
Since developmental aspects are considered early<br />
during drug discovery, the high attrition rate<br />
during the process could be reduced. The<br />
challenges of target validation and clinical proof,<br />
however, remain, but are now actively addressed<br />
by dedicated technology-driven expert groups at<br />
the <strong>Boehringer</strong> <strong>Ingelheim</strong> Global Skill Centers<br />
(GSCs).<br />
Development efforts in Germany support the<br />
research centres in Biberach and Vienna with<br />
all early and late development functions. For<br />
increased efficiency, the late chemistry, manufac-<br />
turing and control, as well as the development of<br />
inhalation devices, have been centralised in<br />
Germany for compounds stemming from all<br />
research sites.<br />
“The key to success is ‘never stop striving for more!’,” comments<br />
Dr Michel Pairet, Senior Vice-President Research in Biberach, on the<br />
ambitious goals for the upcoming year. “We want to see one or two of<br />
our compounds achieving clinical proof of concept, and three to four<br />
compounds to successfully complete phase I clinical trials. What’s<br />
more, we plan to bring four or five new high-quality compounds into<br />
preclinical development. And more: <strong>Boehringer</strong> <strong>Ingelheim</strong> regards<br />
it a critical endeavour to fully integrate new biological entities in its<br />
project portfolio.”<br />
Dr Pairet forecasts a busy year of R&D at Biberach: seven new<br />
compounds which have been added to the preclinical portfolio last<br />
year will now have to be further characterised. “In addition, we are<br />
looking forward to having the first compounds coming out of collaborative<br />
research with academic groups or biotechs.”<br />
The research teams’ outstanding efficiency is attributed to two main<br />
factors – the company’s size and the fact that <strong>Boehringer</strong> <strong>Ingelheim</strong><br />
is family-owned: “Our scientists have the spirit of freedom to work<br />
and think in the long term, concentrating on true medical need and<br />
compound safety, rather than on glossy presentations to investors.”<br />
For the future, teams will prepare to enter new therapeutic areas for<br />
which there is a high unmet medical need. “With the new structure<br />
we are well prepared for future tasks, since we allocate development<br />
resources on a global basis jointly with our colleagues in Ridgefield.<br />
Germany will, furthermore, be the link between research and<br />
manufacturing, since we have the late stage chemistry manufacturing<br />
and control responsibility for the entire portfolio. Last but not least,<br />
the excellent exchange with our colleagues from research and<br />
medicine position us well for the challenges of a full portfolio,” says<br />
Dr Wolfgang Baiker, Senior Vice-President Development in Germany.<br />
Dr Wolfgang Baiker,<br />
Senior Vice-President<br />
Development,<br />
Germany<br />
Our R & D sites<br />
our r & d drive<br />
Dr Michel Pairet,<br />
Senior Vice-President<br />
Research, Germany
Ridgefield, USA<br />
Cardiovascular, immunology<br />
and inflammation, non-clinical<br />
development<br />
Research and Development at <strong>Boehringer</strong> Ingel-<br />
heim Pharmaceuticals, Inc. was established in<br />
1979 and was built up as a centre for immune &<br />
inflammatory diseases. Only a few years ago, in<br />
2003, it also became the R&D competence centre<br />
for cardiovascular diseases.<br />
In the area of cardiovascular diseases, chronic<br />
heart failure, atherosclerosis, hypertension and its<br />
sequelae are targeted. In immunology & inflam-<br />
mation, <strong>Boehringer</strong> <strong>Ingelheim</strong>’s focus is on<br />
autoimmune diseases such as rheumatoid arth-<br />
ritis, psoriasis and multiple sclerosis. In the last<br />
three years, the Ridgefield site has seen major<br />
investments in staff and facilities with the aim of<br />
strenghtening the previously mentioned key indi-<br />
cation area pipeline.<br />
In order to strengthen our early development<br />
capabilities, a new physical science building has<br />
been erected and is about to be opened. It will<br />
provide a state-of-the-art facility for analytical<br />
science and chemical development.<br />
With the aim of benefitting all of our global<br />
research sites, <strong>Boehringer</strong> <strong>Ingelheim</strong> has recently<br />
established global skill centers (GSCs) to strengthen<br />
its position in technology areas of strategic impor-<br />
tance. Ridgefield has established the GSC for high<br />
throughput cloning and expression and shares<br />
responsibility for the alternative lead identification<br />
and compound pool optimisation the GSCs<br />
with Biberach, Germany.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
“My most interesting and satisfying experiences have been seeing the<br />
fruits of our research tested in patients for the first time,” says Paul<br />
Anderson, Senior Vice-President Research at the US R&D centre.<br />
“That is what our work is all about.” Dr Anderson outlines that apart<br />
from the classical research another focus of the efforts in Ridgefield is<br />
the build-up of a pipeline of NBEs (see page 42). Capitalising on the<br />
expertise of the Biopharmaceuticals business, the teams will be able<br />
to advance innovative NBE projects in areas where biological therapeutics<br />
can provide important advances.<br />
The confidence in the success is based on solid ground. “The distribution<br />
of our seven therapeutic areas to specific sites among our four<br />
major drug discovery centers allows each site to focus, with a critical<br />
mass, on the therapeutic areas under its responsibility, and gives each<br />
site the focus and autonomy of a biotech company with the resources<br />
and backing of a major international pharmaceutical company,” he<br />
stresses.<br />
There is a positive picture for what is to come: “In recent years, we<br />
have successfully built a truly globalised development structure which<br />
has strengthened our non-clinical development in Ridgefield. Our<br />
new physical science building adds an important capability to achieve<br />
our goal of supporting research in Ridgefield and Laval, but also adds<br />
the needed capacity in development worldwide. Our experience in<br />
working closely with research colleagues provides an important advantage<br />
and drives the rapid and efficient development of compounds in<br />
our therapeutic areas,” notes Dr Peter Farina, Senior Vice-President<br />
Development at <strong>Boehringer</strong> <strong>Ingelheim</strong>, Ridgefield.<br />
Dr Paul Anderson,<br />
Senior Vice-President Research, USA<br />
Dr Peter Farina,<br />
Senior Vice-President<br />
Development, USA
Laval, Canada<br />
Virology<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>’s Research Center in Laval<br />
is one of Canada’s largest pharmaceutical research<br />
sites. Located near Montreal, over 130 scientists<br />
and their complementing support staff are<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>’s experts for discovering<br />
potential treatments for chronic and acute viral<br />
diseases for which either no vaccine exists or<br />
current therapy is lacking or unsatisfactory. The<br />
teams in Laval are dedicated to advance therapeu-<br />
tics for diseases caused by the hepatitis C virus<br />
and the human immunodeficiency virus (causing<br />
AIDS).<br />
HIV research in Laval aims to complement<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>’s portfolio of existing HIV<br />
treatments, e. g. viramune® (nevirapine, a non-<br />
nucleoside reverse transcriptase inhibitor) and<br />
aptivus® (tipranavir, a protease inhibitor). Further<br />
compounds under development will be added to<br />
the armentarium of drugs to treat HIV-positive<br />
patients, particularly those where prior therapy<br />
has failed due to development of a resistance.<br />
State-of-the-art technology in the key areas chem-<br />
istry and biological sciences, such as the nuclear<br />
magnetic resonance (NMR) and X-ray technology,<br />
as well as computer-aided image analysis, push<br />
projects forward.<br />
The increase in the number of research projects in<br />
Laval are being complemented by the extension of<br />
the research facility to about double the size. The<br />
building is planned to be inaugurated in early<br />
2008.<br />
“What is most rewarding in my position is to receive<br />
the positive response from collaborators regarding our<br />
scientists and projects – and it’s humbling. Universally,<br />
I hear our scientists’ high level of motivation, and the<br />
obvious excitement they get from the science that they<br />
do is unique,” relates Dr Michael Cordingley, Senior Vice-<br />
President Research, about the teams in Laval.<br />
By capitalising on research with first molecules in<br />
hepatitis C in recent years and by implementing even better<br />
technology to ferret out bad actors early, the teams will<br />
continue to consolidate the strong position in hepatitis C<br />
virus protease inhibitor and polymerase inhibitor devel-<br />
opment in 2007. “We will also strengthen our activities<br />
within our collaborative programme, for example with the<br />
Australian biotech Biota Holdings, for additional comple-<br />
mentary targets.”<br />
The work is far from done in the HCV area. Current treat-<br />
ment options still carry the serious safety and tolerability<br />
problems associated with the standard care. “Our aspira-<br />
tion therefore is to introduce oral combination therapy<br />
which will deliver patients effective and well tolerated<br />
oral treatments, rather than inconvenient injectables.”<br />
The focus in Laval is on discovering antivirals with comple-<br />
mentary mechanisms suitable for use together to combat<br />
resistance and provide durable efficacy and safety. “Overall,<br />
we aim for nothing less than providing safe and effective<br />
novel oral medicines to improve treatment outcomes for<br />
HCV and HIV-infected patients,” emphasises Dr Cordingley.<br />
Dr Michael Cordingley,<br />
Senior Vice-President Research,<br />
Canada<br />
Our R & D sites<br />
our r & d drive
Vienna, Austria<br />
Oncology<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>’s dedicated drug discovery<br />
center for innovative cancer medicines is located<br />
in Vienna. Oncology was created as a new thera-<br />
peutic area at <strong>Boehringer</strong> <strong>Ingelheim</strong> in response<br />
to the substantial unmet medical needs of cancer<br />
patients and the tremendous advances in under-<br />
standing cancer biology, fuelled by the human<br />
genome project, with new insights into cancer<br />
genes and the biochemical signalling pathways<br />
gone awry in malignant cells.<br />
Research in Vienna reveals that scientific excellence<br />
and the ambition to discover and develop<br />
new medicines are not limited by national borders:<br />
the more than 200 researchers in <strong>Boehringer</strong><br />
<strong>Ingelheim</strong>’s laboratories come from more than a<br />
dozen countries worldwide. Together with the<br />
global development center in Biberach and colleagues<br />
in Medical, the discovery teams are committed<br />
to new treatment choices for patients (with<br />
locally advanced or metastatic cancers).<br />
The oncology research campus is part of the<br />
Regional Center Vienna, which has business<br />
responsibility for Austria and twenty-nine<br />
countries in Central and Eastern Europe. From<br />
2000 to 2007, a highly modern, state-of-the-art<br />
research infrastructure has been built up at the<br />
Regional Center. Only recently, a new biology<br />
research building has been opened, which<br />
complements the chemistry research building<br />
inaugurated in 2002. Within a very short time-<br />
span, innovative drug candidates from in-house<br />
research – both small-molecule chemicals and<br />
human monoclonal antibodies – have been<br />
advanced into development, including three<br />
compounds currently in phase II clinical trials.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
Of the nearly 25 million people diagnosed with malignant<br />
cancers worldwide, more than half can be treated today<br />
with long-lasting benefit; however, “close to seven million<br />
cancer deaths per year are simply not acceptable,” explains<br />
Dr Wolfgang Rettig, Senior Vice-President Research in Vienna.<br />
“Available treatment options, particularly surgical inter-<br />
ventions, are least promising when the cancer has spread to<br />
distant organs, and at this stage of the disease the need for<br />
more effective, targeted therapies with fewer side effects<br />
becomes plainly visible. One in every three women and one<br />
in every two men will be diagnosed with a malignant cancer<br />
during their lifetimes, and this is a challenge we take very<br />
personally,” Dr Rettig states.<br />
The time for finding better cancer medicines has never been<br />
better for <strong>Boehringer</strong> <strong>Ingelheim</strong>, since the company can build<br />
on a very strong scientific foundation provided by academic<br />
research centers worldwide. “Nevertheless, the road ahead is<br />
long and arduous,” Dr Rettig forecasts. <strong>Boehringer</strong> <strong>Ingelheim</strong><br />
has entered the field of oncology with the persistence<br />
and long-term vision possible for a family-owned group<br />
of companies, and the outlook for patients is therefore<br />
promising. Already, some cancer types are being treated<br />
very effectively with targeted drugs, although not all<br />
patients benefit equally. According to Dr Rettig: “With many<br />
additional drugs in development, this trend will improve,<br />
and we will continue to change the face of cancer, turning it<br />
into a chronic disease with improved quality of life, one<br />
step at a time.”<br />
Dr Wolfgang Rettig,<br />
Senior Vice-President<br />
Research, Vienna
Our support centres<br />
Kawanishi, Japan<br />
Molecular biology,<br />
non-clinical development<br />
One of <strong>Boehringer</strong> <strong>Ingelheim</strong>’s centres for molec-<br />
ular cell biology is located in Kawanishi, Japan.<br />
Kawanishi is specialised in membrane receptor<br />
targets providing dedicated support for drug<br />
discovery activities. International development is<br />
supported by early pharmaceutical work and ana-<br />
lytical sciences. Furthermore, Kawanishi serves as<br />
a skill center to characterise how drugs interact<br />
with transporter molecules in the body.<br />
Milan, Italy<br />
Chemical synthesis<br />
The Chemistry Research Center Milan, Italy, with<br />
about 30 employees, contributes to advancing<br />
research at an important stage of the process,<br />
namely by providing expertise in synthesis in<br />
exploratory projects and lead optimisation projects<br />
for Biberach.<br />
Buenos Aires, Argentina<br />
Non-clinical development<br />
Our support center in Buenos Aires operates in<br />
close cooperation with the Ridgefield development<br />
site and also provides assistance to production<br />
plants in Argentina, Brazil, Colombia and<br />
Mexico. From Buenos Aires comes added support<br />
on drug formulation and the manufacture of<br />
medication for clinical trials.<br />
our r & d drive<br />
Research Institute of Molecular Pathology<br />
(IMP), Vienna, Austria – an independent<br />
basic research institute<br />
The bridge between our R&D people and academia is reinforced<br />
by the strong link to the renowned Research Institute<br />
of Molecular Pathology (IMP) in Vienna. IMP scientists are at<br />
the forefront of discovery defining fundamental processes<br />
of cell division and differentiation in healthy and diseased<br />
states. In 2001, collaboration started between the IMP and<br />
the Institute of Molecular Biotechnology Austria (IMBA),<br />
which added a new dimension to our academic network.<br />
Our R & D sites
Our expertise in landmark studies<br />
Landmark studies are large-scale, randomised, controlled clinical trials for thousands<br />
of patients recruited from a great number of sites around the world. Results have a<br />
potential to broadly impact on clinical practice. All in all, in the last decade <strong>Boehringer</strong><br />
<strong>Ingelheim</strong> conducted or sponsored some 1,400 studies involving approximately<br />
1.2 million patients in 59 countries in all regions of the world.<br />
Among these studies, the ontarget/<br />
transcend®, profess®, uplift® and<br />
re-volution® trial programmes are land-<br />
mark studies. They progressed according<br />
to plan in <strong>2006</strong>.<br />
The ontarget trial programme, the cardiovas-<br />
cular protection study with micardis® (telmisar-<br />
tan), our angiotensin II receptor blocker, had<br />
recruited over 31,000 patients by 2004, the end<br />
of the recruitment interval. Since then, patients<br />
have been followed up with regular clinical<br />
examinations and are now in the last year of<br />
observation. The primary target of the study is<br />
to determine if the combination of micardis®<br />
and the angiotensin-converting enzyme (ACE)<br />
inhibitor ramipril is more effective in reducing<br />
myocardial infarction, stroke, heart failure and<br />
cardiovascular death compared with ramipril<br />
alone, and, if micardis® 80 mg is at least as<br />
effective as ramipril 10 mg daily.<br />
Among the secondary endpoints are newly<br />
diagnosed congestive heart failure, the need<br />
for cardiovascular revascularisation procedure,<br />
newly diagnosed diabetes, cognitive decline and<br />
dementia. The transcend® trial with micardis®<br />
versus a placebo looks into the same endpoints<br />
but is focused on patients who cannot tolerate<br />
an ACE inhibitor and may benefit from an angiotensin<br />
II receptor blocker instead. Results are<br />
expected in 2008.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
The largest secondary stroke prevention study<br />
profess® exceeded its recruitment target and<br />
has now enrolled 20,333 patients. The primary<br />
endpoint of this trial is time to first recurrent<br />
stroke. profess® compares the efficacy and<br />
safety of aggrenox® (25 mg ASA/200 mg<br />
extended-release dipyridamole) with clopidogrel,<br />
and additionally of micardis® (telmisartan) with<br />
a placebo. First results are expected in 2008.<br />
Every single step matters<br />
Interview with Dr Salim Yusuf<br />
What will the landmark trial ONTARGET mean for patients?<br />
The ONTARGET trial programme is set up to investigate the<br />
potential benefits of the combination of the angiotensin-II<br />
receptor blocker telmisartan (ed: MICARDIS®) and the ACE<br />
inhibitor ramipril in reducing myocardial infarction, stroke, heart<br />
failure and cardiovascular death. We also have a parallel study<br />
called TRANSCEND® where people who can’t take ramipril receive<br />
either telmisartan or placebo. So between these two trials we<br />
will learn whether telmisartan is at least as good as ramipril,<br />
and whether the combination is more effective. This is important<br />
because ramipril has some side effects and a significant proportion<br />
of people can’t tolerate it. If telmisartan is as good as ramipril,<br />
but is tolerated better, that is a positive finding for patients.<br />
The second possibility is that telmisartan when added to ramipril<br />
will have more benefit than either drug alone. That would be the<br />
most exciting finding if confirmed.
uplift® is our 6,000-patient, long-term outcome<br />
study with spiriva® (tiotropium bromide), a<br />
novel once-daily inhaled anticholinergic for the<br />
maintenance treatment of chronic obstructive<br />
pulmonary disease (COPD). The trial has been<br />
set up to prospectively confirm that spiriva® has<br />
the potential to positively influence the progression<br />
of COPD over time. The primary endpoint<br />
is the rate of decline in forced expiratory volume<br />
during the first second of exhalation (FEV1)<br />
over four years in COPD patients. This study is<br />
explored to be completed in 2008 as well.<br />
Do you think that patients will understand the importance of a<br />
“prevention treatment”, i.e. taking tablets for a condition which<br />
does not hurt before infarction or stroke may occur?<br />
The people in ONTARGET have all had a heart attack or stroke,<br />
coronary disease or diabetes or some complications, or are<br />
at high risk of developing these. These are patients who need<br />
multiple approaches to prevent cardiovascular disease. Think of<br />
it like climbing a staircase: every step matters. One step alone<br />
won’t do.<br />
How is the flood of information in this trial processed?<br />
We have more than 700 trial centres in 41 countries. Data comes<br />
in on 40 fax lines open to receive data continuously day and<br />
night. The data are automatically screened and scanned by an<br />
intelligent optical recognition system which enters them into a<br />
special software for a first-level data check. Next, our specialists<br />
check to see if there are things the computer missed. Some 180<br />
individuals, research assistants, research coordinators, medical<br />
officers, statisticians, programmers and administrative staff<br />
collaborate here at The Population Health Research Institute at<br />
re-volution®, the clinical trial programme in<br />
thrombo-embolic disease, involves more than<br />
27,000 patients and investigates dabigatran<br />
etexilate, an orally available thrombin inhibitor<br />
for the prevention and treatment of thromboembolic<br />
diseases. Studies cover the prevention<br />
of deep vein thrombosis following orthopaedic<br />
hip or knee replacement surgery, as well as<br />
treatment of thromboembolism, secondary<br />
prevention of thromboembolism and stroke<br />
prevention in atrial fibrillation. The studies are<br />
scheduled for completion between <strong>2006</strong> and<br />
2009.<br />
McMaster University to make this an efficient process managing<br />
some one and a half to two million pages of data every year. With<br />
ONTARGET we will publish a large number of scientific paper<br />
and analysis will go on for many years after the first announcements<br />
of data in 2008.<br />
Salim Yusuf, Professor of Epidemiology and Cardiology at<br />
McMaster University in Hamilton, Ontario, Canada, leads<br />
the research team for <strong>Boehringer</strong> <strong>Ingelheim</strong>’s ONTARGET<br />
trial programme. Here he discusses the long-term project.<br />
Our expertise in landmark studies<br />
our r & d drive<br />
9
From mind to man – the R & D process<br />
It seems almost as impossible as finding a needle in a haystack.<br />
From more than one million screened molecules, only one<br />
will eventually enter the market as an approved medication.<br />
Drug discovery, pre-clinical and clinical development take<br />
about 1 years and an average investment of USD 00 million.<br />
The development of a drug from mind to market has to<br />
successfully pass through the stages described below.<br />
years ›<br />
Research<br />
Target identification<br />
Drugs usually act on cellular proteins, such as enzymes or<br />
receptors, known as drug targets, which are believed to be<br />
associated with a disease. Scientists use a variety of molecular,<br />
genetic or pharmacological techniques to identify a target<br />
and learn more about how it influences the disease.<br />
research<br />
Target validation<br />
To select targets most likely to be useful for the treatment of a<br />
disease, researchers compare each drug target to others based<br />
on their association with a specific disease and their ability to<br />
regulate biological processes in the body. Tests confirm that<br />
interactions with the drug target effect the desired change in<br />
the behaviour of the diseased cells.<br />
Lead identification<br />
Laboratory assays are developed that allow a rapid screening<br />
of small molecules or proteins. Screening of chemical libraries<br />
representing larger or smaller cellections of molecules that<br />
with drug-like properties will identify leads, compounds that<br />
specifially bind to the desired target.<br />
Lead optimisation<br />
Improvement of the properties of the identified leads in order<br />
to support the selection of those compounds with the greatest<br />
potential to be developed into safe and effective medicines.<br />
The best lead compounds are studied for their therapeutic<br />
effects and how they are absorbed, metabolised and excreted<br />
in living organisms.<br />
development<br />
target<br />
identification target<br />
validation<br />
lead<br />
identification lead<br />
basic research (academia)<br />
pre-clinical<br />
and exploratory research<br />
(industry) optimisation<br />
development<br />
phase I<br />
phase II<br />
1 2 3 4 5 6 7 8
Development<br />
Pre-clinical development<br />
Profiling of the drug candidate with regard to safety according<br />
to regulatory requirements prior to first use in humans is per-<br />
formed. A chemical synthesis is developed and scaled up to<br />
provide the necessary drug quantities for further development<br />
and testing. The best dosage form for administration to pat-<br />
ients and a suitable pharmaceutical formulation are identified.<br />
Phase I<br />
Clinical trials, normally performed in healthy volunteers,<br />
provide results on the absorption, distribution in the human<br />
body and excretion of an investigational compound, and on<br />
short-term tolerability and safety, in order to determine a<br />
preliminary dose range. <strong>Boehringer</strong> <strong>Ingelheim</strong> has two Human<br />
Pharmacological Centers in operation in Germany (<strong>Ingelheim</strong><br />
and Biberach).<br />
Phase II<br />
Efficacy and safety in the target indication is established with<br />
up to several hundred patients usually treated for several weeks<br />
or a few months. These studies allow the determination of the<br />
potential therapeutic dose range.<br />
registration<br />
regulatory<br />
phase III approval phase IV (life cycle management)<br />
9 10 11 12 13 14 15<br />
our r & d drive<br />
Phase III<br />
Phase II results on efficacy and safety are refined and<br />
confirmed in larger patient numbers (several thousands) and<br />
surveillance of long-term treatment as appropriate for the<br />
indication.<br />
Registration / life cycle management<br />
Regulatory approval<br />
After clinical studies, results are submitted to regulatory agencies.<br />
Independent experts give their opinion on whether or not<br />
the drug product should be approved.<br />
Phase IV (life cycle management)<br />
The product is further profiled for more general and broader<br />
real-life usage, in special patient subgroups and in the context<br />
of an even broader concomitant therapeutic environment.<br />
These trials may be extremely large (10,000—30,000 patients)<br />
and therefore can better identify even rare adverse reactions.
New biological entities (NBE)<br />
One of the fastest drug developers<br />
Pharmaceutical companies that develop and launch new<br />
products faster than their competitors perform consistently<br />
better across a number of dimensions, earn higher revenues,<br />
and have lower development costs. These findings were<br />
reported in a newly-completed analysis of the period 2000 to<br />
2005 from the Tufts Center for the Study of Drug Development,<br />
based in Boston, USA.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> is widely recognised as a<br />
world leader in all aspects of biopharmaceutical<br />
manufacturing, from early process development<br />
to large-scale commercial manufacturing in<br />
microbial as well as mammalian expression<br />
systems. Combined with our disease expertise,<br />
our strategy is to create a comprehensive and<br />
proprietary NBE programme, thus addressing<br />
unmet medical needs in several indication areas<br />
and expanding our proprietary NBE product<br />
portfolio beyond actilyse®, metalyse®, imukin®<br />
and beromun®.<br />
To fully exploit our internal synergistic potential,<br />
we have established expertise in human antibody<br />
drug discovery facilitated by in-licensing key<br />
technologies from MorphoSys (phage display)<br />
and Medarex (genetically modified mice). We<br />
have also strengthened our protein technology<br />
infrastructure and allocated dedicated biology<br />
resources.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> was represented amongst a group of<br />
the fastest pharmaceutical companies. All of the fastest<br />
companies shortened their development and regulatory cycles<br />
by as much as 17 months, compared to average-performing<br />
drug developers. They had far less development and regulatory<br />
time variability, stopped projects sooner, instead of moving<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
Our current NBE discovery programme includes<br />
some ten projects, a first step towards a steady<br />
stream of innovative NBE therapeutics in<br />
our development pipeline. Good progress was<br />
achieved during <strong>2006</strong> with several projects<br />
across multiple therapeutic areas moving to the<br />
lead optimisation and pre-development stages.<br />
We are also pursuing a number of biotechnology<br />
collaborations to sustain and strengthen future<br />
delivery of quality NBEs. With FivePrime Therapeutics<br />
we are conducting a high-throughput<br />
functional screen of their proprietary library<br />
of secreted proteins and receptor ectodomains<br />
to identify novel NBE targets for rheumatoid<br />
arthritis. We are also currently looking into<br />
new alliances on technologies that will help<br />
us develop high-quality NBEs as a complement<br />
to our successful alliances with Medarex and<br />
MorphoSys.<br />
them to ever more complex studies, and were better at setting<br />
resource priorities, the survey revealed.<br />
“We have in the last few years noted an increase in our R&D<br />
productivity, as measured by increased output of compounds,<br />
better project success rates and a growing R&D portfolio.<br />
The Tufts survey addresses speed as yet another productivity<br />
parameter. The data further supports the notion that our<br />
international R&D strategy is on the right track,” says<br />
Dr Mikael Dolsten, Executive Vice-President Pharma Research<br />
of <strong>Boehringer</strong> <strong>Ingelheim</strong>. “In view of the very high R&D costs<br />
– one reckons presently with more than EUR 800 million for<br />
the development of a new drug – the speed to get valuable<br />
drugs to the market is crucial, and may give us another competitive<br />
edge over other pharma companies.”
Biomarker and pharmacogenetics<br />
Realising the importance of biomarkers and<br />
pharmacogenetics from early discovery phase<br />
to post-launch in delivering more and safer<br />
medicines with good and predictable efficacy<br />
to patients, this area receives particular attention<br />
in <strong>Boehringer</strong> <strong>Ingelheim</strong>. Biomarkers give an<br />
objective read-out for drug target binding,<br />
immediate downstream physiological effects<br />
(pharmacodynamic biomarkers), pathological<br />
processes (disease biomarkers) or drug-induced<br />
side effects (safety biomarkers). This is<br />
particularly helpful in early clinical development<br />
as a tool to obtain an early indication of drug<br />
effectiveness and safety. Biomarkers are typically<br />
recorded by clinical chemistry measurements<br />
or physiological responses in animal models<br />
and patients. <strong>Boehringer</strong> <strong>Ingelheim</strong> is increasingly<br />
exploring cutting-edge technologies<br />
for biomarker assessment, including imaging,<br />
expression profiling and proteomics in our<br />
discovery and early development projects.<br />
In pharmacogenetics the genetic variation<br />
between patients is studied in order to explain<br />
potential differences in the response to drugs.<br />
This area is becoming increasingly important for<br />
understanding efficacy and side effects for the<br />
individual patient, with a particular focus on<br />
polymorphisms (i. e. having multiple alleles of a<br />
gene within a population) in the drug target itself,<br />
as well as in drug metabolising enzymes and<br />
drug transporters. In <strong>2006</strong> <strong>Boehringer</strong> <strong>Ingelheim</strong><br />
started to put in place a strong infrastructure to<br />
support our clinical development project teams<br />
to efficiently use biomarkers and pharmacogenetics.<br />
The newly built function includes<br />
laboratories for clinical chemistry and pharmacogenetic<br />
analyses, and will provide capacity for<br />
fully automated long-term storage of several<br />
million anonymised DNA samples obtained from<br />
patients during clinical development. The new<br />
function also includes a state-of-the-art sample<br />
logistics infrastructure and data mining and<br />
modelling capabilities.<br />
New biological entities (NBE) / Biomarker and pharmacogenetics<br />
our r & d drive
The development of<br />
our businesses<br />
We have committed ourselves to the goal<br />
of serving mankind through research into<br />
diseases and the development of new drugs<br />
and therapies in the areas of human pharmaceuticals<br />
and animal health. Our businesses<br />
follow our patient-orientated approach. They<br />
are divided into two main business areas:<br />
Human Pharmaceuticals, that accounts for<br />
96 % of our business, and Animal Health that<br />
accounts for 4 % of our business.<br />
Net sales (in EUR million) 00 2005 Growth in %<br />
Human Pharmaceuticals 10, 00 9,1 1,0 11 %<br />
Prescription Medicines<br />
8,311 7,247 1,064 15 %<br />
– Branded Prescription Medicines<br />
7,654 6,712 942 14 %<br />
– Generic Prescription Medicines<br />
657 535 122 23 %<br />
Consumer Health Care 1,064 1,052 12 1 %<br />
Industrial Customer<br />
— Pharma Chemicals<br />
809 847 -38 -5 %<br />
— and Pharmaceuticals Production<br />
306 299 7 2 %<br />
— Biopharmaceuticals<br />
503 548 -45 -8 %<br />
Others 16 28 -12 -43 %<br />
Animal Health 1 1 %<br />
Total 10, 9, 1,0 9 11 %<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6
Serving patients
Rin Fujima, Kyoto, Japan, suffers from high blood pressure,<br />
a serious risk for the brain, heart and kidneys.
“I wake up refreshed ...”<br />
“When I woke up in the morning, I no longer felt refreshed from sleep. I went to my doctor Haruteru<br />
Hasuo who found that my blood pressure was far too high. Fortunately, apart from high blood<br />
pressure, my checkup revealed no other disorders, such as hyperlipidaemia or diabetes,” recalls<br />
Rin Fujima, a 60-year-old housewife living near Kyoto. She was prescribed an angiotensin-II-receptorblocker<br />
to control her blood pressure. “I now measure my blood pressure before taking my<br />
medication every morning. I’ve seen great improvement.” After taking the medication things got<br />
back to normal for her.<br />
However, high blood pressure or hypertension is not only an unpleasant condition. It is possibly also<br />
the first sign of a serious cardiovascular risk that can be the precursor to stroke and heart attack.<br />
Uncontrolled, this 24-hour condition can cause damage to vital organs, such as the heart, kidneys or<br />
brain, over the long term. Sharp rises in blood pressure occur in the early hours, coinciding with an<br />
increase in life-threatening heart attacks and strokes.<br />
“I can do so much by exercising and<br />
having a healthy life style, but I also<br />
need effective medicine to lower my<br />
blood pressure,” Rin Fujima<br />
“We know that more than half of the patients who appear to have well-controlled blood pressure<br />
are not effectively protected when their blood pressure is measured over a 24-hour period,” notes<br />
Professor Toshiro Fujita, chairman of the department of internal medicine at the graduate school<br />
of medicine and faculty of medicine, University of Tokyo. “There is a need for patients to receive<br />
powerful blood pressure lowering treatments that work over the full 24-hour period,” he urges.<br />
“I can do so much by exercising and having a healthy life style,” says Rin, “but I also need effective<br />
medicine to lower my blood pressure. I’m convinced that my new treatment and my new way of life<br />
now complement each other. And I wake up refreshed like I used to.”<br />
Cardiovascular disease remains the No. 1 cause of death globally and is responsible for every one in<br />
three deaths worldwide – an estimated 17 million people a year. It is also a major cause of disability,<br />
and contributes significantly to the escalating costs of healthcare.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6
Human Pharmaceuticals<br />
Branded prescription<br />
medicines<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> is recognised as an innovative<br />
company which discovers, develops and markets<br />
new medications. We focus on the therapeutic<br />
needs of our ultimate customer, the patient.<br />
During <strong>2006</strong>, we continued to build and<br />
strengthen our clinical development programme<br />
by including nearly 40,000 patients in (Good<br />
Clinical Practice) clinical trials of phase I to IV.<br />
With these new patients included the number of<br />
patients actively engaged in clinical trials exceeded<br />
50,000 patients on average every day throughout<br />
the year.<br />
Currently, our focus is on the following therapeutic<br />
areas: respiratory diseases, central nervous<br />
system (CNS) diseases, virology, cardiovascular<br />
diseases, immunology/inflammation, oncology,<br />
metabolic diseases and urology.<br />
Top products<br />
Branded prescription medicines<br />
Net sales <strong>2006</strong> in millions of EUR change<br />
spiriva® 1,381 +45.2 %<br />
micardis® 967 +33.6 %<br />
flomax® 922 +27.8 %<br />
combivent® 671 +19.6 %<br />
mobic® 579 -31.8 %<br />
sifrol® 536 +23.4 %<br />
viramune® 276 -4.1 %<br />
atrovent® 263 +5.4 %<br />
aggrenox® 225 +30.9 %<br />
catapresan® 217 +23.7 %<br />
Respiratory diseases<br />
Respiratory diseases have long been a major focus<br />
area for <strong>Boehringer</strong> <strong>Ingelheim</strong> and we dedicate<br />
ample resources to research in this field. Our main<br />
objective in pulmonary research is to further<br />
improve treatment options for chronic obstructive<br />
pulmonary disease (COPD) and asthma.<br />
COPD and asthma<br />
COPD is currently the fourth most common cause<br />
of death, yet up to three-quarters of sufferers in<br />
Europe and 45 % in the USA go undiagnosed. This<br />
suggests a major unmet need for treatment for<br />
this debilitating lung disease.<br />
Americas<br />
xxxx<br />
The major cause of COPD is tobacco smoking. The<br />
disease is progressive with an ongoing decline in<br />
lung function, which results in increasing breathlessness,<br />
reduction in the capacity to exercise, and<br />
a subsequent diminishment of quality of life.<br />
of which: USA<br />
xxxx<br />
Sales of branded prescription medicines<br />
by therapeutic area<br />
Central nervous system<br />
9.8 %<br />
Muscoloskeletal/<br />
rheumatology<br />
7.7 %<br />
Gastrointestinal/<br />
metabolic 3.0 %<br />
Urology<br />
12.6 %<br />
HIV 4.4 %<br />
Others 1.9 %<br />
Cardiovascular<br />
23.5 %<br />
Respiratory<br />
37.1 %<br />
Prescription Medicines<br />
serving patients<br />
9
50<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>’s respiratory portfolio con<br />
sists of major COPD and asthma products:<br />
spiriva® (tiotropium bromide), combivent® (ipra<br />
tropium bromide / salbutamol) and atrovent®<br />
(ipratropium bromide).<br />
spiriva® is a oncedaily inhaled medicine recom<br />
mended for firstline regular treatment of COPD.<br />
It contains an anticholinergic agent which acts on<br />
airway constriction, a dominant mechanism in<br />
COPD. It opens the narrowed airways of COPD<br />
patients for a full 24 hours to help patients to<br />
breathe more easily, thereby positively impacting<br />
the clinical course of COPD and helping to change<br />
the way patients live with their disease. It is the<br />
first inhaled treatment to provide significant and<br />
sustained improvement in lung function with<br />
oncedaily dosing.<br />
In 2005, spiriva® became <strong>Boehringer</strong> <strong>Ingelheim</strong>’s<br />
first blockbuster medicine, that is one with annual<br />
turnover exceeding USD 1,000 million. spiriva®<br />
posted growth in net sales<br />
to EUR 1,400 million, or<br />
USD 1,700 million, in <strong>2006</strong>.<br />
spiriva® expanded its<br />
position as a global medication<br />
for COPD. With the<br />
successful launch of the<br />
product in France in <strong>2006</strong>,<br />
spiriva®, which is globally<br />
copromoted with Pfizer<br />
Inc., is now available to<br />
patients in most countries<br />
of the world. About six<br />
million patients affected<br />
by COPD worldwide have<br />
been treated with spiriva®<br />
in <strong>2006</strong>. This reflects<br />
the benefits spiriva®<br />
provides to COPD<br />
patients.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
spiriva® is a novel anticholinergic<br />
medicine<br />
recommended for firstline<br />
regular treatment of COPD.<br />
It is the first inhaled treatment<br />
to provide significant and<br />
sustained improvement in<br />
lung function over 24 hours<br />
with oncedaily dosing.<br />
Our clinical studies in respiratory diseases<br />
The year <strong>2006</strong> was highlighted by several important<br />
successes in the spiriva® clinical trial programme.<br />
The importance of spiriva® for the<br />
treatment of COPD was focused on by over 70<br />
publications, including review articles and<br />
abstracts. Several publications from primary and<br />
secondary data analyses were issued, including<br />
the publication of the oneyear mistral® trial in<br />
France in which spiriva® demonstrated significant<br />
reductions in COPD exacerbations.<br />
Important clinical trial data presented in <strong>2006</strong><br />
also demonstrated significant improvements in<br />
lung function in patients with milder disease<br />
symptoms and those diagnosed with both COPD<br />
and asthma. Both patient populations are considered<br />
important patient groups who may be under<br />
treated with required inhaled anticholinergics.<br />
uplift®, the global 6,000patient landmark study<br />
with spiriva®, is investigating the drug’s potential<br />
to impact the course of the<br />
disease by slowing the<br />
decline in pulmonary<br />
function, which is one of<br />
the devastating consequences<br />
of COPD. All<br />
parameters of good clinical<br />
trial conduct indicate<br />
that this study will successfully<br />
enter its last full<br />
year of followup in 2007<br />
and be completed in<br />
2008.<br />
On the basis of excellent<br />
clinical study results, the<br />
European label for<br />
spiriva® HandiHaler®<br />
was extended to include<br />
the improvement of physi
cal exercise capacity and the reduction of exacerbations<br />
in COPD. spiriva® is now the first COPD<br />
drug which incorporates information about exacerbations<br />
and exercise in a broad population of<br />
COPD patients on its label.<br />
spiriva® is currently delivered to patients via our<br />
HandiHaler® device. In future, patients will also<br />
be able to benefit from spiriva® delivered via<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>’s respimat® Soft Mist<br />
Inhaler (SMI), a novel propellant-free, multi-dose,<br />
inhaler that generates a slow-moving, long-lasting<br />
cloud (the soft mist) with a high fine particle<br />
fraction (less than 5.8 μm). As a result, deposition<br />
“I feel now like another man”<br />
“I have smoked for 30 years which has left me with chronic<br />
obstructive pulmonary disease,” says seventy-year-old Frenchman<br />
Jacques Luchier, a retired food industry bacteriologist. “The first<br />
time I met my pulmonary specialist and he told me I had very<br />
severe COPD, I was caught completely off guard. I was scared,<br />
as you think about death and that you’ll end up in a hospital bed<br />
with tubes everywhere to keep you alive.”<br />
COPD causes significant deterioration of lung function resulting<br />
in breathlessness, activity limitation and associated disability.<br />
Some 600 million people currently live with COPD, and the<br />
disease is projected to be the world’s third leading cause of death<br />
by 2020.<br />
serving patients<br />
Jacques Luchier started treatment with a novel bronchodilator.<br />
He also undertakes respiratory rehabilitation which consists of<br />
regular supervised exercise, education on COPD and its treatment,<br />
breathing techniques, as well as nutritional and psychological<br />
support.<br />
“The respiratory rehabilitation is very hard to cope with at the<br />
start. You have to really make an effort,” Jacques says. “But you<br />
get to improve your quality of life by inhaling the bronchodilator.<br />
You feel relief, you breathe better, you feel more yourself, you<br />
recover your spirits”. And he adds: “Now I feel like another man.<br />
I feel distinctly better. I feel less handicapped.”<br />
of the drug in the lungs is improved and less<br />
deposition occurs in the mouth and throat compared<br />
to pressurised metered dose inhalers. Attitudes<br />
of patients show a high level of satisfaction<br />
with this device.<br />
After completion of the pivotal studies for spiriva®<br />
in our propellant-free respimat® SMI we have<br />
submitted a registration file in the EU under the<br />
“decentralised procedure” and in addition in several<br />
other countries around the world. The completion<br />
of the US submission will be one of our<br />
key activities for 2007.<br />
Prescription Medicines<br />
1
Our R & D for respiratory diseases<br />
Our worldwide launch of spiriva® (tiotropium)<br />
provided a medication to improve COPD therapy<br />
and strengthened our leading position in this field.<br />
We are striving for further innovations by devel-<br />
oping bronchodilators with alternative mecha-<br />
nisms. These new bronchodilators are being for-<br />
mulated in innovative inhalation devices.<br />
In addition, <strong>Boehringer</strong> <strong>Ingelheim</strong> in <strong>2006</strong> entered<br />
into a worldwide collaboration, development and<br />
licence agreement with the British company<br />
Vectura. The aim of the collaboration is to develop<br />
a multi-dose dry powder inhaler as a <strong>Boehringer</strong><br />
<strong>Ingelheim</strong> branded device, to deliver a range of<br />
proprietary <strong>Boehringer</strong> <strong>Ingelheim</strong> respiratory<br />
products, mainly for the treatment of COPD and<br />
asthma. We currently have numerous bronchodilator<br />
programmes in development, six of them<br />
in clinical studies.<br />
Extending our product portfolio to drugs that<br />
target treatment of the underlying inflammation<br />
and the tissue remodelling process are further key<br />
goals in our COPD research. Inflammation in<br />
COPD patients is provoked by an infiltration of<br />
the lungs by macrophages and neutrophils.<br />
This is only poorly controlled by current, widelyused<br />
anti-inflammatory drugs, such as corticosteroids.<br />
We are therefore working on alternative<br />
anti-inflammatory mechanisms, specifically targeting<br />
macrophage and neutrophil-driven inflammation.<br />
In addition, we aim at preventing or delaying tissue<br />
remodelling that is induced by chronic inflammation<br />
by targeting lung growth factors. Two<br />
first-in-class mechanisms targeting mucous<br />
hyperplasia and fibrosis are being tested clinically.<br />
Beyond COPD, such new mechanisms have a<br />
therapeutic potential in idiopathic pulmonary<br />
fibrosis (IPF), a life-threatening disease, and in<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
severe asthma, where mucous plugging is considered<br />
the main cause of death.<br />
Our research in asthma is aimed at new mechanisms<br />
and immunological paradigms that would<br />
allow us to replace or reduce the doses of inhaled<br />
steroids by providing anti-inflammatory therapy<br />
better tolerated by patients. Another goal is to<br />
provide a new treatment for specific syndromes<br />
with high, unmet medical need, such as severe,<br />
steroid-resistant asthma.<br />
Diseases of the<br />
central nervous system<br />
According to World Health Organization (WHO)<br />
predictions, diseases of the central nervous system<br />
will constitute an increasing medical need in this<br />
century, attributable to an exponential increase of<br />
these diseases in patients beyond 65 years of age,<br />
combined with an aging population. To date,<br />
available therapeutic treatments are still unsatisfactory<br />
for the majority of CNS diseases.
“Like a great round of golf“<br />
“When in 2003 I faced my diagnosis of Parkinson’s disease, I tried to deal with it with the spirit of a true competitor,”<br />
says Cherie Zaun, a professional golfer from Glendale, California, USA. “Despite at first feeling helpless, I read up on<br />
everything about how to live with the disease and set out to battle it. I was still only in my early 50s.”<br />
“Today, I’m able to teach and play golf again. Living with Parkinson’s is not all that different from doing a great<br />
round of golf – it takes practice and determination,” Cherie explains. She is mother of three and former winner of<br />
the Virginia State Amateur Championship, former member of the Duramed Future Tour and one-time head coach<br />
for the University of Southern California Women’s Golf Team. She is still playing in some West Coast tournaments<br />
and qualifiers. For three years she has been taken a dopamine agonist for the treatment of Parkinson’s disease.<br />
“I’m exercising, too, finding yoga and golf especially helpful. But I do not want to just focus on my own health,”<br />
Cherie comments. “I’ve decided to take an active role in patient education. Together with <strong>Boehringer</strong> <strong>Ingelheim</strong><br />
I’ve developed patient materials specifically for people who have been recently diagnosed with Parkinson’s.<br />
And I act as spokeswoman for ‘Planning Your Course’, a patient education programme supported by <strong>Boehringer</strong><br />
<strong>Ingelheim</strong> and the US National Parkinson’s Foundation (NPF).”<br />
Diseases of the central nervous system (CNS) are<br />
one of the most important therapeutic areas for<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>. Our product portfolio con-<br />
sists of drugs for the treatment of Parkinson’s<br />
disease and restless legs syndrome (RLS), as well<br />
as for treatment of major depressive disorder<br />
(MDD) and diabetic peripheral neuropathic pain<br />
(DPNP).<br />
Parkinson’s disease and restless legs syndrome<br />
sifrol® / mirapexin® / mirapex® (pramipexole),<br />
a product from <strong>Boehringer</strong> <strong>Ingelheim</strong> research, is<br />
a dopamine agonist that was first approved in<br />
1997 for the treatment of the signs and symptoms<br />
of idiopathic Parkinson’s disease (PD), as monotherapy<br />
or in combination with levodopa.<br />
After a decade of treatment for Parkinson’s<br />
patients, a new key milestone was achieved with<br />
the approval of sifrol® / mirapexin® / mirapex®<br />
for the symptomatic treatment of moderate to<br />
severe idiopathic restless legs syndrome (RLS) in<br />
<strong>2006</strong>, both in the European Union and the USA.<br />
serving patients<br />
Pramipexole has significant efficacy on the key<br />
symptoms of restless legs syndrome (RLS) and<br />
beneficial effects on the symptoms frequently<br />
affecting RLS patients, such as daytime sleepiness,<br />
mood disturbance, and overall reduced quality of<br />
life. Patients often have difficulties in describing<br />
their symptoms, with sleep disturbance often<br />
being the most frequent reason why people with<br />
RLS seek medical advice. We expect that the<br />
impressive efficacy of RLS as shown in our clinical<br />
trial programme will favourably impact and<br />
strengthen the market position of sifrol®.<br />
sifrol® / mirapexin® / mirapex® continued to<br />
show strong growth in <strong>2006</strong> in the Parkinson’s<br />
disease indication, too. At the end of October<br />
<strong>2006</strong>, the brand ranked No. 6 among <strong>Boehringer</strong><br />
<strong>Ingelheim</strong>’s best-selling products, with total net<br />
sales of EUR 536 million, up 23 % against the<br />
same period in 2005. It is the world’s best-selling<br />
dopamine agonist, with a market share of more<br />
than 22 %. The estimated cumulative worldwide<br />
exposure since 1997 is 2.2 million patient years.<br />
Prescription Medicines
Our clinical studies in Parkinson’s disease<br />
and RLS<br />
The continued research interest in sifrol®/<br />
mirapexin® / mirapex® is reflected in a comprehensive<br />
phase IV clinical trials programme that is<br />
underway in both indications, PD and RLS, comprising<br />
more than 2,800 patients. It will investigate<br />
additional aspects of these diseases in an<br />
effort to provide data on the effects of sifrol® /<br />
mirapexin® / mirapex® in improving the quality<br />
of life in patients with these conditions. A study<br />
recently reported (Barone P. et al., J Neurol 253,<br />
601–607 [<strong>2006</strong>]) highlights the positive effects of<br />
sifrol® on depressive symptoms in patients with<br />
PD which we plan to confirm in further studies.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
Depression and diabetic peripheral<br />
neuropathic pain<br />
Major depressive disorder (MDD), a common disorder<br />
of complex, often recurring symptoms<br />
affecting the mind and body, can be life-threatening<br />
and certainly disabling, according to WHO<br />
research. The neuropathology of depression is not<br />
fully understood, but the two neurotransmitters,<br />
serotonin and noradrenalin, seem to play a major<br />
role in the development and course of the disease.<br />
cymbalta®/xeristar® (duloxetine hydrochloride)<br />
is a potent and balanced dual reuptake inhibitor<br />
of both serotonin and noradrenalin that provides<br />
rapid, sustained relief of the emotional and<br />
painful physical symptoms of depression and<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> is directing<br />
major efforts into its research<br />
and development of drugs for the<br />
treatment of diseases of the central<br />
nervous system. The most recent<br />
indication for which we gained<br />
market approval for our medication<br />
mirapex®/sifrol® was RLS.<br />
Characterised by a distressing urge<br />
to move the legs, RLS is usually<br />
associated with uncomfortable or<br />
sometimes painful sensations in<br />
the legs, with symptoms being<br />
worse at night and while at rest.
gives patients a better chance of getting well and<br />
staying well. A recently completed placebo-<br />
controlled study with duloxetine showed clear<br />
therapeutic effects of the drug on painful body<br />
symptoms in patients suffering from depression.<br />
This favourable profile of duloxetine can help to<br />
address an important aspect of the clinical<br />
symptoms of depression.<br />
Serotonin and noradrenalin also play a major role<br />
in the neuronal modulation of pain signals, sug-<br />
gesting a role for duloxetine. Through its exten-<br />
sive clinical programme, duloxetine has also been<br />
successfully developed for the treatment of<br />
diabetic peripheral neuropathic pain (DPNP), and<br />
in <strong>2006</strong> was launched in Germany, Mexico and<br />
Brazil in the DPNP indication.<br />
In November 2002, Eli Lilly and Company and<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> signed a long-term agree-<br />
ment to jointly develop and commercialise<br />
duloxetine. At year-end 2005, cymbalta® had<br />
been successfully launched in more than 20 co-<br />
promotion countries worldwide. In Germany,<br />
cymbalta® has been the most successful anti-<br />
depressant launch in the country to date. During<br />
<strong>2006</strong>, cymbalta® was launched in 11 additional<br />
countries in Europe, Latin America and Asia. Key<br />
<strong>2006</strong> milestones include <strong>Boehringer</strong> <strong>Ingelheim</strong>’s<br />
successful launch of xeristar® in the co-market-<br />
ing countries of Italy, Spain and Greece.<br />
To support continued medical education concern-<br />
ing these important and potentially debilitating<br />
diseases, <strong>Boehringer</strong> <strong>Ingelheim</strong> and Lilly hosted a<br />
series of educational events to raise awareness<br />
and understanding of depression and pain man-<br />
agement in Europe, Latin America and Asia.<br />
cymbalta® and xeristar® generated combined<br />
revenues of EUR 53 million, more than 100 %<br />
growth over 2005.<br />
Depression is one of the most<br />
frequent psychiatric disorders,<br />
but is often undiagnosed or is<br />
under-treated. This may be<br />
because up to about 70 % of<br />
patients later diagnosed with<br />
depression cite physical symptoms<br />
as the reason they initially<br />
visited their primary care<br />
physican. New data shows that<br />
cymbalta® (duloxetine hydrochloride)<br />
significantly reduced<br />
both painful and emotional<br />
symptoms of depression,<br />
resulting in an increased likelihood<br />
for patients to reach<br />
remission.<br />
Female hypoactive sexual desire<br />
disorder (FHSDD)<br />
Hypoactive sexual desire disorder (HSDD), a con-<br />
dition in which patients suffer from their decreased<br />
serving patients<br />
sexual desire, is the most common form of female<br />
sexual dysfunction. It is an important and defined<br />
medical condition that can be identified and diagnosed.<br />
Epidemiological studies indicate that up to<br />
one in five women suffer from decreased sexual<br />
desire.<br />
Over 60 % of the patients are moderately to<br />
extremely distressed because of their low desire.<br />
Flibanserin, a centrally active compound with a<br />
unique mechanism of action, is a novel approach<br />
for the treatment of decreased sexual desire in premenopausal<br />
women. The medical definition for<br />
the condition is hypoactive sexual desire disorder<br />
(HSDD) with marked distress and or interpersonal<br />
difficulties. Thus focusing on this condition, four<br />
phase III studies have been initiated. One of them<br />
has already fully recruited more than 1,000<br />
Prescription Medicines
patients. High interest to participate in these<br />
studies supports our understanding that there is<br />
substantial medical need and patient demand. We<br />
expect the phase III programme to run until 2008<br />
and provide us with pivotal results for registra-<br />
tion.<br />
Our R & D in CNS<br />
Our research in CNS diseases focuses on novel<br />
treatment concepts for the major neurodegenera-<br />
tive disorders, Alzheimer’s and Parkinson’s<br />
disease, both being prominent consequences of<br />
the ageing population. Our research efforts to<br />
interfere with disease progression in Alzheimer’s<br />
and Parkinson’s disease focus on targets estab-<br />
lished by pathohistology and genetics.<br />
Moreover, we are investigating approaches for<br />
reducing treatment-induced motor complications<br />
(dyskinaesias), a major medical problem for patients<br />
with late stage Parkinson’s disease. Our activities<br />
in Alzheimer’s disease are, for example, aimed at<br />
reducing amounts of the amyloid-beta peptide,<br />
the major mediator of this fatal disorder, and<br />
additionally searching for pro-cognitive therapies<br />
beyond acetylcholine restoration in this disease.<br />
In order to expand these approaches, we have<br />
entered into an exclusive worldwide collaboration<br />
and license agreement with the Belgian company<br />
Ablynx to discover and develop new therapies for<br />
Alzheimer’s disease, using Nanobodies®, a novel<br />
class of therapeutic proteins.<br />
An additional focus lies on chronic pain, a condition<br />
for which medical attention is sought most<br />
frequently, yet satisfactory treatment options are<br />
still limited. New molecular targets, such as ion<br />
channels and G-protein coupled receptors<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
(GPCRs), which are involved in pain transduction<br />
pathways and have been validated in neuropathic<br />
and inflammatory pain models, form the basis for<br />
our drug discovery efforts in the chronic pain<br />
indication. Our drug discovery activities in the<br />
indication migraine address a new mechanism of<br />
action to interfere with cerebral vasodilatation for<br />
which we were the first research group to obtain<br />
clinical proof of concept.<br />
Virology<br />
Antiviral therapies for many serious, life-threatening<br />
chronic and acute viral diseases are lacking<br />
or are unsatisfactory. New antiviral therapeutics<br />
for the treatment of the human immunodeficiency<br />
virus type 1 (HIV-1) and the hepatitis C virus<br />
(HCV) are therefore in the focus. These two pathogens<br />
have each emerged epidemically in recent<br />
decades, infecting millions of people globally.<br />
HIV/AIDS<br />
In <strong>2006</strong>, the AIDS pandemic continued to grow.<br />
Now about 40 million people are infected with<br />
HIV. <strong>Boehringer</strong> <strong>Ingelheim</strong> aims at improving<br />
HIV/AIDS therapy by providing physicians and<br />
patients with innovative antiretroviral (ARV)<br />
drugs.<br />
aptivus® (tipranavir), a non-peptidic protease<br />
inhibitor, blocks the viral protease, an enzyme<br />
needed to complete HIV replication. In co-administration<br />
with low dose ritonavir, aptivus® is<br />
indicated for combined antiretroviral treatment of<br />
HIV infection in highly treatment-experienced<br />
(HTE) patients with resistance to multiple protease<br />
inhibitors (PI).
aptivus® was launched in the USA in July 2005<br />
and in the EU in November 2005, reaching net<br />
sales of EUR 53 million in <strong>2006</strong>.<br />
viramune® (nevirapine), which posted net sales<br />
of EUR 276 million in <strong>2006</strong>, was the first com-<br />
pound of the class of non-nucleoside reverse<br />
transcriptase inhibitors (NNRTI) to be launched<br />
in 1996 as a powerful component of combination<br />
therapy of HIV-1 with a favourable long-term<br />
tolerability. This product is now available in some<br />
100 countries, making it one of the most widely<br />
used compounds in chronic HIV-1 therapy worldwide.<br />
viramune® has also been demonstrated to be<br />
beneficial alone as a single oral dose in preventing<br />
transmission of HIV-1 from the infected mother<br />
to the newborn. A single dose administered to the<br />
mother during labour and a single dose to the<br />
infant after birth has shown to significantly reduce<br />
Since the introduction of HAART (highly active<br />
antiretroviral retroviral therapy) in the late 1990s, mortality<br />
due to AIDS has been dramatically reduced in<br />
the western world. In these countries HAART –<br />
normally a combination therapy consisting of<br />
three antiretroviral drugs – has transformed formed the<br />
life-threatening disease into a chronic illness.<br />
Thus the goal of the therapy can be now<br />
defined as: prolonging the the patient’s life, while<br />
maintaining taining the best possible quality quality of health health<br />
and life. However, up to now it has not been<br />
possible to eradicate the virus from the body.<br />
The patient therefore therefore has to undergo a lifelong<br />
treatment.<br />
the HIV transmission rate. This simple and effective<br />
treatment, also tested successfully in combination<br />
with zidovudine/lamivudine, has particular<br />
value in the healthcare setting of developing<br />
countries, and as such is recommended by the<br />
WHO (see also page 10).<br />
For more information, please visit the website<br />
www.pmtctdonations.org<br />
serving patients<br />
Our clinical studies and R & D in virology<br />
After the worldwide introduction of aptivus®,<br />
physicians had a powerful therapeutic to treat<br />
HIV patients with highly resistant virus. The superiority<br />
of aptivus® over a group of comparator PI’s<br />
in our resist trials was the basis for accel-<br />
erated, conditional approval in the<br />
USA and the EU in 2005. In<br />
the meantime, long-term<br />
Prescription Medicines
maintenance data with controlled observation of<br />
up to 96 weeks have become available. The supe-<br />
rior efficacy over the ongoing comparator treat-<br />
ment is fully maintained both for aptivus® with<br />
two other active antiretroviral drugs and aptivus®<br />
in combination with new drugs as for example<br />
the injectable enfurvitide. Both in the USA and in<br />
Europe we have submitted long-term follow-up<br />
data together with additional phase IV study<br />
results and expect traditional approval in the USA<br />
in 2007.<br />
“I just cannot believe it ...<br />
... I didn’t think I would survive the year,” says Meike Nörder<br />
(right), a 41-year-old former cook from the north German<br />
town of Oldenburg.<br />
“I’ve been HIV-positive for 16 years. The debilitating effects<br />
of the infection, and long-term multiple resistance to drug<br />
treatments, have made normal life impossible for me, but<br />
I still keep home for my partner and our teenage son,” says<br />
Meike about her situation. “Over the years, I’ve taken a<br />
number of different treatment regimens which did not<br />
sufficiently control my viral load to an undetectable level<br />
and have rendered the virus resistant to many anti-HIV<br />
medications.”<br />
In <strong>2006</strong>, she began to take a novel protease inhibitor. Her<br />
new HIV treatment – in conjunction with other anti-AIDS<br />
drugs – brought significant improvement in key virus<br />
counts. “Within a month, my viral load dropped below<br />
the measurable limit for the first time. When I heard this<br />
news I was speechless.”<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
Our R&D activities in HIV aim at developing new<br />
treatment options for all HIV patients, but espe-<br />
cially those who have failed prior therapy due to<br />
the development of drug resistance. Our research<br />
in this area has identified a new NNRTI as a fol-<br />
low-up to our existing HIV treatment viramune®.<br />
Moreover, our discovery efforts are addressing<br />
several novel targets for future HIV therapy.<br />
Our hepatitis C virus research is directed toward<br />
identifying inhibitors targeting essential viral<br />
“Naturally, I do experience side effects, including tiredness.<br />
But the side effects are all tolerable and bearable,”<br />
she notes. “The rapid recovery of my immune system was<br />
a real surprise for me and brought to halt an HIV-specific<br />
encephalopathy, unlike in the previous two winters when<br />
my immune cell levels were low and made me susceptible<br />
to infections. My CD4 T-lymphocyte cell count went from<br />
13 % in February <strong>2006</strong> immediately before the new treatment<br />
began to 18 % in May. By September it was up to<br />
24 %. Over the same period my viral load dropped from<br />
32,600 to below 47.”<br />
Meike says: “I’ve not only found renewed hope concerning<br />
my own health. I’m also actively promoting AIDS awareness,<br />
visiting schools and other institutions in my region<br />
to tell of my own experiences of living with HIV and drug<br />
resistance.”
enzymes, such as the HCV serine protease and<br />
RNA polymerase. Such new mechanisms offer the<br />
potential for new therapies with improved safety<br />
and efficacy compared to current treatments of<br />
chronic hepatitis C.<br />
Our virology drug discovery group in Laval has<br />
developed compounds with an alternative mode<br />
of action for the treatment of HCV infection. In<br />
clinical trials in infected patient volunteers, we<br />
established the short-term-efficacy for a new anti-<br />
viral principle and have one other compound in<br />
clinical phase I.<br />
Our ongoing activities in HCV continue to exploit<br />
these antiviral targets together with other novel<br />
approaches and are complemented by partnering<br />
efforts. In <strong>2006</strong>, we initiated a collaboration with<br />
the Australian company Biota to jointly discover<br />
and develop Biota’s novel nucleoside analogues<br />
designed to treat HCV infections and other<br />
diseases.<br />
serving patients<br />
Prescription Medicines<br />
9
Top Story: Actilyse
Børge Madsen, Copenhagen, Denmark.<br />
Thanks to rapid treatment he fully recovered from a stroke.
“I was fortunate to get the right treatment<br />
promptly and efficiently at the local hospital.<br />
My recovery came fast. Only three days after<br />
being admitted, I was able to leave hospital.”<br />
Børge Madsen<br />
“My recovery came fast”<br />
“I was making a cup of coffee in my kitchen on 1 May <strong>2006</strong> when I had a stroke. Luckily,<br />
my wife Lis came home a little later with the grandchildren. She found me paralysed and<br />
unable to speak. Straight away she called the emergency services and an ambulance<br />
quickly transferred me to the local hospital,” says Børge Madsen, a 64-year-old retired<br />
schoolteacher from Copenhagen. After a neurological examination and an immediate brain<br />
scan, he was given a thrombolytic therapy to treat the stroke.<br />
An ischaemic stroke occurs when a blood clot blocks a blood vessel in the brain, interrupting<br />
blood flow to an area of the brain, killing cells in the immediate vicinity from within minutes<br />
to a few hours after the stroke. The time it takes to transport stroke patients to hospital<br />
is decisive to their recovery, or even their survival. But the administration of a thrombolytic<br />
agent is only the first step. Careful further treatment and therapy in a hospital also has a<br />
crucial impact on the health and recovery of the patient.<br />
“I was fortunate to get the right treatment promptly and efficiently at the local hospital,”<br />
Børge says. “My recovery came fast. By around noon, I felt I was regaining the ability<br />
to move my fingers. Later that day, I was able to write. It was fantastic. Only three days<br />
after being admitted, I was able to leave hospital.”<br />
“My relatively good health played a significant role,” Børge says. “I’ve been physically active<br />
all my life and always played football, most recently with the old boys. And I used to work<br />
as a voluntary sports journalist for the local newspaper. Okay, I was a bit overweight and my<br />
blood pressure was a little too high. But otherwise I was fit. And I always have been. The<br />
doctors also tell me that this has helped me.”<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6
Cardiovascular diseases<br />
Despite significant advances in the understanding<br />
and treatment of cardiovascular disease, it remains<br />
the leading cause of premature death in western<br />
societies and is predicted to become the most<br />
common cause of premature death worldwide<br />
within the next decade.<br />
Our product portfolio consists of drugs for the<br />
treatment of hypertension, acute myocardial<br />
infarction and treatment of acute massive pulmonary<br />
embolism, as well as stroke treatment and<br />
prevention.<br />
Hypertension and cardiovascular protection<br />
Hypertension is a major risk factor for cardiovascular<br />
morbidity and mortality. The organs at risk<br />
are primarily the heart, the main blood vessels,<br />
the brain and the kidneys. Furthermore, it is<br />
strongly linked to stroke and heart attack as well<br />
as other associated clinical conditions.<br />
Approximately 1 billion people are affected by<br />
hypertension worldwide. The prevalence of essential<br />
hypertension increases steadily with age. As<br />
the population as a whole ages, the prevalence of<br />
hypertension will increase even further.<br />
The primary goal of antihypertensive treatment is<br />
to reduce the long-term total risk for cardiovascular<br />
morbidity and mortality. To achieve this,<br />
current evidence suggests that blood pressure<br />
values should be targeted as low as possible.<br />
micardis® offers powerful 24-hour<br />
blood pressure control. Despite<br />
treatment options, some 80 % of<br />
hypertensive patients in the USA and<br />
Western Europe remain untreated.<br />
Beyond antihypertensive treatment, the aim of<br />
additional cardiovascular protection requires<br />
serving patients<br />
treatment of all identified risk factors and associ-<br />
ated clinical conditions accessible by therapeutic<br />
approaches and/or changes in lifestyle.<br />
With micardis® (telmisartan), our angiotensin II<br />
receptor blocker (ARB), and micardisplus®/<br />
micardis® hct (telmisartan in a fixed dose combination<br />
with the diuretic hydrochlorothiazide),<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> offers two innovative<br />
options and flexibility for the treatment of essential<br />
hypertension. micardis® has the longest halflife<br />
in the ARB class and a high affinity for the<br />
angiotensin-I receptor, providing powerful blood<br />
pressure control over 24 hours with a once-daily<br />
dosage, including the early morning hours when<br />
blood pressure surges.<br />
micardis® / micardisplus® / micardis® hct<br />
generated net sales of EUR 967 million in <strong>2006</strong>,<br />
representing growth of 34 %. This made it our<br />
second biggest prescription medicine and secured<br />
it blockbuster status.<br />
Our clinical studies in hypertension<br />
and cardiovascular protection<br />
The micardis® landmark trials in cardiovascular<br />
protection, ontarget and transcend®,<br />
Prescription Medicines
continued to perform according to our best expec-<br />
tations with excellent patient retention and no<br />
concern from safety review board assessments.<br />
For both trials we are setting up all necessary<br />
logistics to recruit more than 30,000 cardiovascu-<br />
lar high-risk patients within a short time period at<br />
the end of 2007 and in early 2008.<br />
In parallel to the ongoing ontarget and<br />
transcend® studies, the protection® programme<br />
was concluded in hypertension. amadeo was<br />
the last in a series of studies involving 6,500<br />
patients in 32 countries. All studies were positive<br />
and the protection® programme showed a bene-<br />
ficial effect of micardis® and micardisplus®/<br />
micardis® hct on renal organ protection in<br />
hypertensive patients, also when compared to<br />
other established therapies.<br />
Acute myocardial infarction<br />
Every year, approximately three million people<br />
worldwide suffer from acute myocardial infarc-<br />
tion (AMI), or heart attack. However, only about<br />
47 % are diagnosed and treated. The most impor-<br />
tant factor for a successful treatment of AMI is<br />
time to treatment. Thrombolytic therapy is established<br />
as one of the most successful modern<br />
AMI treatment options, in particular in patients<br />
in whom percutaneous transluminal coronary<br />
angiography (PTCA) cannot be performed within<br />
90 minutes after first medical contact.<br />
metalyse® (tenecteplase) is the only thrombolytic<br />
to be administered as a single bolus for the thrombolytic<br />
treatment in AMI for patients, in whom a<br />
coronary intervention cannot be performed. With<br />
its ease of administration, thrombolysis with<br />
metalyse® is very well suited for pre-hospital and<br />
in-hospital thrombolysis to keep the time from<br />
the onset of symptoms to effective treatment as<br />
short as possible.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> AnnuA l RepoR t <strong>2006</strong><br />
actilyse® (alteplase) is also indicated for the<br />
thrombolytic treatment in AMI as well as in<br />
thrombolytic treatment in acute massive<br />
pulmonary embolism with haemodynamic<br />
instability. actilyse® is also approved for the<br />
treatment of acute ischaemic stroke.<br />
In <strong>2006</strong>, both products continued to be leaders<br />
in their class and posted combined net sales of<br />
EUR 159 million.<br />
Stroke treatment and prevention<br />
Stroke is one of the leading causes of death<br />
and disability in the developed world. The<br />
WHO estimates that 5.1 million people die<br />
from stroke each year.<br />
Almost one in four men and one in five women<br />
aged 45 can expect to have a stroke, if they live<br />
to their 85th year. A stroke occurs when a<br />
blood clot blocks an artery in the brain (ischaemic<br />
stroke), or when a blood vessel ruptures<br />
(haemorrhagic stroke), interrupting blood flow<br />
to an area of the brain. A stroke kills brain<br />
cells in the immediate area beginning a few<br />
minutes after onset.<br />
metalyse® is indicated for the<br />
treatment of acute mycardial<br />
infarction. It is in particular<br />
suitable for patients in whom<br />
a coronary intervention can<br />
not be performed. It can also<br />
be administered as a prehospital<br />
lysis in the ambulance.
actilyse® is the first and only thrombolytic indi-<br />
cated for treatment of acute ischaemic stroke<br />
within three hours after symptom onset. Addi-<br />
tionally, the company is currently investigating<br />
the efficacy of actilyse® within the 3 –4.5 hour<br />
time window through the ecass 3 trial which, if<br />
positive, will allow a larger proportion of patients<br />
to benefit from treatment.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> is also the sole sponsor of<br />
sits-most. This is the largest international stroke<br />
registry with the objective of optimising the<br />
thrombolytic treatment of acute stroke and providing<br />
a benchmarking tool for best practice for<br />
treating stroke patients worldwide. The laudable<br />
results of the sits-most study, which enrolled<br />
6,483 patients from 285 European centres, have<br />
confirmed the safety and efficacy of actilyse® for<br />
“I didn’t let a stroke stop me”<br />
“I suffered the first stroke in 2003 at a training camp in Tashkent,<br />
Uzbekistan. Two more followed in Germany. I was paralysed on one<br />
side and I couldn’t speak,” recounts German national wrestling team<br />
trainer Alexander Leipold. The former national, European and world<br />
title-holder says with good humour: “When fate strikes, it often picks<br />
me out. But I wasn’t going to let a stroke stop me from leading an<br />
active life.”<br />
serving patients<br />
After rehab at the Medical Park Bad Rodach and treatment with a<br />
medication for reducing the risk of further strokes, Alexander, at 35,<br />
resumed his wrestling career in 2003, winning acclaim from leading<br />
German sportsmen. In 2005, he won the world masters title for<br />
wrestlers over 35 years of age in Teheran, Iran. The same year, he also<br />
switched to his current role as trainer.<br />
Alexander lives with his wife and two children in the German state of<br />
Bavaria. “But apart from my sport, I’m also keen to help others fight<br />
strokes, too”, he says. “This is the reason why I work as an ambassador<br />
for German Stroke Aid.”<br />
acute stroke treatment as demonstrated in the<br />
previous pooled randomised trials. This was published<br />
in the Lancet at the beginning of 2007.<br />
aggrenox®/asasantin® retard/(extended<br />
released dipyridamole + acetyl salicylic acid (ASA))<br />
is indicated to reduce the risk of secondary stroke<br />
in patients who have had a transient ischaemicattack<br />
(TIA) or completed ischaemic stroke due to<br />
thrombosis. It generated net sales of EUR 225 million<br />
in <strong>2006</strong> with a growth of 31 %.<br />
The use of aggrenox®/asasantin® retard as a<br />
first-line treatment for secondary stroke prevention<br />
is recommended in many international<br />
guidelines, such as those issued by the European<br />
Stroke Initiative (EUSI), the UK’s National<br />
Institute of Health and Clinical Excellence (NICE),<br />
Prescription Medicines
the American College of Chest Physicians (ACCP),<br />
as well as the recently issued joint guidelines of<br />
the American Heart and Stroke Association (AHA/<br />
ASA).<br />
For more information please visit the website:<br />
www.stroke-forum.com<br />
Our clinical studies in stroke prevention<br />
profess®, one of <strong>Boehringer</strong> <strong>Ingelheim</strong>’s landmark<br />
studies, has concluded recruitment with<br />
20,300 patients enrolled. It had been designed to<br />
confirm the efficacy, and potentially demonstrate<br />
the superiority, of aggrenox® over clopidogrel<br />
prove as well as to the additional protective benefits<br />
of our ARB micardis® in the prevention of<br />
secondary stroke. As profess® is proceeding to<br />
plan, we foresee final recruitment of patients and<br />
availability of results in 2008.<br />
The independent esprit study (European/<br />
Australasian Stroke Prevention in Reversible<br />
Ischaemia Trial) on prevention of secondary<br />
stroke was published in Lancet, <strong>2006</strong>; 367: 1665–<br />
1673. It found superior efficacy of dipyridamole<br />
extended release in combination with ASA versus<br />
ASA alone. These results with a 20 % risk reduction<br />
for stroke over ASA alone in the ESPRIT<br />
study are in line with our own ESPS 2 results and<br />
support our expectation in favour of a positive<br />
outcome of profess®.<br />
Treatment and prevention of thrombo-embolic<br />
diseases<br />
Our presently largest phase III programme is for<br />
dabigatran etexilate, an oral direct thrombin<br />
inhibitor that we are developing for the prevention<br />
and treatment of thrombo-embolic disease.<br />
Dabigatran is the frontrunner of all new oral anticoagulants<br />
currently being developed, and is<br />
being investigated in the primary prevention of<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
Promising new drug<br />
for blood clot prevention<br />
Therapeutic options for preventing thrombo-embolic diseases<br />
remain limited, despite their being among the most common<br />
causes of death in the aging societies of the industrialised<br />
world.<br />
The anticoagulant dabigatran etexilate, a new direct thrombin<br />
inhibitor discovered and developed by <strong>Boehringer</strong> <strong>Ingelheim</strong>,<br />
holds out the promise of a new drug to fulfil the unmet<br />
therapeutic need.<br />
The most commonly used oral anticoagulant has been<br />
warfarin. Dabigatran etexilate specifically and reversibly<br />
inhibits thrombin, one of the key enzymes for blood clot<br />
formation. It is administered in a fixed dose and has a rapid<br />
onset of action, providing a consistent anticoagulation<br />
effect without the need for time-consuming coagulation<br />
monitoring and dose adjustment.<br />
Major indication areas will be stroke prevention in atrial<br />
fibrillation, the most common form of cardiac arrhythmia,<br />
prevention of deep vein thrombosis (DVT) after hip or knee<br />
replacement surgery, acute DVT treatment and secondary<br />
prevention of DVT.<br />
deep vein thrombosis (DVT) after hip or total knee<br />
replacement, the treatment of acute DVT, the<br />
secondary prevention of DVT and the long-term<br />
prevention of thrombo-embolic events (stroke) in<br />
patients with atrial fibrillation. The phase III trial<br />
programme has been initiated with a group of<br />
studies combined under the umbrella of the<br />
re-volution® programme. With more than<br />
27,000 patients re-volution® is the largest<br />
clinical trial programme in thrombo-embolic<br />
disease.<br />
With studies in all indications successfully imple-<br />
mented, the two indications we advanced most<br />
were the post-surgery prevention of DVT and<br />
stroke prevention in atrial fibrillation. We have<br />
launched a 15,000-patient study (rely) in atrial
fibrillation in some 40 countries involving almost<br />
1,000 study centres. By the end of <strong>2006</strong>, more<br />
than 8,000 patients have been recruited, exceed-<br />
ing our plan by far.<br />
For the prevention of DVT post-orthopaedic sur-<br />
gery pivotal studies have been completed and the<br />
first submission for Europe has been completed.<br />
Additional study results will become available<br />
during 2007 to complement the dataset for a later<br />
US submission file.<br />
Our R & D in cardiovascular diseases<br />
Continuing research efforts in the thrombo-<br />
embolic area resulted in compounds with alterna-<br />
tive anti-thrombotic mechanisms, which also<br />
recently entered clinical development where their<br />
efficacy-safety profile is being compared to that of<br />
direct thrombin inhibitors. We will continue to<br />
develop our cardiovascular research platform in<br />
the area of atherothrombosis and widen our<br />
research to include heart failure.<br />
These research programmes are facilitated by the<br />
use of in vivo imaging studies and enhanced by<br />
external collaborations with academic and bio-<br />
technology industry partners.<br />
Our cardiovascular research programmes also<br />
benefit from close collaboration with scientists<br />
working in related therapeutic areas, such as<br />
metabolic diseases and immunology and inflam-<br />
mation, in order to increase the opportunities for<br />
developing novel therapeutic agents for the fight<br />
against cardiovascular disease.<br />
Immunologic /<br />
inflammatory diseases<br />
Despite advances in treatment, there remains a<br />
large unmet medical need for safe and efficacious<br />
treatments for autoimmune diseases. Our drug<br />
discovery in these therapeutic areas places an<br />
emphasis on gaining a mechanistic understanding<br />
of rheumatoid arthritis, multiple sclerosis and<br />
psoriasis disease processes.<br />
Rheumatic arthritis / osteoarthritis<br />
Rheumatoid arthritis is an autoimmune disease<br />
that affects the body as a whole and may lead to<br />
joint destruction. Osteoarthritis is the most<br />
commonly diagnosed degenerative disease affect-<br />
ing the joints, especially in elderly people. Signs<br />
and symptoms of osteoarthritis can include joint<br />
stiffness, often with a sensation of grinding in the<br />
affected joint.<br />
mobic®/mobec® (meloxicam) is indicated for the<br />
symptomatic treatment of osteoarthritis and<br />
rheumatoid arthritis as well as ankylosing spon-<br />
dylitis (Morbus Bechterew).<br />
The patent exclusivity period in the USA for the<br />
drug ended in July <strong>2006</strong>, and the market entry of<br />
generics resulted in major sales losses for this<br />
product. mobic®/mobec® generated net sales of<br />
EUR 577 million in <strong>2006</strong>.<br />
Our R & D in immunologic<br />
and inflammatory diseases<br />
Together with experts in the field, we are gaining<br />
greater insights into the biology of autoimmune<br />
diseases with a view to identifying novel drug<br />
targets. For example, certain cells play a key role<br />
in perpetuating the inflammation and resulting<br />
tissue destruction observed in the joints of<br />
rheumatoid arthritis patients by secreting<br />
cytokines and other inflammatory mediators.<br />
As a means to identify key pathways operating in<br />
these cells, we have established collaborations to<br />
screen for modulators which may be drug targets<br />
that could form the basis of novel therapies.<br />
Current approaches targeting autoimmune disease<br />
serving patients<br />
Prescription Medicines
include diverse mechanisms that are being<br />
addressed with both small molecules as well as<br />
protein-based therapeutics.<br />
Our activities in the area of new biological entities<br />
(NBEs) have been further strengthened by enter-<br />
ing into a collaborative research and licence<br />
agreement with the US-based biotech company<br />
FivePrime Therapeutics with the goal of discover-<br />
ing novel therapeutic protein products to treat<br />
rheumatoid arthritis and other inflammatory<br />
diseases. Promising new small molecule therapies<br />
are currently being tested in clinical trials to<br />
establish their effectiveness for psoriasis and multiple<br />
sclerosis. By gaining a mechanistic understanding<br />
of immune disease, we can identify those<br />
mechanisms that are also relevant for the pathology<br />
of other diseases and thus expand the<br />
promise of new immunological therapies to additional<br />
medical conditions.<br />
The combination of our current focus on disease<br />
mechanisms, our efforts directed to the identification<br />
of novel drug targets and our expansion into<br />
protein-based therapeutics is maximising our<br />
ability to deliver promising new therapeutic<br />
options for patients suffering from autoimmune<br />
diseases.<br />
Urology<br />
In <strong>2006</strong>, <strong>Boehringer</strong> <strong>Ingelheim</strong>’s product port-<br />
folio in urologic diseases consisted of drugs to<br />
treat benign prostate hyperplasia (BPH) and stress<br />
urinary incontinence.<br />
Benign prostate hyperplasia<br />
The incidence of benign prostate hyperplasia (BPH)<br />
increases with age. Symptomatic BPH in general occurs<br />
in approximately 25 % of men over 40 and in one of<br />
every three men over 65. flomax®/alna® (tamsulosin),<br />
an alpha receptor blocker that has been established<br />
as a standard first-line treatment of BPH symptoms,<br />
is the most widely prescribed medication for them.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> AnnuA l RepoR t <strong>2006</strong><br />
Lower urinary tract symptoms (LUTS) suggestive<br />
of BPH are the most common urological condi-<br />
tion in older men. BPH is characterised by the<br />
presence of several urinary symptoms that can be<br />
related to bladder emptying (voiding or obstructive<br />
symptoms) or filling (storage or irritative<br />
symptoms).<br />
Typical voiding symptoms are hesitancy, weak<br />
stream and intermittency. Typical storage symptoms<br />
are increased daytime frequency, nocturia<br />
and urgency. Nocturia, i.e. awakening one or more<br />
times at night for voiding, reduces the quality of<br />
sleep of the patient and has a significant negative<br />
impact on how the patient feels the next day in<br />
terms of energy level/fatigue, concentration and<br />
mood (sometimes the patient may even get<br />
depressed) and ultimately his overall well-being<br />
and quality of life.
Treatment modalities used to relieve bothersome<br />
LUTS/BPH are designed to reduce the static and/<br />
or dynamic component of obstruction and to<br />
improve the quality of life.<br />
Pharmacological therapy with flomax®/alna®<br />
(tamsulosin), an α1-receptor antagonist, is<br />
indicated for the treatment of this condition and<br />
provides effective and well-tolerated improve-<br />
ment of the symptoms. It relieves obstruction by<br />
relaxing smooth muscles in the prostate and<br />
urethra improving voiding symptoms. It also<br />
improves storage symptoms in which bladder<br />
instability plays an important role.<br />
After the launch of the 0.4 mg capsule in 1996,<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> and its partner Astellas<br />
developed a new tablet formulation using the<br />
technology ocas® (Oral Controlled Absorption<br />
System) to further optimise pharmacological<br />
therapy for LUTS/BPH.<br />
This system provides effective symptom control<br />
during daytime and nighttime, a very good tolerability<br />
and excellent convenience for the patient<br />
(e.g. once-daily dosing without the need of dose<br />
adjustment, medication intake independent of<br />
meals).<br />
flomax®/alna®, using the ocas® technology, has<br />
been available since 2005 in Germany, Spain and<br />
Switzerland. In <strong>2006</strong>, it was launched in Portugal,<br />
France, Canada and Greece.<br />
The capsule formulation started to lose patent<br />
protection in several countries in March <strong>2006</strong>. In<br />
the USA, patent protection will continue until<br />
October 2009. flomax®/alna® capsules and<br />
ocas® tablets generated net sales of EUR 922<br />
million, an increase of 28 % over 2005, placing the<br />
medication third in <strong>Boehringer</strong> <strong>Ingelheim</strong>’s<br />
Human Pharmaceuticals sales ranking.<br />
Stress urinary incontinence<br />
Stress urinary incontinence (SUI) is the involun-<br />
tary loss of urine on effort or exertion, or on<br />
sneezing or coughing. Around 97 % of SUI patients<br />
are female, but less than half of the women suf-<br />
fering from this condition seek treatment.<br />
yentreve®/ariclaim®, with the active ingredient<br />
of duloxetine, is approved in the EU for the treat-<br />
ment of women with moderate to severe SUI. In<br />
<strong>2006</strong>, it was jointly commercialised in several<br />
European countries and Mexico by Eli Lilly and<br />
Company and <strong>Boehringer</strong> <strong>Ingelheim</strong>. yentreve®/<br />
ariclaim® generated revenues of EUR 4 million<br />
in <strong>2006</strong>.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> and Eli Lilly and Company<br />
(USA) jointly decided in February <strong>2006</strong> to change<br />
the contractual agreements for yentreve®/<br />
ariclaim®. Eli Lilly and Company took over sole<br />
worldwide commercialisation rights for the medi-<br />
cation for SUI and potential future, related urinary<br />
incontinence indications, effective as of 15 Janu-<br />
ary 2007.<br />
Oncology<br />
Every year, more than ten million people find<br />
themselves grappling with the medical uncertainties<br />
and emotional upheaval of a newly diagnosed<br />
cancer. Fortunately, an increasing number of<br />
patients benefit from surgery, radiation and<br />
pharmacological medicines, with a complete cure<br />
possible in about 60 % of cases. If the cancer has<br />
spread throughout the body, the hurdles for<br />
effective therapies become higher, but even then<br />
serving patients<br />
cure or disease modification with longer survival<br />
and better quality of life is possible with innovative,<br />
targeted medicines that offer more efficacy<br />
and better tolerability to patients.<br />
Prescription Medicines<br />
9
0<br />
Our clinical studies in oncology<br />
We have embarked on the discovery and develop-<br />
ment of innovative medicines for some of the most<br />
common cancers. Since 2000, research conducted<br />
at <strong>Boehringer</strong> <strong>Ingelheim</strong> Austria has resulted in<br />
promising drug candidates moving into advanced<br />
clinical development. We are conducting clinical<br />
studies of phase II for compounds interfering<br />
with essential drivers of tumour growth: A) aber-<br />
rant growth signalling through activity of epider-<br />
mal growth factor receptor (EGFR) and human<br />
epidermal growth factor (HER 2), B) supply of<br />
oxygen and nutrients to cancer cells by the development<br />
of new blood vessels to the tumour (neoangiogenesis),<br />
and C) targeting inhibition of the<br />
uncontrolled cell division (mitosis).<br />
Current phase I / II target indications for our oral<br />
compounds in antiangiogenesis and signal transduction,<br />
and our intravenous cell-cycle inhibitor,<br />
include non-small-cell lung cancer, breast cancer,<br />
colorectal cancer, prostate cancer, ovarian cancer,<br />
leukaemia and lymphomas.<br />
We are confident that the continued good patient<br />
accrual into our phase II studies will allow us to<br />
establish first proofs of efficacy towards the end of<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
Cell-cycle kinases are cellular<br />
proteins that promote the<br />
process of cell division.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>’s first-inclass<br />
investigational compound<br />
BI 2536 (light blue) seems to<br />
effectively block such a cell-cycle<br />
kinase (the polo-like kinase,<br />
Plk-1) at its active site, leading<br />
to tumour growth inhibition<br />
and tumour regression.<br />
2007 and that the innovative features of our molecules,<br />
once confirmed in phase III trials, will<br />
offer improved treatment choices to cancer<br />
patients.<br />
Our R & D in oncology<br />
The sequencing of the human genome and detailed<br />
studies of genetic changes in human cancer cells,<br />
known as oncogenome signature typing, have<br />
accelerated the identification of mutations and<br />
the knowledge of the faulty cellular circuitry that<br />
underlie the aberrant growth, invasion and metastasis<br />
of cancerous tissues in the body. Moreover,<br />
they provide important clues to new drug targets<br />
and the best match-up of new drugs with the<br />
patients whose cancers are most likely to respond<br />
to the drugs, a process called biomarker-guided<br />
drug development or customised cancer therapy.<br />
New further compounds have entered development<br />
to strengthen our emerging oncology<br />
pipeline and we are continuing our efforts to<br />
develop monoclonal antibody-based drug candi-<br />
dates. As part of our strategic collaboration with<br />
MorphoSys on human antibodies, we have exer-<br />
cised an option for optimising a therapeutic
HuCAL antibody directed against a cancer-related<br />
target molecule and have acquired an exclusive<br />
licence for this project.<br />
Metabolic diseases<br />
Health authorities and governments have been<br />
alarmed by recent epidemiological data suggest-<br />
ing that metabolic diseases, including diabetes<br />
mellitus type II, obesity and dyslipidaemia, will<br />
grow worldwide by a much greater extent than<br />
previously expected. This has been identified as a<br />
major health problem, not only for western countries,<br />
but also in, for example, South America,<br />
India and China. Particularly worrisome is the<br />
increasing prevalence of obesity in children<br />
together with the onset of type II diabetes in<br />
young adults. This disturbing fact leads to the<br />
forecast that today’s children may have a lower<br />
life expectancy than their parents. We are therefore<br />
putting great efforts into the metabolic disease<br />
field with particular focus on diabetes type II,<br />
obesity and dyslipidaemia. Many diabetic patients<br />
are overweight or obese and also suffer from dyslipidaemia,<br />
features of the metabolic syndrome.<br />
Our clinical studies in metabolic diseases<br />
We were particularly pleased with promising first<br />
clinical results of compounds with two different,<br />
but complementary, mechanisms, one that stimulates<br />
insulin secretion and another that facilitates<br />
the renal excretion of glucose.<br />
The first compound with an already established<br />
mode of action is entering phase IIb after very<br />
encouraging four weeks’ results in diabetes type II<br />
patients. We believe that during later phase III this<br />
compound has the potential to develop into a bestin-class<br />
drug providing improved efficacy and<br />
convenience.<br />
serving patients<br />
The second compound in phase I is a first-in-class,<br />
new development, which may offer improved<br />
options for treatment of diabetes mellitus. It has<br />
already established pharmacodynamic effects of<br />
the mode of action and will enter phase II in<br />
patients in 2007. With additional preclinical<br />
development candidates and follow-up compounds<br />
expected to enter the clinic, our metabolic<br />
clinical pipeline will grow and gain further attractiveness<br />
in the near future.<br />
Our R&D in metabolic diseases<br />
New therapeutic approaches for the treatment of<br />
diabetes type II have the potential of delaying or<br />
even inhibiting the progression of the disease.<br />
Several research projects even offer the possibility<br />
of preventing manifestation of the illness. We<br />
have been successful in entering development<br />
with several of our research projects with a variety<br />
of new mechanisms.<br />
In obesity there is a great need for new drugs that<br />
are more efficacious than the existing ones while<br />
providing a high level of patient safety. Research<br />
in that area is directed both at a reduction of appetite<br />
and food intake as well as increasing the<br />
metabolism of energy carriers. We have established<br />
state-of-the-art technologies to carefully<br />
profile advanced compounds in vitro and in vivo.<br />
We also see opportunities to explore the combination<br />
of various mechanisms.<br />
Despite efficacious treatment for the lowering<br />
of low-density lipoprotein (LDL) cholesterol,<br />
60–70 % of cardiovascular events still cannot be<br />
prevented. The role of low levels of high-density<br />
lipoprotein (HDL) cholesterol and malfunction of<br />
the reverse cholesterol transport are hence areas<br />
of increasing research interest. We have started<br />
several new research projects to address this<br />
therapeutic need.<br />
Prescription Medicines<br />
1
Our regions<br />
Americas<br />
In our Americas region, <strong>2006</strong> saw continued<br />
strong development of our product portfolio. Net<br />
sales in our Presciption Medicines business<br />
reached EUR 4,460 million.<br />
The USA remains the main driver of pharmaceutical<br />
growth and is the largest contributor to<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>’s sales and profits. The US<br />
market, a highly competitive environment which<br />
underwent significant changes in <strong>2006</strong>, grew by<br />
8.2 %. <strong>Boehringer</strong> <strong>Ingelheim</strong> continued to develop<br />
above the market average. micardis®, spiriva®,<br />
flomax® and aggrenox® were the main growth<br />
drivers in the USA and compensated for lost sales<br />
of mobic® due to the launch of generic competi-<br />
tors in July.<br />
For the first time, US citizens above 65 years of<br />
age, regardless of income, were given access to<br />
prescription drug coverage by Medicare. This new<br />
coverage (Medicare Part D) began on 1 January<br />
<strong>2006</strong>. <strong>Boehringer</strong> <strong>Ingelheim</strong> ensured that it was<br />
well positioned in the plans to enable a greater<br />
number of US citizens access to our portfolio of<br />
innovative medicines.<br />
In Canada, new regulations on intellectual property<br />
came into law. This established eight years of<br />
data exclusivity for a molecule from the date of its<br />
approval, further protecting the intellectual rights<br />
of the research-driven pharmaceutical industry.<br />
But <strong>2006</strong> also saw the proposal and implementation<br />
of tighter pricing and reimbursement policies<br />
mainly affecting the two major provinces Ontario<br />
and Quebec. This will further limit patient access<br />
to innovative drugs.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
The economic situation in Latin America stabilised<br />
in <strong>2006</strong>. Mexico, our largest operating unit<br />
in Latin America, developed very positively, with<br />
a growth rate of 35 % compared with 2005. The<br />
main growth drivers were flomax®, micardis®,<br />
buscopan®, combivent® and some local key<br />
products. Sales of major drugs, such as spiriva®<br />
and cymbalta®, are growing strongly.<br />
Our South American operating unit, which combines<br />
the management of all Spanish-speaking<br />
countries in the region, enjoyed its first full year in<br />
<strong>2006</strong>. Greater efficiencies are being generated and<br />
marketing efforts simplified by combining strategies<br />
and resources across the whole regional unit.<br />
A cross-country (CN) management structure has<br />
been established and regional centres of excellence<br />
developed for products in our portfolio. Our<br />
Brazilian company celebrated its 50th anniversary<br />
in <strong>2006</strong>. Development here was seen across our<br />
portfolio, with particular success for mirapex®/<br />
sifrol®, the most prescribed drug of its class for<br />
Parkinson’s disease. mirapex® for RLS was<br />
launched in September, reinforcing its market<br />
position. Main drivers of growth were micardis®,<br />
mirapex® and buscopan®.<br />
Europe<br />
Despite an extremely challenging market environ-<br />
ment, our net sales in the Europe region achieved<br />
7 % growth in <strong>2006</strong>. Our three main patent-pro-<br />
tected products, spiriva®, micardis®/micardis-<br />
plus® and sifrol®/mirapexin®, met strong<br />
demand, posting double-digit growth rates. New<br />
product introductions contributed positively to<br />
the growth. xeristar®, an innovative antidepressant,<br />
was successfully launched in Italy, Greece<br />
and Spain. Our new protease inhibitor aptivus®<br />
is now available in almost all markets. spiriva®<br />
was successfully launched in France. On the other
hand, the end of exclusivity in Europe for mobic®<br />
and alna®/pradif®/josir® affected sales signifi-<br />
cantly.<br />
In Italy and France, we grew faster than the over-<br />
all market. In the UK, we matched overall market<br />
growth, but in Germany we were unable to keep<br />
up with the market due to the loss of alna® sales<br />
to generic competition. In contrast to Western<br />
European markets, Eastern Europe showed<br />
dynamic economic growth. This was evident in<br />
the prescription medicines markets, especially in<br />
Russia, where a newly introduced federal pro-<br />
gramme reimburses ‘essential medicines’ to<br />
selected patients. Across Eastern Europe strong<br />
demand for our respiratory products and for<br />
mobic® enabled us to achieve 27 % growth.<br />
The healthcare market, in particular the market<br />
for prescription medicines, remains very difficult<br />
in most European countries. While demand is<br />
increasing due to demographic developments and<br />
the use of innovative products with real benefits<br />
to patients, most healthcare systems are chronically<br />
The USA remained by<br />
far the most important<br />
market for our drugs.<br />
Prescription Medicines (PM)<br />
– which accounted for<br />
79 % of our net sales –<br />
had a turnover of more<br />
than EUR 8.3 billion<br />
to which US sales<br />
contributed 46 %.<br />
The Europe region<br />
achieved 26 % of PM<br />
Americas<br />
, 0<br />
underfunded. Accordingly, governments throughout<br />
Europe are reducing consumption volume by<br />
restricting patient access to innovative medicines<br />
and demanding lower prices.<br />
In <strong>2006</strong>, the Italian government, for instance,<br />
secured a 10 % cut in retail prices. Newly introduced<br />
products, which naturally post above-<br />
average growth rates, were even subjected to an<br />
additional price reduction. France’s Social<br />
Security Financing Law and Germany’s Economic<br />
Optimisation of Pharmaceutical Care Act have<br />
also contributed to market stagnation.<br />
Price referencing has become common practice<br />
across Europe, with price reductions in one<br />
country leading to reductions elsewhere, inducing<br />
a downward spiral. An increasing number of<br />
companies will be forced to refuse such significant<br />
price reductions to avoid this vicious circle. The<br />
result will be the withdrawal of hitherto<br />
reimbursed medicines, less access to drugs and<br />
higher financial contributions from patients.<br />
Overall, the outlook for the European prescription<br />
of which:<br />
USA branded<br />
3,174<br />
USA generics<br />
657<br />
Europe<br />
,1 0<br />
of which: Germany<br />
446<br />
Asia, Australasia,<br />
Africa<br />
1, 9<br />
serving patients<br />
of which: Japan<br />
849<br />
net sales. Net sales Prescription Medicines, excl. licences (in millions of EUR)<br />
Prescription Medicines
medicines market is far from encouraging and any<br />
fresh investment in this region needs to be evalu-<br />
ated with particular care.<br />
Asia, Australasia,<br />
Africa (AAA)<br />
In our AAA region, <strong>2006</strong> was characterised by<br />
continued strong growth in local currency terms.<br />
Our PM business in the AAA region is heavily<br />
dominated by the performance of Japan which<br />
contributes more than 59 % to regional sales and<br />
earnings. Nippon <strong>Boehringer</strong> <strong>Ingelheim</strong> was, for<br />
the second year running, the fastest growing business<br />
among the leading 20 pharmaceutical companies<br />
in Japan. In nearly all the other AAA<br />
countries we outpaced the market. Locally<br />
achieved sales growth was, however, not fully<br />
reflected in euro terms, as most of the region’s<br />
major currencies weakened against the euro during<br />
the reporting period.<br />
The Japanese market for prescription products<br />
remained sluggish. Net sales of our prescription<br />
products increased by 16 % in local currency (by<br />
7 % in euro terms) and by the end of the year our<br />
market share reached 1.7 %, despite a governmentimposed<br />
price cut in April, averaging 5.6 % for our<br />
business.<br />
Australia, our second most important AAA market,<br />
achieved net sales of EUR 118 million and market<br />
share of over 2.3 %. We achieved significant sales<br />
and established a respectable market share of<br />
1.5 % in Turkey, making it our third most important<br />
country in the AAA region.<br />
In South Korea, where we have a joint venture<br />
with a local partner, sales growth exceeded 24 %.<br />
Here we closely follow ongoing governmental<br />
deliberations on positive listing for drug<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
reimbursement. Such deliberations, all being part<br />
of cost containment measures and governmental<br />
restrictions, feature throughout the region. Price<br />
cuts in Taiwan and Indonesia in <strong>2006</strong> caused<br />
particular concern in the pharmaceutical<br />
industry.<br />
In South Africa and neighbouring countries our<br />
growth rate has slowed. This development must,<br />
however, be seen in conjunction with our decision<br />
to grant voluntary licences for viramune® in<br />
South Africa (and also in Egypt, Nigeria, Kenya)<br />
so that generic manufacturers can offer our<br />
antiretroviral drug at generic prices. In fact, in<br />
order to make viramune® more readily available<br />
we announced measures to encourage even more<br />
generic manufacturers to avail themselves of the<br />
opportunity of offering medicines containing the<br />
active ingredient nevirapine to the countries of<br />
the developing world, including the whole of<br />
Africa.<br />
In China, the pharmaceutical market is neither<br />
transparent nor easy, and is in fact dominated by<br />
healthcare reform and generics. Although last<br />
year our Chinese business accounted for only 3 %<br />
of our PM sales in the AAA region, we remain<br />
confident that the huge Chinese market will<br />
gradually make a more significant contribution to<br />
our worldwide business. In <strong>2006</strong>, we completed<br />
the formalities to purchase the outstanding 5 % of<br />
shares in our joint venture, which will give<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> a wholly owned enterprise<br />
in China in 2007.<br />
Our strong growth in nearly all the AAA countries<br />
reflects continuing field force efficiency initiatives<br />
and also the robust development of our core prod-<br />
ucts micardis®, spiriva® and sifrol®. Some<br />
well-established products, such as buscopan®,<br />
combivent® and mucosolvan® also produced<br />
an upward sales trend in some countries.
Generic Prescription<br />
Medicines<br />
The US generic industry posted revenues in excess<br />
of USD 47 billion in <strong>2006</strong> and the market is<br />
expected to grow by 6 % annually over the next<br />
five years. Drivers of this growth include the aging<br />
population, government cost reduction measures,<br />
increased generic utilisation, blockbuster patent<br />
expirations, and the emergence of biogenerics or<br />
copies of biopharmaceuticals (biosimilars).<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>’s Generic Prescription<br />
Medicine (GPM) business in the USA, which<br />
consists of Roxane Laboratories and BenVenue<br />
Laboratories with its unit Bedford Laboratories,<br />
generated net sales of USD 825 million (EUR 657<br />
million), approximately 17 % of overall USA<br />
Prescription Medicines sales in <strong>2006</strong>.<br />
Business Environment<br />
The US generic market was shaped by many<br />
factors in <strong>2006</strong>. There was significant consolida-<br />
tion due to mergers and acquisitions, at the same<br />
time as new international competitors emerged<br />
from Europe and Asia. This increase in the number<br />
of competitors, along with the cost-focused<br />
pharmacopolitical environment, is exerting<br />
continued pressures on margins.<br />
As the size of the generic market continues to<br />
grow, there is also increased competition for<br />
revenues from brand pharmaceutical companies<br />
which show a renewed interest in generics.<br />
Additionally, large multinational generic com-<br />
panies, which have grown through merger and<br />
acquisition, and companies from India, Eastern<br />
Europe and China are playing key roles in this<br />
market.<br />
Roxane Laboratories<br />
Roxane Laboratories focuses on developing<br />
manufacturing and marketing a broad line of oral<br />
solid and liquid medications and intranasal<br />
products. The year <strong>2006</strong> was one of dramatic<br />
growth in which the company achieved net sales<br />
of USD 328 million (EUR 261 million) compared<br />
with USD 242 million (EUR 194 million) in 2005<br />
(+ 35 % in USD terms). Leading this growth<br />
was the launch of fluticasone proportionate<br />
nasal spray, a generic version of GSK’s flonase.<br />
Driven by demographic factors, government’s assumption of the<br />
responsibility for healthcare needs of the uninsured, and efforts to reduce<br />
spiraling costs, the US generic pharmaceutical market will continue its<br />
rapid growth in the coming years. It is anticipated that in 2007 the market<br />
will grow by 15 % to USD 62 billion, versus USD 54 billion in <strong>2006</strong>.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>, by virtue of its US Generic Prescription Medicine<br />
(GPM) subsidiaries Bedford Laboratories and Roxane Laboratories, is poised<br />
to benefit from this growth. By the year 2010, our combined multisource<br />
companies are expected to reach USD 1 billion in sales.<br />
serving patients<br />
Generic Prescription Medicines
Roxane<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> Roxane and Roxane Laboratories<br />
are located in Columbus, Ohio, and are subsidiaries of<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> Corporation (Ridgefield, Connecticut).<br />
These subsidiaries are recognised leaders in<br />
researching, manufacturing and packaging brand name<br />
and generic medications, including oral liquids, tablets<br />
and capsules.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> Roxane (BIRI) is the manufacturing<br />
arm of <strong>Boehringer</strong> <strong>Ingelheim</strong> Corporation. It functions as<br />
a primary site for prescription and multisource pharmaceutical<br />
manufacturing in North America. In addition,<br />
BIRI is one of <strong>Boehringer</strong> <strong>Ingelheim</strong>’s two product launch<br />
sites.<br />
Roxane Laboratories is the research and development<br />
and sales and marketing arm of our multi-source business.<br />
It offers development services for new products<br />
and formulas, oversees the manufacturing process for<br />
its customers, and develops analytical test methods for<br />
potential new products.<br />
Roxane started in 1885 as Columbus Pharmacal, a small,<br />
regional pharmaceutical manufacturer. In 1978, it was<br />
acquired by <strong>Boehringer</strong> <strong>Ingelheim</strong>. Roxane has about<br />
1,000 employees. The sales increased over the past five<br />
years by about 13 % per year, totalling EUR 261 million in<br />
<strong>2006</strong>.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
Fluticasone is the first Roxane product to exceed<br />
the USD 100 million threshold. In <strong>2006</strong>, Roxane<br />
submitted 16 abbreviated new drug applications<br />
(ANDAs) to the US Food & Drug Administration<br />
(FDA), received ten tentative approvals (TAs) and<br />
launched seven new products.<br />
Bedford Laboratories<br />
Bedford Laboratories posted net sales of USD 497<br />
million ( EUR 396 million) in <strong>2006</strong>, a growth rate<br />
of 17 %. Key products for the year included<br />
propofol, octreotide, glucagen®, paclitaxel,<br />
adriamycin®, midazolam and polymyxin B.<br />
Three new products were launched in <strong>2006</strong>,<br />
including ciprofloxacin, an anti-infective; loraze-<br />
pam, an anaesthesia adjunct, and mitoxantrone,<br />
an oncology product. With these three new prod-<br />
ucts, Bedford continues to consolidate its position<br />
in the generic market and remains one of the larg-<br />
est US suppliers of speciality injectable pharma-<br />
ceuticals to hospitals and clinics.<br />
Bedford currently offers 90 injectable products in<br />
254 different configurations, covering a wide<br />
variety of therapeutic classes, mainly in the areas<br />
of oncology, cardiology, anaesthesia, anti-infec-<br />
tive and antipsychotics. It will continue to file ten<br />
to twelve ANDAs each year to create a pipeline of<br />
products that will allow it to maintain a leadership<br />
position in the generic injectable market.
Ben Venue – a world leader in sterile injectable pharmaceuticals<br />
Ben Venue Laboratories (Bedford, Ohio), is part of the <strong>Boehringer</strong> <strong>Ingelheim</strong> group of<br />
companies and a leading producer of sterile injectable pharmaceutical products. Also the<br />
oldest and largest contract manufacturer of sterile injectable products in the USA, it has<br />
with an impressive track record. Ben Venue works with some of the largest pharmaceutical<br />
and biopharmaceutical companies, along with mid-size and virtual pharmaceutical and<br />
biopharmaceutical companies which bring their products for development and manufac-<br />
turing of clinical and commercial supply. Ben Venue has established a reputation for exper-<br />
tise in lyophilisation, or freeze drying, which remains a primary speciality.<br />
Freeze drying (above) extends the shelf life of a product, makes it more stable and allows it<br />
to be stored at room temperature. When its latest expansion is completed, Ben Venue will<br />
have 27 freeze-driers with 718 square meters of lyophilising chamber space. It offers the<br />
ability to support batch sizes from 1 litres to 2,000 litres, from clinical to commercial. Ben<br />
Venue markets its own line of generic injectables to hospitals in North America through<br />
its Bedford Laboratories division, currently offering 90 drugs with 254 configurations,<br />
including oncology, cardiovascular, anaesthesia, antipsychotic and other miscellaneous<br />
products to hospitals and alternate care markets.<br />
serving patients<br />
Generic Prescription Medicines
“Now I know how to keep<br />
them under control”<br />
“When I moved from my home town of Pico in La Pampa to study communication science at the<br />
University of Buenos Aires in the Argentinian capital, I found the change very hard. Pressure from<br />
exams made things even worse,” Mara Lovera, a 25-year-old student, explains. “Every time I had to<br />
take a test I experienced strong discomfort and abdominal pain, which on some occasions forced<br />
me to skip exams.”<br />
Abdominal pain and cramps, a widespread ailment around the world, is more common in women<br />
than in men and can affect people still in their teens. The ailment can strike sufferers at any time and<br />
is one of the most common causes of absence from work. It can also have significant impact on self-<br />
confidence, social life and day-to-day living.<br />
“As the discomfort and pain was constantly disrupting my studies, I went my doctor to find out what<br />
could be done to help me. He explained that what I had were spasms produced by stress and nerves,”<br />
Mara says. The doctor recommended an antispasmodic which suppresses and relieves painful muscle<br />
spasms.<br />
“Since the moment I started taking the medication my problem was solved,” Mara says. “Nowadays,<br />
the pain is not so frequent, but every time my stomach starts to hurt, I know how to treat it and keep<br />
the spasms under control.”<br />
New data presented at the international gastroenterology congress, the Digestive Disease Week,<br />
Los Angeles, in <strong>2006</strong>, showed that the prevalence and severity of abdominal cramping, pain and<br />
discomfort have been globally underestimated. A global epidemiological study showed that one in<br />
four people around the world suffer from this troublesome and sometimes debilitating ailment.<br />
Two- thirds of all sufferers indicated they experience sudden abdominal attacks that begin without<br />
warning. On average, more than one-third of these sufferers experience at least one fierce attack<br />
every week.<br />
Professor Guido N. J. Tytgat, from the Academisch Medisch Centrum of the University of Amsterdam,<br />
comments: “This ailment is classified as a functional gastrointestinal disorder, which means that the<br />
abdomen appears normal, but does not function properly. Despite the painful symptoms associated<br />
with this ailment, proactive management and treatment can significantly improve a sufferer’s quality<br />
of life.”
Mara Lovera, Buenos Aires, Argentina, went through<br />
hard times because of abdominal pain.
0<br />
From plant to the pharmacy – the buscopan® story<br />
The buscopan® story starts in <strong>Ingelheim</strong>,<br />
Germany, where elite Duboisia plants are grown<br />
in greenhouses. These plants are bred to be<br />
resistant against nematodes and beetles. The best<br />
seeds are harvested and then delivered to the<br />
company’s plantations in South America and<br />
Australia for further on-site selection. Here, the<br />
shrubs grow on a large scale. The pharmaceutically<br />
important alkaloid scopolamine which is<br />
contained in the dried leaves and stalks is isolated<br />
and purified. Finally, the active precursor<br />
substance scopolamine is converted in a single<br />
chemical process into hyoscine butylbromide,<br />
the active ingredient of buscopan®.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>’s buscopan® is an<br />
effective over-the-counter medicine which<br />
offers relief from abdominal pain<br />
and discomfort by targeting the<br />
source of the problem. It suppresses<br />
and relieves painful muscle<br />
spasms by travelling directly to<br />
the gastrointestinal tract. It does<br />
not enter the bloodstream, but<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> AnnuA l RepoR t <strong>2006</strong><br />
acts directly on the muscle contractions from<br />
within the digestive tract, causing them to relax,<br />
thus relieving the pain and allowing normal<br />
functioning.<br />
Abdominal cramping, pain and discomfort is a<br />
functional gastrointestinal disorder which can<br />
be painful, embarrassing and often debilitating.<br />
Whilst mild symptoms can be annoying and<br />
unpleasant, severe ones can be unbearable.<br />
Anyone can suffer from abdominal cramping,<br />
pain and discomfort at any time and for any<br />
reason. It affects almost a quarter of the general<br />
population worldwide, with women being more<br />
likely to suffer than men (31 % vs. 22 %). Whilst<br />
there is no difference in the prevalence of the<br />
ailment between different age groups, the<br />
initial onset of symptoms usually<br />
occurs between 27 and 31 years of age.<br />
The causes are manifold and often<br />
difficult to<br />
determine.
Consumer Health Care<br />
Our Consumer Health Care (CHC) business segment achieved net sales of<br />
EUR 1.1 billion in <strong>2006</strong> (+1.1 % against the previous year). All regions of the<br />
CHC business, except Japan, achieved strong growth supported by positive<br />
exchange rate developments. <strong>Boehringer</strong> <strong>Ingelheim</strong> is ranked No. 8 worldwide<br />
among CHC companies and defended its position in <strong>2006</strong>, primarily<br />
through launching new line extensions and switching prescription-only<br />
medicines to over-the-counter (OTC) products. Our key international brands<br />
continued to develop very positively.<br />
Development by brand<br />
buscopan® – positioned as the specialist treat-<br />
ment for abdominal cramping, discomfort and<br />
pain – extended its worldwide No. 1 antispasmodic<br />
brand position, according to IMS data. The<br />
buscopan® franchise produced strong double-<br />
digit growth in <strong>2006</strong>. In Argentina, Colombia and<br />
Paraguay the most recent buscopan® line exten-<br />
sion, buscapina® fem, was successfully intro-<br />
duced for treatment against menstrual pain.<br />
Globally aligned international packaging has now<br />
been introduced in all major countries such as<br />
Argentina, Brazil, Mexico, Germany and Italy a<br />
step towards building a contemporary and com-<br />
pelling global OTC brand.<br />
Top products Consumer Health Care<br />
Net sales in millions of EUR change<br />
dulcolax® 122.0 + 6.2 %<br />
mucosolvan® 108.3 + 18.6 %<br />
pharmaton® 95.6 + 8.2 %<br />
buscopan® 71.2 + 19.6 %<br />
bisolvon® 67.1 + 0.4 %<br />
thomapyrin® 34.2 + 14.2 %<br />
laxoberal® 34.0 + 6.9 %<br />
antistax® 23.2 + 2.7 %<br />
dulcolax® – our leading laxative brand – main-<br />
tained its position as the No. 1 laxative worldwide<br />
and is now marketed in over 100 countries. Posi-<br />
tive performances were achieved in <strong>2006</strong> in<br />
Europe, Asia and the Americas, where our strong<br />
category position was reinforced. In order to con-<br />
tinually strengthen our brand worldwide, a<br />
number of key line and brand extensions are being<br />
developed in order to reinforce dulcolax®’s<br />
global position.<br />
antistax® – our brand for the prevention and<br />
treatment of chronic leg vein insufficiency –<br />
succeeded in delivering another year of growth in<br />
<strong>2006</strong>. Driven by strong double-digit growth in<br />
Italy, Belgium and Russia, antistax® is well on its<br />
way to becoming a leading international player in<br />
the treatment of chronic venous insufficiency.<br />
With a new brand positioning and worldwide<br />
rollout plans in place, antistax® is set to continue<br />
playing a central role in delivering positive busi-<br />
ness growth for our CHC business in the coming<br />
years.<br />
mucoangin® – our sore throat brand – achieved<br />
satisfactory growth in the major markets of<br />
Germany and Mexico. A new product launch was<br />
made in the Netherlands.<br />
serving patients<br />
Consumer Health Care<br />
1
zantac® – an excellent strategic fit<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>’s Consumer Health Care (CHC)<br />
business made an important strategic move in October<br />
<strong>2006</strong> with the acquisition of US rights to the over-the-<br />
counter (OTC) brand zantac® (ranitidine), an H2 blocker<br />
for treating the common disorders heartburn and acid<br />
indigestion.<br />
“Our CHC business ranks as the eighth largest supplier of<br />
self-medication products worldwide, and the well-known<br />
consumer brand zantac® will further strengthen its<br />
presence in the key US market,” says Hans V. Regenauer,<br />
Corporate Senior Vice-President Marketing & Sales<br />
of <strong>Boehringer</strong> <strong>Ingelheim</strong>’s CHC business. The zantac®<br />
rights, acquired under an agreement between <strong>Boehringer</strong><br />
<strong>Ingelheim</strong> Pharmaceuticals, Inc., Johnson & Johnson<br />
and Pfizer, add to the US portfolio a strong consumer<br />
brand that combines well in terms of retailing and sales<br />
and promotion with the flagship brand dulcolax®,<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>’s worldwide leading laxative brand.<br />
“zantac® is an excellent strategic fit that comple-<br />
ments our existing OTC franchise and provides us with<br />
two leading brands in the two largest gastrointestinal<br />
categories – acid reducers and laxatives,” says J. Martin<br />
Carroll, president and CEO of <strong>Boehringer</strong> <strong>Ingelheim</strong>’s<br />
US Corporation.<br />
mucosolvan® – the world’s leading cough expec-<br />
torant – maintained its No. 1 position in <strong>2006</strong> and<br />
achieved good growth performances in Russia,<br />
Mexico and Brazil. New marketing campaigns<br />
were launched in Germany and Russia, as well as<br />
in China and France, where mucosolvan® was<br />
targeted at consumers for the first time.<br />
bisolvon® – the cough remedy – strengthened its<br />
position as one of the leading brands in the world<br />
cough remedies category as a result of new prod-<br />
uct upgrades and product launches.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> AnnuA l RepoR t <strong>2006</strong><br />
Regions<br />
Europe<br />
In <strong>2006</strong>, the region reported sales growth of more<br />
than 5 % compared to the previous year, this in<br />
spite of low incidence in coughs and colds and<br />
strong negative business impact caused by the<br />
delisting activities by the authorities in France.<br />
Strong growth was provided by our flagship<br />
brands dulcolax® and buscopan® which<br />
together posted a growth of almost 20 % against<br />
the previous year.<br />
Together with several small countries, Spain, Italy<br />
and Russia were prime drivers of the positive<br />
development.<br />
Americas<br />
The year <strong>2006</strong> was again positive for the CHC<br />
business in the Americas region, which achieved<br />
growth of 10 % against the previous year. All international<br />
core brands developed positively. The<br />
main growth drivers were the USA, Mexico,<br />
Argentina and Venezuela.<br />
mucosolvan® has<br />
proven to be a very<br />
reliable, trusted<br />
and strong<br />
expectorant for<br />
the treatment of<br />
productive cough.<br />
It is one of the<br />
leading therapies<br />
for cough and is<br />
available around<br />
the world.
Switching reinforces the trend towards<br />
self-medication<br />
Switching – the reclassification of prescription-only<br />
medicines to over-the-counter (OTC) products needing<br />
no prescription – is reinforcing the growing trend towards<br />
self-medication.<br />
Throughout the developed world the explicit policy<br />
adopted by many health authorities in licensing and<br />
reclassifying medicines, is that they should be made<br />
freely available to patients, unless a case can be made<br />
for availability being restricted.<br />
Making medicines more widely available at the pharmacy<br />
as OTC products provides consumers with the opportunity<br />
to buy a wider range of medicinal products. This<br />
deregulation of medicines comes against a background<br />
of pressure on the drugs bill in many countries.<br />
Some governments are already committed to expanding<br />
the range of medicines available for self-medication<br />
towards longer-term chronic conditions and preventive<br />
therapies. zantac®, for which <strong>Boehringer</strong> <strong>Ingelheim</strong><br />
recently purchased the USA rights, is a great example of<br />
a brand which was a prescription blockbuster for many<br />
years, but has now successfully switched globally with<br />
equal OTC success.<br />
In addition, <strong>Boehringer</strong> <strong>Ingelheim</strong>’s self-medication<br />
portfolio also includes other highly successfully switched<br />
products, such as the antispasmodic buscopan® and<br />
mucosolvan®, the cough expectorant.<br />
Asia, Australasia, Africa (AAA)<br />
SSP Co. Ltd. – the No. 3 OTC company in Japan,<br />
whose major shareholder is Nippon <strong>Boehringer</strong><br />
<strong>Ingelheim</strong> Co. Ltd. – defended its position in a<br />
highly competitive market environment. The AAA<br />
region, excluding Japan, achieved strong growth<br />
of 26 % against the previous year. Our international<br />
core brands pharmaton®, bisolvon® and<br />
dulcolax® showed overall sales growth of 10 %.<br />
On the road for leg vein health<br />
serving patients<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>’s antistax® camper van is a wellestablished<br />
mobile consulting room. It tours Italy to raise<br />
public awareness about chronic vein insufficiency.<br />
The tour is conducted in cooperation with the scientific<br />
institute San Raffaele in Milan under the slogan<br />
“Benessere delle Gambe” (Well-being for legs). In <strong>2006</strong>,<br />
the van visited 13 cities from Como to Naples, giving<br />
access to the public, in order to provide them a free<br />
leg-vein check, conducted by a specialist. About 3,000<br />
people, mainly women but also some men, visited the van<br />
for a free consultation, to find out if they suffered from<br />
chronic venous insufficiency, an ailment which can be<br />
associated with heavy, tired, achy and swollen legs.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>’s antistax®, a natural food supplement<br />
can help to maintain leg vein health. It contains the<br />
unique extract of red vine leaf, AS195®.<br />
Consumer Health Care
Top Story: Metacam®
Alexander (left) and Christopher playing together with Tom, a Fjord gelding<br />
which is part of their therapy. The horse had to be treated for colic.
Our friend Tom<br />
Fatima, a 30-year-old Anglo-Arabian mare, and<br />
Miriam who takes care of the horse, still an<br />
important member of the team. And the children<br />
are happy to work with her.<br />
Alexander and Christopher, both nine years old, are two cheerful, outgoing young boys. They love<br />
playing football and computer games. But Fridays are always special for the twins: that is when they go<br />
to see Tom. Tom, a 12-year-old Fjord gelding, is their friend. “He’s so big and blond and soft,” says<br />
Christopher, his eyes gleaming. Riding and handling the horse, feeding and looking after it, is extremely<br />
important for the children’s development, as their health has been impaired since birth.<br />
For about three years Alexander and Christopher have had regular training once a week at the<br />
therapeutic riding centre in Flörsheim-Dalsheim, a town south-west of Frankfurt in Germany. Tom<br />
has been part of the team there now for many years and has been specially trained for the job. The<br />
rhythmic movement of the horse and the therapeutic exercises during a ride relieve Alexander’s<br />
spasticity. The elevated position and being able to move without a wheelchair give him an immense<br />
feeling of freedom. And Christopher finds the horse has a calming effect, particularly the close<br />
physical contact with the animal. Christopher suffers from attention deficit disorder (ADD).<br />
“The most vital aspect of the therapy is the trust between the horse and client,” explains Nora Ringhof,<br />
the boys’ therapeutic riding instructor. “The animal becomes an important partner and friend. Building<br />
trust, through eye-to-eye contact, for instance, is of decisive importance and is only possible over a<br />
long period of time,” she says.<br />
This kind of therapy normalises muscle tone, helps clients control their upper body and head, improves<br />
balance and helps them learn how it feels to move. It is indicated in the case of cerebral movement<br />
disorders, regardless of the cause or severity, multiple sclerosis, spina bifida, postural defects, or lowback<br />
syndromes. Furthermore, the improvement of social skills forms an important part of riding<br />
therapy.<br />
When Tom suddenly developed colic one day, he was given immediate relief by administration of<br />
metacam®, an analgesic and anti-inflammatory drug from <strong>Boehringer</strong> <strong>Ingelheim</strong>. Their very long<br />
intestine makes horses very prone to colic, a disease that can prove life-threatening. Every year about<br />
10% of all horses across the world suffer from equine colic. Many horses can be helped with drug<br />
therapy while others have to undergo intensive surgery in special clinics. Recent research results from<br />
the USA show that metacam® is highly effective in the treatment of this disease. Ms Ringhof adds:<br />
“The children are delighted that Tom found help so quickly and that he’s ready for them again.”<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6
Animal Health<br />
The sound progress of our core business segments in Animal Health, namely<br />
swine and small animals, is a key characteristic of the year <strong>2006</strong>. On the<br />
whole, our global Animal Health business has concluded another successful<br />
year with a growth of 4 %. Adjusted for extraordinary and currency effects,<br />
the business grew by 8 %. This again compares favourably to the industry’s<br />
excellent growth of 6 %.<br />
Overall, we increased sales to EUR 374 million<br />
and have hence continued to strengthen our<br />
position in the global market. With a global mar-<br />
ket share of 3 %, in <strong>2006</strong> we once again ranked<br />
among the top ten animal health companies in<br />
the world.<br />
Regions<br />
Growth was relatively balanced across all regions<br />
and exceeded our expectations everywhere in<br />
<strong>2006</strong>. Once again, Europe brought very gratifying<br />
news, since all countries developed positively<br />
compared to the previous year, showing overall<br />
growth of 10 %. The NAFTA region achieved con-<br />
siderable growth over 2005. Our market leadership<br />
in the porcine vaccine sector was extended further<br />
and, in the first full financial year with our own<br />
independent companion animal team, we achieved<br />
marked sales growth for several products. We<br />
celebrated the 25th anniversary of <strong>Boehringer</strong><br />
<strong>Ingelheim</strong> Vetmedica, Inc. in St. Joseph, Missouri,<br />
our global research and production site.<br />
In Asia, our country organisations, in particular in<br />
China, Thailand and South Korea, achieved<br />
exceptional growth figures, a result of the stringent<br />
focus on pig vaccines in these markets. Japan<br />
showed far-reaching progress in increasing profitability<br />
and improving the product portfolio.<br />
serving patients<br />
Emerging markets<br />
The Animal Health business area extended its<br />
global presence in <strong>2006</strong>. We commenced marketing<br />
our porcine vaccine portfolio through our own<br />
organisation in Brazil, one of the world’s largest<br />
pig markets. In addition, we reorganised our<br />
South American activities with a regional sales<br />
organisation in September. Our teams now very<br />
effectively serve the markets in Argentina, Chile,<br />
Paraguay, Uruguay and the Andean Pact countries.<br />
By newly establishing a sales organisation in<br />
South Africa, we emphasised the geographic<br />
expansion of our business activities in sub-Saharan<br />
Africa. Furthermore, our new subsidiary in<br />
Dubai is to supply the demanding Arab markets,<br />
especially in the small animal, equine and poultry<br />
segments.<br />
In Europe too, additional efforts are dedicated to<br />
opening up new markets, especially in Eastern<br />
Europe. Most recently, all our operations for Austria<br />
and Eastern Europe have been bundled and<br />
are now conducted from a regional centre in<br />
Vienna, which will be fully operational by the first<br />
quarter of 2008. In summary, <strong>2006</strong> was dedicated<br />
to accessing emerging markets and to introducing<br />
and marketing our product portfolio in new<br />
regions – a strategy we intend to continue to pursue<br />
in the future.<br />
Animal Health
Food-producing animals<br />
Swine<br />
The global launch of enterisol® ileitis was one<br />
of the highlights of <strong>2006</strong> in the swine segment.<br />
With the market introduction of this innovative<br />
vaccine in most European countries, in Brazil,<br />
Australia and in New Zealand it grew by 33 %.<br />
However, it became evident that many farmers<br />
still consider the concept of disease prevention to<br />
be a major change of standard practice. The<br />
acceptance and implementation at farm level will<br />
therefore take longer than anticipated. However,<br />
forecast trends indicate that enterisol® ileitis<br />
will already be our biggest selling pig vaccine in<br />
2007. In July <strong>2006</strong>, a survey of participants at the<br />
Congress of the International Pig Veterinary<br />
Society (IPVS) in Copenhagen confirmed that<br />
ileitis is currently seen as the most important sub-<br />
clinical disease in pigs. The unmet therapeutic<br />
need is obviously substantial. But substantial too<br />
is the economic advantage that the use of<br />
enterisol® ileitis brings to pig farmers.<br />
Further highlights of <strong>2006</strong> included the market-<br />
ing authorisation of our new vaccine ingelvac®<br />
circoflex which was granted approval in the<br />
USA in October, and in Canada in November. This<br />
highly efficacious vaccine protects against porcine<br />
circovirus, PCV-2, currently considered to be one<br />
of the greatest unsolved problems in pig production.<br />
This insidious disease dramatically weakens<br />
the animals’ immune system, leaving them<br />
susceptible to infection. The one-shot vaccine<br />
ingelvac® circoflex, which was developed in<br />
record time, is an antigen that effectively controls<br />
this disease in affected herds. Products, such<br />
as enterisol® ileitis and ingelvac®<br />
circoflex, have demonstrated that Boe-<br />
hringer <strong>Ingelheim</strong> Animal Health can rapidly<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
and effectively respond to emerging diseases by<br />
supplying medical innovations and economically<br />
beneficial solutions to pig producers.<br />
As to the future, we are confident that we will be<br />
able to maintain strong growth in the swine seg-<br />
ment and aim to become the global No. 1 in pig<br />
vaccines in the near future. Fiftyfive scientific<br />
publications presented at the <strong>2006</strong> IPVS congress<br />
have substantiated our market and opinion-lead-<br />
ing position.<br />
Cattle<br />
Our support for US search dogs<br />
“Over the past decade, we’ve found out about the vital role<br />
rescue dogs play when properly trained with a skilled fire-<br />
fighter to save lives. This is the human-animal bond at its most<br />
profound. Over the years, the canines and their firefighter<br />
partners have responded to national and local disasters such<br />
as 9/11, Hurricane Katrina and many other regional and state<br />
disasters. We thank <strong>Boehringer</strong> <strong>Ingelheim</strong> for their belief in<br />
our mission and for their support in being part of the search,”<br />
says Wilma Melville, founder of the National Disaster Search<br />
Dog Foundation (NDSDF).<br />
The mission of the NDSDF is to produce the most highly trained<br />
canine search and rescue teams in the USA. In response to<br />
the shortage of such teams, <strong>Boehringer</strong> <strong>Ingelheim</strong> Vetmedica<br />
is enabling a greater number of search and rescue dogs to be<br />
The cattle segment also posted<br />
significant growth in <strong>2006</strong>.<br />
Our traditional mastitis<br />
products continue to<br />
enjoy great popularity in<br />
the market due to their<br />
outstanding efficacy.
located, trained and placed with fire departments under a<br />
three-year partnership deal.<br />
In return, the NDSDF has given the company exclusive affiliation<br />
with a search dog, Lola, a Black Labrador (right) handled<br />
by Johnny Subia of the Seaside Fire Department in California.<br />
She was selected as the metacam® search dog.<br />
In metacam®, <strong>Boehringer</strong> <strong>Ingelheim</strong> offers a medication that<br />
benefits canines (and other animals) suffering from osteoarthritis,<br />
the most common cause of impaired mobility in dogs.<br />
One of a new generation of effective non-steroidal antiinflammatory<br />
drugs, it reduces within hours inflammation and<br />
relieves pain associated with osteoarthritis, while minimising<br />
the side effects seen with less selective substances.<br />
Encouraging growth rates for these products, for<br />
instance mamyzin® and benestermycin®, have<br />
supported our decision to make additional invest-<br />
ments in this segment. In January <strong>2006</strong>, we<br />
acquired the mastitis product line of Leo Animal<br />
Health in the United Kingdom and Ireland.<br />
Productivity in the cattle business – as in many<br />
other Animal Health areas – is closely linked to<br />
animals’ well-being. Consequently, efficient treatment<br />
of pain and inflammation will increase<br />
productivity. With growth of over 10 %, metacam®<br />
again made strong inroads into this market. In<br />
addition, the cattle vaccines business in the USA<br />
developed very well in <strong>2006</strong>. At the same time,<br />
the divestment of our ectoparasite portfolio has<br />
further streamlined our product segment in the<br />
US and facilitates our global focus on vaccines,<br />
mastitis products and pharmaceutical<br />
specialties.<br />
Companion animals<br />
serving patients<br />
Small animals<br />
The positive trend in our business in the small<br />
animals segment continues apace. Due to the<br />
strong brand awareness, highly efficacious products<br />
and successful marketing strategies, we can<br />
look back on another record-breaking year in the<br />
companion animals segment. In <strong>2006</strong>, we focused<br />
on the long-term treatment of dogs and cats with<br />
osteoarthritis and other painful locomotor diseases.<br />
Not only did we make impressive gains in<br />
this sector with our top brand metacam®, but we<br />
also responded to the wishes of veterinarians and<br />
dog owners for a new dosage form by launching<br />
metacam® chewable tablets for short-term postoperative<br />
treatment in Europe and Australia.<br />
Additional synergy effects were clearly apparent<br />
for metacam® injectable solution.<br />
Animal Health 9
90<br />
serving patients<br />
Our second flagship product for companion ani-<br />
mals, vetmedin®, a product based on pimobendan,<br />
secured further market shares in <strong>2006</strong> in the<br />
fiercely competitive small animal market. The<br />
outstanding efficacy of this drug in endocardiosis<br />
in dogs was recently underlined by a scientific<br />
study called Vetscope. By dilating the blood ves-<br />
sels and increasing the contractility of the heart<br />
muscle, the animals not only lived much longer<br />
than after treatment with angiotensin-converting<br />
enzyme (ACE) inhibitors, but also significantly<br />
showed fewer symptoms – a clear indication of<br />
improved quality of life. Thus, it is no surprise that<br />
vetmedin® more than surpassed our expectations<br />
in the reporting year, achieving growth of over<br />
20 %. We plan to increase market penetration even<br />
further over the next few years to be able to offer<br />
vetmedin® across the globe.<br />
Horses<br />
Our company’s global equine business has clearly<br />
followed the positive trend of all other business<br />
areas. Milestone achievements were the launch of<br />
the metacam® oral suspension for musculoskeletal<br />
diseases in horses in Europe, as well as<br />
the market introduction of equitop gonex®<br />
in Germany, a product available without pres-<br />
cription for regulating and stabilising joint<br />
and connective tissue metabolism. Furthermore,<br />
the European marketing authorisation for<br />
metacam® injectable<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
solution for pain relief in equine colic was another<br />
landmark accomplishment, providing an essential<br />
component for the treatment of gastrointestinal<br />
diseases and supplementing buscopan®, sedivet®<br />
and pronutrin®. Hence, the ground is prepared<br />
for further growth in the equine sector in the<br />
future.<br />
Research and<br />
development<br />
For many years, <strong>Boehringer</strong> <strong>Ingelheim</strong> Animal<br />
Health has been investing a high percentage of its<br />
sales in research and development. In <strong>2006</strong>, it<br />
totalled around 13 % of our net sales. Innovation<br />
is the imperative basis of our organic growth<br />
strategy. Consequently, we commit ourselves to<br />
further substantial investment in our global R&D<br />
infrastructure and in a European vaccines research<br />
and development centre in the years ahead. We<br />
also note with considerable optimism the sound<br />
progress in our product pipeline and the high level<br />
of expertise in the control of emerging diseases<br />
as well as the expertise in developing novel<br />
chemical formulations. Through the discovery of<br />
new pharmaceutical solutions, molecules or<br />
vaccines we can offer added value to<br />
veterinarians and animal owners, thus<br />
benefiting mankind.
Our Customer Orientation<br />
Our customer orientation
9<br />
How innovations are made<br />
The world of biopharmaceutical production has in the last five years grown<br />
immensely due to ever-increasing market demand for monoclonal antibodies<br />
(MAbs) and other therapeutic proteins. As many antibody-based therapies are<br />
applied in high doses – for example in oncology – there is a need to ensure<br />
high production capacity with high yield. <strong>Boehringer</strong> <strong>Ingelheim</strong> is meeting this<br />
need by continuously improving biopharmaceutical production of therapeutics<br />
derived from mammalian cell culture (Biberach, Germany) and bacterial<br />
fermentation (Vienna, Austria). For gene therapeutics and DNA products<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>’s expertise is increasingly in demand too.<br />
At our biopharmaceutical site in Vienna we have<br />
developed a fusion protein technology which uses<br />
the bacteria E. coli to produce efficiently therapeutic<br />
proteins. E. coli serves as a bacterial<br />
expression system and core of a process which<br />
ultimately delivers a therapeutic protein yield that<br />
is four times that of current industrial standards.<br />
This achievement will further strengthen the<br />
company’s competitiveness in the area of produc-<br />
tion of therapeutics of bacterial origin. Due to the<br />
creativity and know-how of our teams in process<br />
development and manufacturing, <strong>Boehringer</strong><br />
<strong>Ingelheim</strong> offers very economic, high-yield<br />
processes performed in our modern facilities.<br />
In 2000, <strong>Boehringer</strong> <strong>Ingelheim</strong> Austria entered<br />
the area of plasmid DNA products, an important<br />
therapeutic molecular structure which helps to<br />
develop gene therapeutics and vaccines. During<br />
the last five years, <strong>Boehringer</strong> <strong>Ingelheim</strong> has<br />
advanced its plasmid DNA product yields from 50<br />
mg/l to 2,000 mg/l – a 40-fold yield increase.<br />
After the successful validation of the new Vienna<br />
plant, <strong>Boehringer</strong> <strong>Ingelheim</strong> became the preferred<br />
partner for the immediate uptake of late-stage and<br />
commercial products to be produced in E. coli and<br />
yeast. These include therapeutic proteins, antibody<br />
fragments, protein scaffolds and plasmid<br />
DNA products.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
For some years now, <strong>Boehringer</strong> <strong>Ingelheim</strong> Pharma<br />
in Biberach has had an international reputation<br />
as a reliable contract developer and manufacturer<br />
of biopharmaceuticals from mammalian cells and,<br />
as such, has cultivated a long-standing and synergistic<br />
relationship with highly respected companies<br />
in the biopharmaceutical arena.<br />
Recombinant proteins are manufactured by means<br />
of fermentation in bioreactors. Cultivation depends<br />
here on optimal conditions for cell growth and<br />
production of the drug substance. The organisms<br />
used (cell cultures or bacteria) are highly sensitive<br />
to any changes such as temperature, pH, oxygen<br />
and carbon dioxide saturation, length of the<br />
process or excipients used. Biopharmaceutical<br />
Process Development in Biberach tests and evaluates<br />
at once the different cultivation conditions for<br />
mammalian cell cultures (e.g. CHO cells) on a small<br />
scale. These tests make it possible to determine the<br />
optimal growth conditions for the cells which will<br />
later be implemented in the large-scale bioreactors<br />
for market production. This important part of<br />
development is essential for the economic production<br />
of drug substances with high-yield processes.
On a biopharmaceutical compound’s way from<br />
mind to market there are many hurdles to over-<br />
come. The Biberach teams have successfully<br />
addressed these challenges and many projects<br />
have been advanced into late stages: three new<br />
cell culture products in oncology and in respiratory<br />
diseases have recently been transferred from<br />
the small-scale process development level to the<br />
large-scale production level. This is one step<br />
further on our way to be able to finally apply for<br />
international marketing authorisation.<br />
Furthermore, <strong>Boehringer</strong> <strong>Ingelheim</strong> successfully<br />
entered the Japanese oncology business by signing<br />
a manufacturing agreement with a major Japanese<br />
pharmaceutical company for a monoclonal antibody<br />
in the field of oncology.<br />
our customer orientation<br />
In Biberach, <strong>Boehringer</strong> <strong>Ingelheim</strong> has also developed<br />
a high expression system (bi-hex) which<br />
uses mammalian cell cultures (CHO cells) to<br />
obtain a high yield of the therapeutic protein of<br />
interest. The bi-hex platform meets demands for<br />
shorter development times of a new biological<br />
medicine and follows the paradigm do-it-rightthe-first-time<br />
to avoid unnecessary costs and<br />
delays. The bi-hex system has a four-fold higher<br />
yield from mammalian cells than the current<br />
industrial standard.<br />
Since most modern biopharmaceutical treatments<br />
cannot be taken in tablet form, patients have to<br />
inject the medication using a syringe. With prefilled<br />
syringes the convenience for patients can be<br />
increased usually resulting in a better compliance<br />
How innovations are made<br />
9
9<br />
and treatment success. The worldwide need for<br />
such devices is constantly on the increase.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> established a new aseptic<br />
filling line for pre-filled syringes in Biberach for<br />
this therapeutic need.<br />
Our biopharmaceutical activities also support the<br />
development of <strong>Boehringer</strong> <strong>Ingelheim</strong>’s Animal<br />
Health product pipeline. The support focuses on<br />
R&D activities, such as the evaluation of anti-<br />
microbial peptides, for the treatment of chronic<br />
bacterial infections that cannot be efficiently<br />
controlled by conventional antibiotics, and the<br />
investigation of the safety and efficacy of recom-<br />
binant cytokines for the treatment of certain<br />
canine tumours in a new galenic formulation.<br />
New biotechnology course started<br />
Confirming our leading position in biopharma-<br />
ceuticals development and manufacture, we have<br />
extended our resources for cell line development<br />
services for third parties and have established a<br />
global manufacturing network with collaboration<br />
partners in manufacturing in Asia, Europe and<br />
the USA.<br />
Our biopharmaceutical Industrial Customer<br />
business is not only growing faster than the mar-<br />
ket average but is at the same time adding value to<br />
research and development activities within the<br />
company to ensure a sustained biological product<br />
pipeline with the aim of developing innovative<br />
therapeutic proteins that ultimately benefit<br />
patients.<br />
October <strong>2006</strong> saw the first 35 students begin a pioneering degree course in pharmaceutical biotechnology<br />
at the School of Technology, Biberach, the German town that is home to <strong>Boehringer</strong> <strong>Ingelheim</strong>’s<br />
main biopharmaceuticals site. Studies started only days after the inauguration of a EUR 8.6 million<br />
faculty building.<br />
“This project is of great importance beyond the region for the competitiveness of biopharmaceuticals<br />
in Germany, as well as for patients who attach new hopes to this technology for treatment of their<br />
diseases. Every third medicine being approved today is of biopharmaceutical origin,” Professor Rolf<br />
Werner, Senior Vice-President, Corporate Division Biopharmaceuticals, <strong>Boehringer</strong> <strong>Ingelheim</strong>, said.<br />
The 3.5-year course, which leads to a bachelor’s degree, concentrates on biopharmaceutical production<br />
processes and is more focused than previous study options serving the industry.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>’s Biberach site houses the largest biopharmaceutical production facility in<br />
Europe. The new specialised faculty, set up by <strong>Boehringer</strong> <strong>Ingelheim</strong> in partnership with the local,<br />
regional and federal authorities, as well as commercial partners, represents an important investment<br />
in ensuring the future skills base.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6
Pharmaceuticals<br />
Production<br />
Our Pharmaceuticals Production Division<br />
launches and produces <strong>Boehringer</strong> <strong>Ingelheim</strong>’s<br />
own drugs in a globally coordinated production<br />
network. Each site has a distinctive strength<br />
focusing on launch or seamless supply. Production<br />
sites are competitive centres of business process<br />
excellence with distinctive competencies in<br />
managing, for example, new technologies and<br />
product life cycle.<br />
In <strong>2006</strong>, major investments, such a that for the<br />
respimat®, dabigatran or the LogiPack Center in<br />
<strong>Ingelheim</strong>, were made.<br />
Ben Venue, Bedford, Ohio, USA, one of the world’s<br />
largest sterile injectables manufacturers, also<br />
invested more than USD 50 million in a new<br />
manufacturing facility which will come on line in<br />
2007. For the mid-term, <strong>Boehringer</strong> <strong>Ingelheim</strong><br />
plans to invest a total of more than EUR 1.3 billion<br />
for new products, mainly in Germany and the<br />
USA. Optimising the assets of <strong>Boehringer</strong> Ingel-<br />
heim’s corporate network will further contribute<br />
to increasing efficiency.<br />
Pharmaceuticals Production also offers its capa-<br />
bilities and capacities to our Industrial Customer<br />
business. <strong>Boehringer</strong> <strong>Ingelheim</strong> produces for key<br />
clients, such as Pfizer, Sanofi, GlaxoSmithKline,<br />
Novartis, Bristol Myers Squibb, Sankyo, Sagmel<br />
and Valeant.<br />
our customer orientation<br />
Pharma Chemicals<br />
The sales figures of our worldwide Pharma Chem-<br />
icals business developed very well. Consolidated<br />
sales amounted to EUR 158 million in <strong>2006</strong>,<br />
clearly exceeding the 2005 level (EUR 140 mil-<br />
lion). The importance of the US market increased<br />
further.<br />
The excellent positioning of our large established<br />
line products also contributed to the gratifying<br />
sales development. The phenylephrine business<br />
continued growing at a high level, guaifenesin<br />
sales doubled and ketoprofen volumes developed<br />
very well, especially in Japan. The development in<br />
the new business development area was also<br />
favourable. A couple of very promising projects<br />
will ensure future growth.<br />
Pharmaceuticals Production / Pharma Chemicals<br />
9
9<br />
Our investments in <strong>2006</strong><br />
As a result of dynamic business growth, global investments in tangible fixed assets at <strong>Boehringer</strong><br />
<strong>Ingelheim</strong> increased significantly in <strong>2006</strong>. They totalled EUR 596 million, which is an increase of 12 %<br />
on the previous year.<br />
Major investment projects that began in <strong>2006</strong> included expansion of the chemical production facilities<br />
in Petersburg, Virginia, USA, and Fornovo, Italy. With an investment volume totalling more than EUR<br />
170 million, these projects will ensure a long-term supply of active pharmaceutical ingredients (APIs)<br />
for pharmaceutical production.<br />
An especially important investment project is the expansion of the production facilities of <strong>Boehringer</strong><br />
<strong>Ingelheim</strong> microParts at the site in Dortmund, Germany, where production capacity for respimat®<br />
devices is set to double by 2009 through expansion of the on-site production area and systems. This<br />
will be accompanied by an increase in the number of employees in Dortmund from approximately<br />
350 to 500 by 2010.<br />
In addition to the opening of a new biology research centre in Vienna, Austria, a new centre for<br />
pharmaceutical research and development was inaugurated in Biberach, Germany, in <strong>2006</strong> (right).<br />
With an investment of approximately EUR 50 million, this new building provides a modern working<br />
environment for around 130 employees for administering and applying new active ingredients.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6
Counterfeits – a real threat<br />
for patients<br />
According to World Health Organization (WHO) figures,<br />
about 10 % of all pharmaceuticals are counterfeit, are fakes<br />
or substandard drugs. People in developing countries are<br />
regularly confronted with this problem, also developed<br />
countries too are increasingly affected by this kind of crimi-<br />
nal activity. The main sources for counterfeit drugs are in<br />
Asia and Latin America.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> products were also subject to this<br />
criminal activity. Since 2001, when the Corporate reporting<br />
system was installed, over 100 cases had been reported from<br />
inside or outside the Corporation.<br />
There are several reasons for the rise of counterfeit<br />
medications: weak regulatory oversight, missing legal<br />
framework for prosecution and penalisation, untrained<br />
customs and a supply chain which is not sufficiently<br />
Two-dimensional barcodes are small and can store much<br />
more information than older one-dimensional barcodes.<br />
They are therefore useful for pharma packages. To give<br />
the maximum protection for the patient they should be<br />
combined with tamper-resistant closures.<br />
our customer orientation<br />
controlled by inspections and not well protected against<br />
penetration of faked products. New distribution channels<br />
like the internet are not yet sufficiently controlled either.<br />
“One company alone cannot solve the problem,” says<br />
Dr Thomas Zimmer, Head of Corporate Safety, Quality<br />
& Environmental Protection. Dr Zimmer represents<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> in the European Federation of<br />
Pharmaceutical Industries Associations (EFPIA) as the<br />
chairman of the anticounterfeiting ad hoc group and<br />
as a member of the WHO taskforce IMPACT.<br />
The strategy for combating counterfeits in the developed<br />
world involves a couple of different approaches: a tamper-<br />
resistant package, which is combined with a two-dimen-<br />
sional randomised barcode specific to one individual pack-<br />
age, and a database to support the authentication process of<br />
products as close to the customer as possible, ideally in<br />
pharmacies. In the USA, other techniques, such as radio<br />
frequency identification (RFID) labels are currently being<br />
discussed as too are so-called “pedigrees” which document<br />
each stop a product has made in the supply chain. To<br />
specifically address the Latin American market <strong>Boehringer</strong><br />
<strong>Ingelheim</strong> founded an internal taskforce intended to<br />
collaborate with other companies and local agencies to<br />
contribute to respective solutions.<br />
“But the solution is not only a technical one,” Dr Zimmer<br />
says. “There is in general an over-reliance on technology.<br />
Communication with the public is needed.”<br />
It is a fight which requires patience, persistence and sustained<br />
effort. “This battle can be won, but you can only<br />
win it step by step,” underlines Dr Zimmer.<br />
Investments / Counterfeits<br />
9
9<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6
Group Management <strong>Report</strong> <strong>2006</strong>
Group Management <strong>Report</strong><br />
Business and operating<br />
environment<br />
Overview<br />
The world economy in <strong>2006</strong> maintained the<br />
positive development of the previous year.<br />
Economic growth was broadly based. The<br />
primary contributors to this were the economies<br />
of East Asia, the United States and the euro zone<br />
too, which in <strong>2006</strong> showed a strong increase in<br />
its real gross domestic product (GDP).<br />
In Germany too economic development in<br />
<strong>2006</strong> was favourable. With a growth rate of<br />
2.7 %, real GDP was higher than it had been<br />
since 2000. In contrast to the previous years,<br />
domestic demand, alongside continued, strong<br />
exports, also contributed decisively to this<br />
gratifying development. In particular, the sales<br />
Net sales by businesses <strong>2006</strong><br />
(in millions of EUR)<br />
Prescription Medicines<br />
7,247<br />
Consumer Health Care<br />
1,052<br />
Biopharmaceuticals<br />
548<br />
Pharma Chemicals and<br />
Pharmaceuticals Production<br />
299<br />
Animal Health<br />
361<br />
’05 ’06<br />
8,311<br />
1,064<br />
503<br />
306<br />
374<br />
100 <strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
tax increase, from 16 % to 19 %, announced<br />
for 2007, led to extensive purchases of durable<br />
consumer goods being brought forward.<br />
The pleasing development in <strong>2006</strong> also extended<br />
to the labour market. The number of unemployed<br />
fell distinctly and the number of people in<br />
employment rose further.<br />
The favourable economic development can,<br />
however, only to a very limited extent be applied<br />
to the research-driven pharmaceutical industry.<br />
The growth rate for the world pharmaceutical<br />
industry, discounting currency effects, slowed<br />
again in <strong>2006</strong> – already the third year in succes-<br />
sion.<br />
The reasons for this development are various. In<br />
first place is certainly the fact that a number of<br />
important products from leading pharmaceutical<br />
Net sales by region <strong>2006</strong><br />
Net (in millions sales by of region EUR) <strong>2006</strong><br />
(in millions of EUR)<br />
Americas<br />
Americas 4,559<br />
4,559<br />
Europe<br />
Europe 3,117<br />
3,117<br />
Asia, Australasia,<br />
Asia, Australasia, Africa<br />
Africa 1,859<br />
1,859<br />
’05 ’06<br />
’05 ’06<br />
5,388<br />
5,388<br />
3,295<br />
3,295<br />
1,891<br />
1,891<br />
Total<br />
Total<br />
9,535<br />
9,535<br />
10,574<br />
10,574
companies lost their patent protection. Due to<br />
the subsequent generic competition, these<br />
products were sold at substantially lower prices.<br />
On the other hand, it is becoming increasingly<br />
difficult to close the sales gaps caused by<br />
expiring patent protection with new products.<br />
The number of new registrations still trails<br />
behind the high points of previous years.<br />
Nor was <strong>Boehringer</strong> <strong>Ingelheim</strong> able to avoid the<br />
worldwide trend of declining growth rates in the<br />
industry. Following turnover growth, according<br />
to the healthcare information provider IMS<br />
Health, of 24 % in 2005, discounting currency<br />
effects, primarily borne by innovative launches<br />
(spiriva® and micardis®) and extraordinary<br />
effects (mobic®), growth of only 8.4 % was<br />
achieved in <strong>2006</strong>. However, as in the last seven<br />
years, this exceeded overall market growth<br />
(6.1 % in <strong>2006</strong>). A significant cause of the slowed<br />
growth at <strong>Boehringer</strong> <strong>Ingelheim</strong> is that our anti-<br />
rheumatic mobic®, as expected, faced generic<br />
competition in the USA from summer <strong>2006</strong><br />
and compared to 2005 experienced a decline<br />
in turnover of EUR 250 million.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>’s growth in <strong>2006</strong> was<br />
again borne by all three regions, each of which<br />
surpassed its respective market growth. This<br />
testifies to the international orientation and<br />
strength of our group. The strongest growth was<br />
achieved in the Asia, Australasia, Africa (AAA)<br />
region, with 15 % at constant exchange rates<br />
according to IMS Health. In the Americas region<br />
turnover growth was 9 %, discounting currency<br />
effects. In Europe we posted market growth of<br />
4.6 % at comparable exchange rates.<br />
Net sales<br />
(in millions of EUR) <strong>2006</strong> 2005 Change<br />
Prescription Medicines 8,311 7,247 +15 %<br />
Consumer Health Care 1,064 1,052 +1 %<br />
Biopharmaceuticals 503 548 -8 %<br />
Pharma Chemicals and<br />
and Pharmaceuticals<br />
Production<br />
306 299 +2 %<br />
Animal Health 374 361 +4 %<br />
Borne by growth in all three regions, group net<br />
sales were increased by 10.9 % to almost EUR<br />
10.6 billion. The favourable development of the<br />
business in the last few years (2005: +17 %, 2004:<br />
+10.5 %) has thus continued. As in 2005, exchange<br />
rate developments in <strong>2006</strong> had no decisive impact<br />
on turnover growth. The Japanese yen only lost<br />
some 6% of its value compared with the previous<br />
period, which only had an effect of less than -1 %<br />
on group net sales.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>’s most important sales<br />
segment is the Prescription Medicines (PM)<br />
business that again in <strong>2006</strong> developed very<br />
favourably, with an increase of 15 %.<br />
Net sales by region<br />
(in millions of EUR) <strong>2006</strong> 2005<br />
Americas 5,388 4,559<br />
Europe 3,295 3,117<br />
Asia, Australasia, Africa 1,891 1,859<br />
Group Management <strong>Report</strong> 101
102<br />
In our Animal Health business, with growth of<br />
10 %, we further reinforced our No. 10 position<br />
internationally and thereby secured a market<br />
share of 3 % in this highly competitive market.<br />
We considered growth of 1 % for our Consumer<br />
Health Care (CHC) as unsatisfactory. The main<br />
reason lies in the restrained development of our<br />
business in Japan, which, in addition, suffered<br />
from the marked depreciation of the Japanese<br />
yen. We expect the acquisition at the end<br />
of <strong>2006</strong> of the medication zantac® in the USA<br />
to give us strong growth in CHC business in<br />
this market in 2007.<br />
We anticipated the 8 % decline in turnover in<br />
the Biopharmaceuticals segment, as the previous<br />
period had been positively affected by certain<br />
extraordinary factors (2005 growth in this<br />
segment amounted to 40 %).<br />
In the business area PM we further extended<br />
the market position of our main sales generators<br />
spiriva®, flomax® and micardis®. In these<br />
products <strong>Boehringer</strong> <strong>Ingelheim</strong> now has three<br />
medications with sales volumes exceeding<br />
USD 1 billion. spiriva®, one of the most prescribed<br />
medications for the treatment of chronic<br />
obstructive pulmonary disease (COPD), achieved<br />
the strongest growth with a 45 % increase on the<br />
previous year. micardis®, a medication for the<br />
treatment of hypertension, achieved growth of<br />
34 %, which underlines the strength of this<br />
medication in this highly contested market<br />
segment. micardis® has thereby met our expec-<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
tations and we assume that it has further growth<br />
potential that can gain additional momentum on<br />
publication of the results of the ontarget<br />
study in 2008. flomax®/alna®, a medication for<br />
the treatment of benign prostatic hyperplasia<br />
(BPH), achieved sales growth of 28 %. This<br />
growth is primarily attributable to its market<br />
success in the USA, where it holds a market share<br />
of around 57 %. We expect another important<br />
turnover driver from the <strong>2006</strong> market approval<br />
for sifrol®/mirapex® in the indication restless<br />
legs syndrome (RLS) in both Europe and the USA.<br />
The generic competition for our mobic® in the<br />
USA had been anticipated, but some months later<br />
than it actually happened. For the first time, the<br />
US Food and Drug Administration (FDA) granted<br />
market approval to 14 applicants simultaneously,<br />
which immediately after they entered the market<br />
led to a dramatic decline in prices.<br />
As in previous periods, the positive influence of<br />
our concepts Value through Innovation (VTI)<br />
and Lead & Learn was of importance in <strong>2006</strong>.<br />
Both have continued to play a decisively<br />
formative role in our corporate culture and are<br />
a significant basis for successful cooperation at<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>. With a series of projects<br />
we have ensured that these principles will<br />
continue to be translated into reality so that<br />
we can thereby also successfully meet the<br />
challenges of the future.
To summarise, we see the success of <strong>2006</strong> once<br />
again as confirmation of our business efforts.<br />
In the business areas Research and Development,<br />
Production, Marketing and Sales we regard<br />
ourselves as well-equipped and look to the future<br />
with confidence.<br />
The most important figures for earnings for <strong>2006</strong><br />
are as follows:<br />
(in millions of EUR) <strong>2006</strong> 2005 Change<br />
Net sales 10,574 9,535 +10.9 %<br />
Operating income 2,140 1,923 +11.3 %<br />
Return on net sales (as %) 20.2 20.2<br />
Research and Development<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> has firmly anchored<br />
in its guiding principles (Leitbild) the mission<br />
of helping people suffering from diseases by<br />
researching innovative medicines. Against this<br />
background, the worldwide deployment of<br />
resources in research and development are of<br />
prime importance. In the reporting period,<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> spent EUR 1,574 million<br />
in this business area, thereby increasing our<br />
R&D expenditure by 15.7 % against the previous<br />
period and again investing 14.9 % of our net sales<br />
in our own R&D activities.<br />
In our Human Pharmaceuticals business, R&D<br />
expenditure as a share of net sales was 15.0 %<br />
(2005: 14.4 %). We have distributed our global<br />
research activities to our sites in Germany, the<br />
USA, Austria and Canada. In addition to each<br />
site’s focussing on certain fields of research,<br />
numerous international project teams ensure<br />
that necessary know-how concerning successful<br />
project management is available. <strong>Boehringer</strong><br />
<strong>Ingelheim</strong> has concentrated its R&D on seven<br />
therapeutic areas:<br />
• respiratory diseases<br />
• virology<br />
• oncology<br />
• metabolic diseases<br />
• cardiovascular diseases<br />
• central nervous system diseases<br />
• immunology and inflammation<br />
Research and development <strong>2006</strong> 2005 2004 2003 2002<br />
Total expenditure (in millions of EUR) 1,574 1,360 1,232 1,176 1,304<br />
– as % of net sales 14.9 14.3 15.1 15.9 17.2<br />
Human Pharma. expend. (in millions of EUR) 1,527 1,318 1,195 1,140 1,264<br />
– as % of HP net sales 15.0 14.4 15.3 16.1 17.4<br />
Average number of employees 6,003 5,678 5,471 5,362 5,205<br />
Investments in tangible assets (in millions of EUR;<br />
without investments in infrastructure) 125 116 97 93 97<br />
Group Management <strong>Report</strong> 103
104<br />
Our medications spiriva®, combivent® and<br />
atrovent® have for many years given us a<br />
leading position in the treatment of COPD.<br />
spiriva®, our first blockbuster medication, is one<br />
of the medicines that is most often prescribed for<br />
this indication. The product, co-promoted with<br />
Pfizer, Inc., was also launched in France in <strong>2006</strong><br />
and is now available in most countries. We<br />
assume that the clinical study uplift®, the<br />
outcome of which we expect in 2008, will further<br />
reaffirm the medicinal efficacy of spiriva® with<br />
additional favourable results.<br />
In the therapeutic area of central nervous system<br />
diseases we have in the dopamine agonist<br />
sifrol®/mirapex® (pramipexole) a successful<br />
medication for the treatment of Parkinson’s<br />
disease. In <strong>2006</strong>, pramipexole was also given<br />
market approval by the EU and the FDA for the<br />
treatment of RLS. Together with Lilly, <strong>Boehringer</strong><br />
<strong>Ingelheim</strong> has developed the antidepressant<br />
cymbalta® that has already been introduced in<br />
more than 20 countries. In Germany cymbalta®<br />
has developed into the most successful introduction<br />
of an antidepressant.<br />
In the area of virology <strong>Boehringer</strong> <strong>Ingelheim</strong> has<br />
had for years, with the medication viramune®, a<br />
successful drug in the non-nucleoside reverse<br />
transcriptase inhibitor (NNRTI) class. The introduction<br />
of aptivus® in 2005 complemented our<br />
portfolio of treatments for the immune deficiency<br />
disease AIDS. A further focus in virological<br />
research is in the area of the hepatitis C virus.<br />
With growth of more than 30 % in <strong>2006</strong>,<br />
micardis® (angiotensin II receptor blocker) is<br />
one of the fastest growing <strong>Boehringer</strong> <strong>Ingelheim</strong><br />
products. The medication has developed highly<br />
successfully since launch and is a cornerstone<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
of our therapy area cardiovascular diseases. We<br />
assume that the presentation of the results of the<br />
large-scale studies ontarget and transcend®<br />
(together including more than 30,000 patients)<br />
at the beginning of 2008 will show that the<br />
spectrum for using micardis® can be further<br />
widened substantially. The clinical study<br />
profess®, with over 20,000 patients, to demon-<br />
strate the efficacy of aggrenox® in secondary<br />
stroke prevention, will be concluded in 2008.<br />
Here too we expect an outcome that promises<br />
success. In dabigatran we have a highly<br />
promising substance in clinical phase III in the<br />
therapeutic area cardiovascular diseases for the<br />
prevention and treatment of thrombo-embolic<br />
diseases.<br />
In the urology area <strong>Boehringer</strong> <strong>Ingelheim</strong><br />
markets flomax®/alna®, a medication<br />
in-licensed from Astellas, for the treatment<br />
of benign prostate hyperplasia (BPH).<br />
In the areas oncology and metabolic diseases,<br />
newer research areas for <strong>Boehringer</strong> <strong>Ingelheim</strong>,<br />
we have some interesting development products<br />
in clinical phase II.<br />
Our own previously mentioned research efforts<br />
are complemented by strategic alliances and<br />
in-licensing. Here we can note our exemplary<br />
cooperation with Ablynx for researching and<br />
developing new forms of therapy for Alzheimer’s<br />
disease based on Nanobodies® developed by<br />
Ablynx.<br />
With several compounds in clinical phases II<br />
and III, and a number of substances in the<br />
pre-clinical phase, we will be able to ensure<br />
the flow of new products.
Production<br />
Production sites belonging to the <strong>Boehringer</strong><br />
<strong>Ingelheim</strong> group of companies produce the<br />
company’s own pharmaceutical products within<br />
the framework of a global network. Catchphrases<br />
like “Business Process Excellence” and<br />
“Customer Relation Excellence” characterise the<br />
management culture at these sites. Compliance<br />
and optimisation are among the main focus<br />
areas when new products or technologies are<br />
implemented.<br />
Significant investments in <strong>2006</strong> were at the<br />
site at Cleveland, Ohio, USA to expand our<br />
production capacity (> EUR 50 million) and<br />
in our LogiPack-Center (packaging facility)<br />
at the site in <strong>Ingelheim</strong>, Germany.<br />
With an investment volume of more than<br />
EUR 250 million in our production plants over<br />
the next few years we will establish the basis to<br />
be able to meet future demands on capacity and<br />
fulfil the ever-growing regulatory requirements<br />
of the authorities.<br />
In the area of chemical production we will in<br />
the next few years invest a total of over EUR 150<br />
million at the sites Petersburg, Virginia, USA and<br />
Fornovo, Italy. With these plants and the existing<br />
capacity at <strong>Ingelheim</strong> and Malgrat, Spain we will<br />
guarantee active substance supply for<br />
our pharmaceutical products, and with a view<br />
to our planned launches, on a lasting basis.<br />
At both of our biopharmaceutical production<br />
sites, Biberach, Germany and Vienna, Austria,<br />
capacity was expanded markedly over the past<br />
few years. We consider ourselves very wellequipped<br />
for the next few years, underpinned<br />
by continued strong demand for biotechnological<br />
capacity in which <strong>Boehringer</strong> <strong>Ingelheim</strong> is established<br />
and recognised as a leading manufacturer.<br />
Environmental and employee protection<br />
The safety of employees and protection of the<br />
environment play a central role for <strong>Boehringer</strong><br />
<strong>Ingelheim</strong> at all of our sites. This high priority is<br />
also expressed by the fact that this aspect is<br />
written down in our Leitbild. Our aim is to avoid<br />
damaging impact on the environment and to<br />
conserve natural resources in conducting our<br />
activities. For us, it goes without saying that we<br />
respect and adhere to the legal requirements in<br />
the respective countries. Indeed, we also go<br />
beyond the legally defined demands, where we<br />
regard it as purposeful. Our established processes<br />
in the field of environmental, health and safety<br />
(EH&S) are the foundation for the successful<br />
implementation of the basic principles of<br />
environmental policy. Here our objective is<br />
to scrutinise our existing procedures in a<br />
continuous process of improvement constantly<br />
in search of improvement potential. We ensure<br />
consistent groupwide adherence to these<br />
standards through environmental audits at our<br />
sites (<strong>2006</strong>: 13 environmental audits). Within the<br />
framework of our participation in “Responsible<br />
Care”, the global initiative of the chemical<br />
industry, we have also committed ourselves to its<br />
basic principles.<br />
The certification of our sites at Fornovo, Italy<br />
and Yamagata, Japan, by external inspectors in<br />
accordance with ISO 14001 confirmed our high<br />
internal standards. In this we also see an<br />
incentive to build on our excellent position in<br />
these areas.<br />
Group Management <strong>Report</strong> 105
106<br />
Employee reporting<br />
The sustained, positive development of our<br />
business has led to a further expansion of the<br />
number of our employees. Averaged over the year,<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> in <strong>2006</strong> employed 38,428<br />
people. This corresponds to growth of 3 %,<br />
following 5 % growth in 2005.<br />
In the reporting year, we, through a series<br />
of programmes and events, intensified and<br />
established as a central element of our working<br />
culture, the Lead & Learn concept that has<br />
been implemented since 2005. In this we see a<br />
significant basis to further create Value through<br />
Innovation in order to face the challenges ahead.<br />
An important goal of our human resources work<br />
is to recruit and retain the best people on a lasting<br />
basis. <strong>Boehringer</strong> <strong>Ingelheim</strong> offers talented<br />
employees various paths to personal and leadership<br />
development in order to develop further<br />
their abilities. We are convinced that our remuneration<br />
schemes also put us in a very good,<br />
competitive position. Our system of financial<br />
rewards provides, in addition to a basic marketorientated<br />
salary, for a variable salary element<br />
that essentially follows company success and the<br />
achievement of personal targets. Alongside this,<br />
our extensive social contributions play an important<br />
role in the overall remuneration concept.<br />
As in previous years, <strong>Boehringer</strong> <strong>Ingelheim</strong><br />
in <strong>2006</strong> again received recognition in many<br />
countries in conjunction with opinion polls to<br />
find the best employers. Part of our fundamental<br />
beliefs is not to rest on our laurels. In 2007,<br />
we will conduct a group-wide opinion survey<br />
among our employees. From the results of this<br />
survey we will access further improvement<br />
potential.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
In addition, an important part of our human<br />
resources work is our commitment to education.<br />
In the reporting period, we offered apprenticeships<br />
to 667 young people in Germany, thereby<br />
raising the previous year’s level once again. In<br />
the years before, we had already at the Biberach<br />
and <strong>Ingelheim</strong> sites taken account of the social<br />
challenge of creating a better work-life balance<br />
and, in cooperation with the local communities,<br />
promoted and supported the establishment of<br />
day-care centres for children.<br />
In <strong>2006</strong>, a childcare centre with 130 places was<br />
also built at our site at Ridgefield, Connecticut,<br />
USA.<br />
Social responsibility<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> has for more than 100<br />
years taken care of its social responsibility in a<br />
very extensive and highly attentive manner. Our<br />
understanding is that our responsibility applies<br />
to our patients, our employees and their families<br />
as well as the communities and countries in<br />
which we operate (Good Corporate Citizenship).<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> orientates itself after the<br />
basic principles of “corporate governance” and<br />
“corporate social responsibility”, as proposed<br />
by various international organisations (United<br />
Nations, World Health Organization, Organisation<br />
for Economic Cooperation and Development<br />
and the EU). These principles are employed in<br />
our strategic deliberations, our corporate culture<br />
and our daily business.
In the area of HIV/AIDS therapy, we have for<br />
years considered it our duty to undertake the<br />
special social task of making our medication<br />
viramune® available to patients who would<br />
otherwise receive an inadequate supply of<br />
medicine. Through our donation programme<br />
we support activities that clearly reduce the risk<br />
of transmission of HIV from mother to child<br />
during birth using an antiretroviral therapy. For<br />
this purpose we make our AIDS medication<br />
viramune® available free of charge. In <strong>2006</strong>,<br />
we in addition reduced the price for viramune®<br />
for some developing countries and within the<br />
framework of the Accelerating Access Initiative<br />
(AAI) programme we offer these countries considerable<br />
price reductions. Furthermore, we have<br />
in the meantime granted seven manufacturing<br />
licences that allow generic production in the<br />
developing countries concerned.<br />
At the same time in <strong>2006</strong>, we sought through<br />
numerous clinical studies with aptivus® and<br />
viramune® to gain further insights into the<br />
treatment and therapy of AIDS.<br />
Another given for our social responsibility as<br />
a company is, where possible, to encourage<br />
and support the voluntary commitment of our<br />
employees. Many of our employees engage<br />
voluntarily in their free time in social projects<br />
and make a decisive contribution where help<br />
is called for.<br />
Results from operations,<br />
financial position and<br />
net assets<br />
Results from operations<br />
Independent market data show that <strong>Boehringer</strong><br />
<strong>Ingelheim</strong> again grew faster than the overall<br />
market in <strong>2006</strong>. We thereby gained market share<br />
for the seventh consecutive year. This success<br />
was all the more remarkable, as <strong>Boehringer</strong><br />
<strong>Ingelheim</strong> achieved this growth essentially with<br />
its own resources, i.e. with products from its own<br />
research. According to current market data,<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> ranks 15th among the<br />
world’s largest pharmaceutical companies, with<br />
a market share of 2 %.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> increased its net sales by<br />
10.9 % in <strong>2006</strong> to EUR 10,574 million. Exchange<br />
rate movements, compared to the previous period<br />
2005, had a slightly negative impact (-1 %) on<br />
this development. When analysing our growth, it<br />
must be noted that changes in the consolidation<br />
were negligible. The acquisition of the product<br />
zantac® in the USA took place at the end of<br />
<strong>2006</strong> and has not yet affected our turnover<br />
development.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> is divided into the businesses<br />
Human Pharmaceuticals and Animal<br />
Components of growth in net sales (as %) <strong>2006</strong> 2005 2004 2003 2002<br />
Price/quantity/new introductions 12.1 17.4 16.1 7.8 10.1<br />
Acquisition and sale of businesses –0.3 –0.5 –0.5 –0.2 7.1<br />
Currency effect –0.9 0 –5.1 –10.2 –4.0<br />
Group Management <strong>Report</strong> 107
108<br />
Health. The Human Pharmaceuticals business<br />
encompasses the segments PM, CHC as well<br />
as Industrial Customers. In <strong>2006</strong>, this business<br />
achieved net sales of EUR 10,200 million,<br />
corresponding to growth of 11 %. The Human<br />
Pharmaceuticals business thereby accounted<br />
for 96 % of group net sales.<br />
Prescription Medicines<br />
PM is by far the most important segment in<br />
our Human Pharmaceuticals business. In <strong>2006</strong>,<br />
net sales of EUR 8,311 million were achieved,<br />
corresponding to growth of 14.7 % compared<br />
to the previous year (2005: EUR 7,247 million).<br />
The significance of this segment is evident in<br />
that it accounts for 81 % of our Human Pharma-<br />
ceuticals business.<br />
This gratifying development was borne by our<br />
strategic products which all showed marked<br />
growth:<br />
Net sales<br />
(in millions of EUR) <strong>2006</strong> 2005 Growth<br />
spiriva® 1,381 951 45 %<br />
micardis® 967 724 34 %<br />
aggrenox® 225 172 31 %<br />
flomax®<br />
sifrol®/mirapex®<br />
922<br />
536<br />
721<br />
434<br />
spiriva® continued to develop favourably and<br />
28 %<br />
23 %<br />
is our fastest growing product. For the products<br />
micardis® and aggrenox® we also expect<br />
further growth in the next few years, supported<br />
by the outcomes of clinical studies. In <strong>2006</strong>,<br />
our medication sifrol®/mirapex® was granted<br />
market approval in the indication RLS, so we<br />
can also expect further growth from the<br />
extended spectrum of use in 2007. Due to the<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
loss of exclusivity for mobic® in the USA in <strong>2006</strong>,<br />
we had, as already mentioned, to take a drop in<br />
net sales of this product exceeding EUR 250<br />
million which will be even greater in the 2007<br />
period.<br />
The overwhelmingly strongest region in the<br />
PM segment is the Americas, with a 54 % share<br />
of group net sales. With only a very modest<br />
foreign exchange influence, growth of 8.9 % was<br />
achieved, discounting currency effects. Growth<br />
of 8.5 % in the pharmaceutical market was<br />
thereby surpassed once again. Net sales for the<br />
region amounted to EUR 4.5 billion. As a single<br />
market, the USA was the largest and most important<br />
country for <strong>Boehringer</strong> <strong>Ingelheim</strong>, with an<br />
86 % share of net sales. In the US market the<br />
products spiriva®, micardis® and flomax®<br />
showed very gratifying development, all achieving<br />
double-digit growth.<br />
In the Europe region a net sales volume of<br />
EUR 2,180 million was achieved, giving the<br />
region a share of 26 % in this segment. Market<br />
growth of 3.9 % in the region was exceeded<br />
slightly. The country in this region with the<br />
biggest turnover was Germany, which contributed<br />
EUR 446 million to total net sales. This<br />
represented a 2 % decline in net sales in our<br />
home market compared to the previous period.<br />
Our businesses in Eastern Europe showed very<br />
pleasing development, with many countries<br />
achieving double-digit growth.<br />
Exchange rate movements, particularly that of<br />
the Japanese yen, had a negative impact on net<br />
sales development in the AAA region. At constant<br />
exchange rates, we grew 15 %, markedly above<br />
the overall market that had a growth rate of
only 2 %. The region’s overall net sales reached<br />
EUR 1,379 million, with Japan in the leading<br />
position with a 62 % share of net sales. In <strong>2006</strong>,<br />
Japan’s total net sales in PM amounted to EUR<br />
849 million.<br />
Consumer Health Care<br />
In the business segment CHC we increased<br />
our net sales to EUR 1,064 million, a rise of 3 %<br />
compared to the previous year, discounting<br />
currency effects. We continue to pursue our<br />
strategic orientation with a focus on defined key<br />
brands. In <strong>2006</strong>, we distinctly strengthened our<br />
presence on the over-the-counter (OTC) market<br />
in the USA by acquiring the product zantac®.<br />
Together with our product dulcolax® we<br />
now have a strong position there in the gastrointestinal<br />
medications segment.<br />
The most important product groups in this<br />
segment in <strong>2006</strong> were:<br />
Net sales<br />
(in millions of EUR) <strong>2006</strong> 2005 Growth<br />
dulcolax® 122 115 6 %<br />
mucosolvan® 108 91 19 %<br />
pharmaton® 96 88 9 %<br />
buscopan® 71 59 20 %<br />
Business development was very different from<br />
region to region. While the Americas (+ 10 %)<br />
and Europe (+ 5 %) marked increases in net sales,<br />
turnover in the AAA region (- 9 %) declined. The<br />
reason for the weak development in the AAA<br />
region was the depreciation of the Japanese yen<br />
against the euro.<br />
Industrial Customers<br />
In our Industrial Customers business we have<br />
brought together the third party business of<br />
Pharmaceuticals Production, the Pharma<br />
Chemicals area and our contract manufacturing<br />
of Biopharmaceuticals. Total net sales for these<br />
three business areas in <strong>2006</strong> amounted to EUR<br />
809 million, thereby falling below the figure for<br />
the previous year. It must be noted that the 2005<br />
figures contained favourable, one-off effects in<br />
Biopharmaceuticals. Contract manufacture of<br />
biotechnologically produced medications takes<br />
the most important place.<br />
Animal Health<br />
In the global markets in animal health products,<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> is in No. 10 position, with<br />
a market share of 3 %. Compared to the previous<br />
year, net sales were increased in <strong>2006</strong> by 4 %,<br />
despite the sale in 2005 of some non-strategic<br />
product groups. On the basis of comparable<br />
underlying business, growth in <strong>2006</strong> was 8 %<br />
in local currency terms. Net sales amounted to<br />
EUR 374 million.<br />
Worldwide growth was achieved by the following<br />
product groups in particular:<br />
Net sales<br />
(in millions of EUR) <strong>2006</strong> 2005 Growth<br />
enterisol ileitis® 22 17 29 %<br />
vetmedin® 19 16 19 %<br />
metacam® 75 68 10 %<br />
Group Management <strong>Report</strong> 109
110<br />
From a regional point of view, Europe showed<br />
marked growth. With an increase of 10 %, net<br />
sales reached a volume of EUR 179 million.<br />
Development in the other two regions showed a<br />
slight decline. In the Americas region this was<br />
attributable to the sale of certain product groups,<br />
while in AAA the currency effect of the Japanese<br />
yen had a negative impact.<br />
Expenditure and income<br />
Total operating costs were 5.5 % higher than in<br />
2005 and reached EUR 8,848 million. In 2005,<br />
they amounted to EUR 8,388 million. Personnel<br />
costs rose by 6 % in <strong>2006</strong> to EUR 2,836 million,<br />
which reflects an increase in the average headcount<br />
by 1,022 employees.<br />
Depreciations remained at the 2005 level at<br />
EUR 530 million. Other operating expenses rose<br />
by EUR 425 million (+ 12 %). Overall, operating<br />
income increased by EUR 217 million compared<br />
to 2005 and now amounts to EUR 2,140 million.<br />
The return on net sales was maintained at the<br />
2005 level of 20 %.<br />
The financial income in the reporting period<br />
amounted to EUR 102 million and was<br />
significantly affected by the sale of a number<br />
of financial assets. Borne by increase in income<br />
from operations, income before taxes rose to<br />
EUR 2,243 million and was thereby EUR 355<br />
million, or 19 %, distinctly higher than in 2005.<br />
Tax expenses amounted to EUR 514 million,<br />
corresponding to a tax ratio of 23 % (2005: 20 %).<br />
Here, it must be taken into consideration that due<br />
to regulations of the German commercial code,<br />
personal taxes on group activities levied on the<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
shareholders may not be shown as tax expenses.<br />
These are presented as withdrawals from accu-<br />
mulated group equity.<br />
Taking this extraordinary effect into considera-<br />
tion, the actual tax ratio is markedly higher than<br />
the value shown in the profit and loss statement.<br />
To sum up, net income rose to EUR 1,722 million.<br />
This signifies a EUR 231 million increase<br />
compared to 2005.<br />
Financial position<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>’s financial management<br />
instruments and methods are aligned with<br />
international standards for a modern<br />
industrial company. The goal of the financial<br />
management is to support the business strategy<br />
of our company by providing or investing financial<br />
assets, taking account of the foreign<br />
exchange risk.<br />
As a result of <strong>Boehringer</strong> <strong>Ingelheim</strong>’s international<br />
orientation, exchange rate fluctuations<br />
have a considerable impact on the measure of<br />
the company’s success. Here, the exchange rate<br />
development of the US dollar represents the<br />
highest single risk. Within the framework of<br />
group-wide financial reporting, foreign exchange<br />
risk is regularly investigated and analysed. To<br />
secure against this risk, particularly from goods<br />
and services, derivative financial instruments are<br />
employed. The manner and extent of these<br />
measures are regulated by the relevant group<br />
guideline.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>’s good economic development<br />
in <strong>2006</strong> is also reflected in the development
of the cash flow, which rose by EUR 248 million<br />
compared to 2005 to EUR 2,317 million (+ 12 %).<br />
The cash flow from operating activities is EUR<br />
1,500 million, clearly exceeding funds used for<br />
investment activities. In <strong>2006</strong>, we increased<br />
our investment efforts again (+ EUR 64 million)<br />
and entered an investment volume of EUR 596<br />
million in tangible assets. There was an addition<br />
of EUR 451 million to the intangible assets,<br />
essentially due to the acquisition of the product<br />
zantac® in the USA. Securities and liquid funds<br />
stood at EUR 3,934 million at year-end.<br />
To summarise, it can be noted that, because<br />
of existing liquidity, the given capital structure<br />
and the available funding potential, the financial<br />
preconditions for successfully realising our<br />
strategy remain in place.<br />
In Germany the new galenics building in<br />
Biberach and the new packaging facility<br />
(LogiPack-Center) in <strong>Ingelheim</strong> were completed.<br />
Furthermore, a number of new investment<br />
projects were started in Germany. Particularly<br />
noteworthy are the expansion of our production<br />
plants at the Dortmund site (BI microParts),<br />
the new chemical laboratory and a new works<br />
canteen in <strong>Ingelheim</strong>. In Biberach additional<br />
investments in the biotechnical active ingredient<br />
production facilities were started.<br />
In Italy we laid the foundation stone for a new<br />
chemical synthesis facility at the Fornovo site.<br />
In addition, we have commenced activities<br />
for building a new synthesis plant in Petersburg,<br />
Virginia, USA. It was also decided to expand<br />
production capacity at the Ben Venue site in<br />
Cleveland, Ohio. In the USA construction was<br />
also started at the site at Ridgefield, Connecticut<br />
on a laboratory building in order to increase<br />
our research capacity.<br />
Net assets<br />
Total assets in <strong>2006</strong> stood at EUR 11,845 million,<br />
the same level as in the previous year. Tangible<br />
and intangible assets are covered by <strong>Boehringer</strong><br />
<strong>Ingelheim</strong>’s total equity.<br />
By actively managing the days of sales outstand-<br />
ing of our receivables, we achieved an increase of<br />
the receivables, discounting currency effects, that<br />
was disproportionately small relative to the<br />
expansion of our business.<br />
Due to the transfer of liquid funds into the<br />
financial assets, liquid assets declined, compared<br />
to the previous year, to EUR 866 million (2005:<br />
EUR 1,167 million).<br />
Group equity increased compared to the<br />
previous year to EUR 5,363 million (2005:<br />
EUR 4,825 million) because of the favourable<br />
business development. Long-term disposable<br />
capital (equity, pension provisions and long-term<br />
liabilities) amounted to EUR 7,450 million,<br />
corresponding to 63 % of the balance sheet total.<br />
This year again, this item covers all the intangi-<br />
ble and tangible assets, inventories and liabilities<br />
as well as almost half the liquid assets.<br />
The balance sheet and the related balance sheet<br />
ratios round off the altogether favourable picture<br />
that the earnings and financial position have<br />
already drawn.<br />
The combined evaluation of the net assets,<br />
financial position and results of operations<br />
shows that <strong>Boehringer</strong> <strong>Ingelheim</strong> is a soundly<br />
financed and profitable company. In <strong>2006</strong>, we<br />
created a firm basis for our further business<br />
development.<br />
Group Management <strong>Report</strong> 111
112<br />
<strong>Report</strong> on post-balance<br />
sheet date events<br />
Since the end of the financial year <strong>2006</strong>, we<br />
have not become aware of any events that are of<br />
material significance to the group of companies,<br />
or could lead to a reappraisal of its asset, financial<br />
or earnings position.<br />
Risk report<br />
The <strong>Boehringer</strong> <strong>Ingelheim</strong> group’s risk management<br />
system has proved effective over recent<br />
years and the concept was unchanged in the<br />
reported period.<br />
With the participation of the country organisations,<br />
and the inclusion of various function<br />
holders, business-specific risks are systematically<br />
reported and monitored.<br />
Our strategy and planning processes, which<br />
focus over several years, also form a significant<br />
element of our active risk management. Hereby,<br />
we ensure that all risks known to us are reported,<br />
thoroughly analysed and evaluated. Following<br />
the appropriate classification, counter-measures<br />
are commenced and their implementation<br />
consistently monitored.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
Within the framework of the audit plan approved<br />
by the Board of Managing Directors, internal<br />
auditing conducted routine and extraordinary<br />
audits worldwide during the reporting year.<br />
The focus was the efficiency of structures and<br />
processes, securing assets, adherence to legal<br />
requirements and guidelines, the functionality<br />
of systems and the effectiveness of internal<br />
controls.<br />
Currency and interest rate risks, which arise<br />
because of our group’s international business<br />
relationships, are constantly examined and<br />
limited by appropriate hedging strategies. From<br />
the portfolio of receivables and liabilities on<br />
trade accounts no risk arose for the <strong>Boehringer</strong><br />
<strong>Ingelheim</strong> group which exceeds the industry<br />
norm. This equally applies to the default risks<br />
that are mainly secured against economic and<br />
political uncertainties.<br />
Risks in the area of environmental health and<br />
safety are minimised preventively by adherence<br />
to our own very high safety standards. For<br />
possible incidents appropriate emergency plans<br />
are in place that are regularly tested and trained.<br />
Furthermore, <strong>Boehringer</strong> <strong>Ingelheim</strong> has<br />
risk-adjusted insurance coverage.<br />
In addition to the general business risks associated<br />
with the industry, we are not currently<br />
aware of any risks that substantially threaten the<br />
further development of <strong>Boehringer</strong> <strong>Ingelheim</strong>’s<br />
business.
<strong>Report</strong> on expected<br />
developments<br />
The good results of the financial year <strong>2006</strong><br />
confirmed our internal planning parameters.<br />
Our businesses and functions have, within the<br />
framework of our planning processes, in the<br />
reporting period adapted their multi-year<br />
planning on the basis of current development.<br />
The insights gained from this essentially<br />
confirm our strategic parameters and targets.<br />
For our key brands spiriva®, micardis®,<br />
flomax® and sifrol® we foresee further<br />
growth potential in 2007. For spiriva® and<br />
micardis® we expect positive outcomes in<br />
the next two years from various clinical studies,<br />
such as uplift® (spiriva®) and ontarget and<br />
transcend® (both micardis®). For the product<br />
flomax® we anticipate further market growth in<br />
the relevant indication, especially in the important<br />
US market, from which our product will<br />
benefit. The market approval received from the<br />
European authorities and the FDA in <strong>2006</strong><br />
for our product sifrol® in the indication RLS<br />
will further reinforce the development of this<br />
product. We expect the results in 2008 of the<br />
profess® study on micardis® and aggrenox®,<br />
a medication to prevent the risk of secondary<br />
stroke.<br />
The spiriva® respimat® Soft Mist Inhaler<br />
(SMI) was filed for registration with the Euro-<br />
pean authorities in <strong>2006</strong>. For 2007, it is planned<br />
to put together the documentation for filing<br />
with the US authorities. Studies confirm that<br />
the SMI is preferred by our patients compared<br />
to other dosage forms. This gas propellant-free<br />
mist generation achieves improved uptake of<br />
the active ingredient via the lungs.<br />
At the beginning of <strong>2006</strong>, we began<br />
re-volution®, the largest clinical study<br />
programme to date in thrombo-embolic diseases,<br />
in which 27,000 patients worldwide will take<br />
part. It will investigate dabigatran, a novel, orally<br />
available thrombin inhibitor researched and<br />
developed by <strong>Boehringer</strong> <strong>Ingelheim</strong> for the<br />
prevention and treatment of thrombo-embolic<br />
conditions.<br />
Other important development projects are in<br />
phases II and III. For flibanserin a number of<br />
phase III studies were commenced in <strong>2006</strong>.<br />
Flibanserin is a novel treatment approach for the<br />
treatment of hypoactive sexual desire disorder<br />
(HSDD). In the oncology area, one of our newer<br />
fields of research, we have developed some promising<br />
approaches in cancer therapy. Several<br />
clinical phase II studies were initiated in <strong>2006</strong>.<br />
We expect their outcomes in 2007.<br />
Group Management <strong>Report</strong> 113
114<br />
For the financial year 2007, we assume turnover<br />
growth in single figures. One reason for this is<br />
the loss of exclusivity for our product mobic®<br />
in the USA in <strong>2006</strong>. For this product alone we<br />
estimate that we will have a decline in net sales<br />
of more than EUR 350 million in 2007. The fact<br />
that we, in spite of everything, expect growth in<br />
net sales exceeding 5 %, is testimony to the<br />
strength and balance of our portfolio.<br />
On the basis of current planning, we expect net<br />
sales of more than EUR 11 billion in 2007. For<br />
2008, we plan to exceed the EUR 12 billion mark<br />
for the first time.<br />
With approximately EUR 700 million we will<br />
again increase our investment expenditure<br />
in 2007 compared to the previous year. Our<br />
investments will be concentrated in the areas of<br />
production and research. Major projects in the<br />
chemicals area to ensure that we can meet future<br />
active ingredient demand were approved with a<br />
total investment volume of more than EUR 160<br />
million. In the research area projects for modernising<br />
and expanding our capacity at our German<br />
and US sites have been decided. With these<br />
investments we will establish the necessary<br />
preconditions to also be able to conduct<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 6<br />
innovative research long term and thereby be<br />
able to guarantee the necessary flow of new<br />
products in the future.<br />
Although further concentration occurred in the<br />
pharmaceutical industry in <strong>2006</strong>, especially in<br />
the German market, our declared goal remains<br />
to manage <strong>Boehringer</strong> <strong>Ingelheim</strong> long term as<br />
an independent, family-owned company. Our<br />
endeavour in this context is to achieve aboveaverage<br />
growth in the market that will deliver<br />
a corresponding increase in the value of the<br />
company. To this end, we will also continue to<br />
keep a close eye on the profitability of our group.<br />
With the success of the year <strong>2006</strong> we were able<br />
to link up with the very good figures of the<br />
previous year and further improve our turnover<br />
and net income. This confirms our strategic<br />
orientation and gives us confidence that we can<br />
reach our demanding goals in the future too. We<br />
will continue to take every measure in order for<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> to be able to successfully<br />
develop further. We consider this a duty towards<br />
all stakeholders, primarily towards all patients<br />
for whom we wish to make effective and safe<br />
medicines available in the future.
Consolidated<br />
Financial Statements <strong>2006</strong>
Overview of the major consolidated companies<br />
Germany<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong><br />
Pharma GmbH & Co. KG,<br />
<strong>Ingelheim</strong><br />
<strong>Boehringer</strong> <strong>Ingelheim</strong><br />
Vetmedica GmbH, <strong>Ingelheim</strong><br />
*sole general partner:<br />
<strong>Boehringer</strong> AG<br />
116<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> GmbH <strong>Boehringer</strong> <strong>Ingelheim</strong><br />
Europe GmbH<br />
Distribution<br />
Production<br />
Research<br />
Finland<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong><br />
Finland Ky, Espoo<br />
Norway<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong><br />
Norway KS, Asker<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> a n n u a l r e p o r t 2 0 0 6<br />
C. H. <strong>Boehringer</strong> Sohn*<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong><br />
International GmbH<br />
Austria<br />
Forschungsinstitut für Molekulare<br />
Pathologie Gesellschaft mbH,<br />
Vienna<br />
Belgium<br />
SCS <strong>Boehringer</strong> <strong>Ingelheim</strong><br />
Comm. V., Brussels<br />
China<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong><br />
International Trading (Shanghai)<br />
Co. Ltd., Shanghai<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> Shanghai<br />
Pharmaceuticals Co. Ltd.,<br />
Shanghai<br />
Philippines<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> (Phil.) Inc.,<br />
Manila<br />
South Korea<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> Korea Ltd.,<br />
Seoul (50 %)<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> Vetmedica<br />
Korea Ltd., Seoul<br />
Argentina<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> S.A.,<br />
Buenos Aires<br />
Australia<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> Pty. Ltd.,<br />
North Ryde<br />
Austria<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> Austria<br />
GmbH, Vienna<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong><br />
Pharma Ges.m.b.H., Vienna<br />
Brazil<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> do Brasil<br />
Quimica e Farmaceutica Ltda.,<br />
São Paulo<br />
Solana Agro Pecuaria Ltda.,<br />
Arapongas<br />
Canada<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> (Canada)<br />
Ltd., Burlington<br />
Chile<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> Ltda.,<br />
Santiago de Chile<br />
Colombia<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> S.A., Bogotá<br />
Czech Republic<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> s.r.o.,<br />
Prague<br />
Denmark<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> Danmark<br />
A/S, Copenhagen<br />
Ecuador<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> del Ecuador<br />
Cia. Ltda., Quito
C. H. <strong>Boehringer</strong> Sohn Grundstücksverwaltung GmbH & Co. KG<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong><br />
Auslandsbeteiligungs GmbH<br />
France<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong><br />
France S.A.S., Paris<br />
Labso Chimie Fine S.A.R.L.,<br />
Blanquefort<br />
Greece<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> Ellas AE,<br />
Athens<br />
Indonesia<br />
PT <strong>Boehringer</strong> <strong>Ingelheim</strong><br />
Indonesia, Jakarta<br />
Italy<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> Italia S.p.A.,<br />
Reggello<br />
Bidachem S.p.A.,<br />
Fornovo S. Giovanni<br />
Istituto De Angeli srl,<br />
Reggello<br />
Japan<br />
Nippon <strong>Boehringer</strong> <strong>Ingelheim</strong><br />
Co. Ltd., Kawanishi<br />
SSP Co. Ltd., Tokio (57 %)<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong><br />
Vetmedica Japan Co. Ltd.,<br />
Kawanishi<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong><br />
Seiyaku Co., Ltd., Yamagata<br />
Netherlands<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> B. V.,<br />
Alkmaar<br />
Poland<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> Sp.zo.o.,<br />
Warsaw<br />
Portugal<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> Lda.,<br />
Lisbon<br />
Unilfarma Lda., Lisbon<br />
South Africa<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> (Pty.) Ltd.,<br />
Randburg<br />
<strong>Ingelheim</strong> Pharmaceuticals (Pty.)<br />
Ltd., Randburg<br />
Spain<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> España S.A.,<br />
Barcelona<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> S.A.,<br />
Barcelona<br />
Europharma S.A., Barcelona<br />
Laboratorios Fher S.A., Barcelona<br />
Sweden<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> AB,<br />
Stockholm<br />
Switzerland<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong><br />
(Schweiz) GmbH, Basel<br />
Pharmaton S.A., Lugano<br />
Taiwan<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> Taiwan Ltd.,<br />
Taipei<br />
Thailand<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> (Thai) Ltd.,<br />
Bangkok<br />
Turkey<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> Ilac<br />
Ticaret A.S., Istanbul<br />
United Kingdom<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> Ltd.,<br />
Bracknell<br />
Venezuela<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> C.A.,<br />
Caracas<br />
Pharma Investment Ltd.,<br />
Burlington, Canada<br />
USA<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> Corp.,<br />
Ridgefield, Connecticut<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong><br />
Pharmaceuticals, Inc.,<br />
Ridgefield, Connecticut<br />
Ben Venue Laboratories, Inc.,<br />
Bedford, Ohio<br />
Roxane Laboratories, Inc.,<br />
Columbus, Ohio<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong><br />
Vetmedica, Inc.,<br />
St. Joseph, Missouri<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong><br />
Roxane, Inc., Columbus, Ohio<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong><br />
Chemicals, Inc.,<br />
Petersburg, Virginia<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong><br />
Investment Ltd.,<br />
Burlington, Canada<br />
Mexico<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong><br />
Promeco S.A. de C.V., Mexico City<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> Vetmedica<br />
S.A. de C.V., Guadalajara<br />
Overview of the major consolidated companies<br />
117
118<br />
C. H. <strong>Boehringer</strong> Sohn, <strong>Ingelheim</strong><br />
Consolidated balance sheet<br />
Assets (in millions of EUR) Notes 1) 31.12.<strong>2006</strong> 31.12.2005<br />
Intangible assets (3.1) 554 233<br />
Tangible assets (3.2) 2,886 2,900<br />
Financial assets (3.3) 3,043 3,396<br />
Fixed assets 6,483 6,529<br />
Inventories (3.4) 1,280 1,229<br />
Accounts receivable (3.5) 2,333 2,143<br />
Securities 79 80<br />
Cash and cash equivalents 866 1,167<br />
Current assets 4,558 4,619<br />
Deferred taxes 746 821<br />
Deferred charges and prepaid expenses 58 49<br />
Total assets 11,845 12,018<br />
Liabilities and equity (in millions of EUR) Notes 1) 31.12.<strong>2006</strong> 31.12.2005<br />
Shareholders’ capital 178 178<br />
Group reserves 3,415 3,001<br />
Balance sheet currency conversion difference -140 -61<br />
Net income 1,722 1,491<br />
Equity 5,175 4,609<br />
Minority interests 188 216<br />
Group equity 5,363 4,825<br />
Provisions (3.6) 4,459 4,754<br />
Accounts payable (3.7) 1,774 2,174<br />
Liabilities 6,233 6,928<br />
Deferred taxes 182 204<br />
Deferred charges 67 61<br />
Total liabilities and equity 11,845 12,018<br />
1) For explanation, see relevant section in the Notes to the Consolidated Financial Statements.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> a n n u a l r e p o r t 2 0 0 6
C. H. <strong>Boehringer</strong> Sohn, <strong>Ingelheim</strong><br />
Consolidated profit and loss statement<br />
(in millions of EUR) Notes 1) <strong>2006</strong> 2005<br />
Net sales (4.1) 10,574 9,535<br />
Changes in inventories 40 175<br />
Other internal work performed and capitalised 4 3<br />
Other operating income 370 598<br />
Total revenues 10,988 10,311<br />
Material costs (4.2) -1,484 -1,613<br />
Personnel costs (4.3) -2,836 -2,671<br />
Amortisation of intangible and depreciation of tangible assets (4.4) -530 -531<br />
Other operating expenses (4.5) -3,998 -3,573<br />
Operating income 2,140 1,923<br />
Financial income (4.6) 102 -35<br />
Holding income (4.7) 1 0<br />
Income before taxes 2,243 1,888<br />
Taxes 2) (4.8) -514 -374<br />
Income after taxes 1,729 1,514<br />
Third-party share -7 -23<br />
Net income (4.9) 1,722 1,491<br />
1) For explanation, see relevant section in the Notes to the Consolidated Financial Statements.<br />
2) Due to legal requirements the disclosure of the shareholders’ personal taxes arising from<br />
consolidated business activities as tax expenses is not allowed. These taxes are shown as<br />
withdrawals from the accrued group capital.<br />
Consolidated balance sheet / Consolidated profit and loss statement<br />
119
120<br />
C. H. <strong>Boehringer</strong> Sohn, <strong>Ingelheim</strong><br />
Cash flow statement<br />
(in millions of EUR) <strong>2006</strong> 2005<br />
Income after taxes 1,729 1,514<br />
Write-downs/write-ups on fixed assets 1) 527 529<br />
Change in provisions for pensions 61 26<br />
Cash flow 2,317 2,069<br />
Change in other provisions -184 561<br />
Other non-cash income and expenses -5 43<br />
Gain on disposals of fixed assets -30 -4<br />
Increase of inventories -99 -90<br />
Increase of accounts receivable and other assets not related to<br />
investing or financing activities -302 -385<br />
Decrease/increase of trade accounts payable and other liabilities<br />
not related to investing or financing activities -197 196<br />
Cash flow from operating activities 1,500 2,390<br />
Investments in intangible assets -451 -57<br />
Investments in property, plant and equipment -596 -532<br />
Investments in non-current financial assets 1) -11 -6<br />
Proceeds from disposals of intangible assets 2 2<br />
Proceeds from disposals of property, plant and equipment 92 43<br />
Proceeds from disposals of non-current financial assets 1) 13 21<br />
Cash flow from investing activities –951 –529<br />
Cash payments to shareholders and minority shareholders -1,088 -1,360<br />
Cash proceeds from borrowings/repayments of loans -96 26<br />
Cash flow from financing activities –1,184 –1,334<br />
Change in liquid funds from cash relevant transactions -635 527<br />
Changes in liquid funds due to changes in scope of consolidation 0 0<br />
Changes in liquid funds due to exchange rate movements -16 43<br />
Securities and liquid funds 2) as of 1. 1. 4,585 4,015<br />
Securities and liquid funds 2) as of 31. 12. 3,934 4,585<br />
1) excl. fixed-asset securities<br />
2) liquid funds, securities within fixed and current assets<br />
(+) = source of funds, (–) = use of funds<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> a n n u a l r e p o r t 2 0 0 6
C. H. <strong>Boehringer</strong> Sohn, <strong>Ingelheim</strong><br />
Statement of changes in group equity<br />
(in millions of EUR)<br />
Shareholders’<br />
capital 1)<br />
Accrued<br />
group<br />
capital<br />
thereof<br />
currency<br />
effects<br />
Group Equity<br />
Equity<br />
Minority<br />
interests<br />
thereof<br />
currency<br />
effects<br />
Balance as of 31. 12. 2004 178 4,185 –168 4,363 193 –29 4,556<br />
Contributions 0 0 0 0 0 0 0<br />
Withdrawals 0 –1,352 0 –1,352 0 0 –1,352<br />
Net income 0 1,491 0 1,491 23 0 1,514<br />
Change of scope of consolidation 0 0 0 0 7 0 7<br />
Other changes 0 107 107 107 –7 2 100<br />
Balance as of 31. 12. 2005 178 4,431 –61 4,609 216 –27 4,825<br />
Contributions 0 0 0 0 0 0 0<br />
Withdrawals 0 -1,077 0 -1,077 0 0 -1,077<br />
Net income 0 1,722 0 1,722 7 0 1,729<br />
Change of scope of consolidation 0 0 0 0 0 0 0<br />
Other changes 0 -79 -79 -79 -35 -24 -114<br />
Balance as of 31. 12. <strong>2006</strong> 178 4,997 -140 5,175 188 -51 5,363<br />
1) The shareholders’ capital consists of the equity of C. H. <strong>Boehringer</strong> Sohn and C. H. <strong>Boehringer</strong> Sohn Grundstücksverwaltung<br />
GmbH & Co. KG. It consists only of capital of the limited partners. The shareholders’ personal taxes arising from consolidated<br />
business activities are shown as withdrawals from the accrued group capital.<br />
Cash flow statement / Statement of changes in group equity<br />
Group<br />
equity<br />
121
122<br />
C. H. <strong>Boehringer</strong> Sohn, <strong>Ingelheim</strong><br />
Notes to the consolidated financial statements <strong>2006</strong><br />
1 Principles and methods<br />
1.1 General principles<br />
The consolidated financial statements of <strong>Boehringer</strong> <strong>Ingelheim</strong> for the fiscal year <strong>2006</strong> have been<br />
prepared pursuant to section 264a German Commercial Code (HGB) by applying the group accounting<br />
regulations of section 290 to 314 HGB.<br />
In accordance with section 297, paragraph 1 HGB, the consolidated financial statements are composed<br />
of the consolidated balance sheet, the consolidated profit and loss statement, notes to the consolidated<br />
financial statements, the consolidated cash flow statement and the statement on changes in equity.<br />
1.2 Companies included in the consolidation<br />
The ultimate parent of <strong>Boehringer</strong> <strong>Ingelheim</strong> is C. H. <strong>Boehringer</strong> Sohn. <strong>Boehringer</strong> AG is the sole<br />
unlimited managing partner of this company.<br />
Besides C. H. <strong>Boehringer</strong> Sohn there is C. H. <strong>Boehringer</strong> Sohn Grundstücksverwaltung GmbH &<br />
Co. KG whose unlimited partner is under the unified management of C. H. <strong>Boehringer</strong> Sohn.<br />
The <strong>Boehringer</strong> <strong>Ingelheim</strong> Group of companies consists of 137 affiliated companies in and outside<br />
Germany. In addition to C. H. <strong>Boehringer</strong> Sohn and C. H. <strong>Boehringer</strong> Sohn Grundstücksverwaltung<br />
GmbH & Co. KG, a further 104 companies in which C. H. <strong>Boehringer</strong> Sohn holds directly or indirectly<br />
the majority of voting shares are included in the consolidated financial statements.<br />
29 companies were not consolidated in the reporting year, as the net assets, financial position and<br />
results of operations of these companies were insignificant to <strong>Boehringer</strong> <strong>Ingelheim</strong>. Combined they<br />
represent less than 1 % of the Group’s net sales, equity and net profit.<br />
A further two companies are subject to bylaws containing enduring restrictions.<br />
Compared to the previous year, the total number of affiliated companies was reduced by six:<br />
• five companies were closed down,<br />
• a further three companies were dissolved due to mergers and<br />
• two companies were established<br />
A separate statement of interests held by <strong>Boehringer</strong> <strong>Ingelheim</strong> will be submitted to the authority<br />
operating the German Federal Gazette in order to place it in the Register of Companies.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> a n n u a l r e p o r t 2 0 0 6
The following subsidiaries were exempted from the reporting and disclosure obligations in accordance<br />
with section 264, paragraph 4 HGB in conjunction with section 264, paragraph 3 HGB:<br />
• <strong>Boehringer</strong> <strong>Ingelheim</strong> GmbH, <strong>Ingelheim</strong><br />
• <strong>Boehringer</strong> <strong>Ingelheim</strong> International GmbH, <strong>Ingelheim</strong><br />
• Dr. Karl Thomae GmbH, Biberach<br />
• <strong>Boehringer</strong> <strong>Ingelheim</strong> Europe GmbH, <strong>Ingelheim</strong><br />
• <strong>Boehringer</strong> <strong>Ingelheim</strong> Vetmedica GmbH, <strong>Ingelheim</strong><br />
• <strong>Boehringer</strong> <strong>Ingelheim</strong> Secura Versicherungsvermittlungs GmbH, <strong>Ingelheim</strong><br />
• <strong>Boehringer</strong> <strong>Ingelheim</strong> Grundstücks-GmbH, <strong>Ingelheim</strong><br />
• <strong>Boehringer</strong> <strong>Ingelheim</strong> Finanzierungs GmbH, <strong>Ingelheim</strong><br />
Exempted from reporting and disclose obligations of annual financial statements according to HGB<br />
regulations for joint stock companies under section 264b HGB are:<br />
• C. H. <strong>Boehringer</strong> Sohn, <strong>Ingelheim</strong><br />
• C. H. <strong>Boehringer</strong> Sohn Grundstücksverwaltung GmbH & Co. KG, <strong>Ingelheim</strong><br />
• <strong>Boehringer</strong> <strong>Ingelheim</strong> Pharma GmbH & Co. KG, <strong>Ingelheim</strong><br />
1.3 Consolidation methods<br />
For inventories, accounts receivable and payable, and the income and expense items, business<br />
transactions between the companies consolidated were eliminated as part of the debt consolidation,<br />
according to section 303 HGB, the elimination of inter-company profits according to section 304 HGB,<br />
and the income and expense consolidation according to section 305 HGB.<br />
The purchase method of accounting was used for the capital consolidation of those subsidiaries that<br />
were included for the first time in the consolidated financial statements. First-time consolidation takes<br />
place at the time of the respective company becoming a subsidiary.<br />
The goodwill of two major companies wholly acquired in 1997 was amortized according to plan over<br />
10 years (last portion in <strong>2006</strong>).<br />
Credit balances from capital consolidation primarily represent retained earnings during group<br />
membership; they therefore have the characteristics of equity and are included in group reserves.<br />
Notes to the consolidated financial statements <strong>2006</strong> 123
124<br />
1.4 Currency conversions<br />
The financial statements prepared in foreign currencies were translated into euros, the functional<br />
currency of the group parent company, C. H. <strong>Boehringer</strong> Sohn, according to the year-end method.<br />
All assets and liabilities have been converted at the year-end rate. The profit and loss statement and,<br />
consequently, net income, were converted at the average annual rate for the reporting year.<br />
Translation differences due to the conversion of foreign currencies are shown as a balancing item in<br />
the equity without impact on income.<br />
The functional currency of subsidiaries is the respective local currency. <strong>Annual</strong> financial statements in<br />
high inflation countries are in principle drawn up in accordance with German Accounting Standard<br />
14 (GAS 14); in the financial year <strong>2006</strong>, no group company was affected by the high inflation<br />
accounting. All positions in individual financial statements drawn up in prior years in hard currencies<br />
(in US dollars or euros), were translated into the new functional currency on 1 January <strong>2006</strong> at the<br />
respective spot rate.<br />
The most important currencies for <strong>Boehringer</strong> <strong>Ingelheim</strong> reflect the following changes in the reporting<br />
year (base 1 euro):<br />
year-end rate average annual rate<br />
31.12.<strong>2006</strong> 31.12.2005 <strong>2006</strong> 2005<br />
US dollar 1.32 1.18 1.26 1.24<br />
Japanese yen 156.93 139.90 146.06 136.87<br />
Pound sterling 0.67 0.69 0.68 0.68<br />
Canadian dollar 1.53 1.37 1.42 1.51<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> a n n u a l r e p o r t 2 0 0 6
2 Accounting and evaluation methods<br />
2.1 Fixed assets<br />
Intangible and tangible assets are shown at purchase or manufacturing cost, net of regular straightline<br />
depreciation, according to the technical and economic situation. The following periods of use<br />
were applied:<br />
Buildings 20 years<br />
Technical facilities and machinery 10 years<br />
Other facilities, operating and business equipment 3 to 10 years<br />
Diverging from the declining-balance method of depreciation applied in the individual financial<br />
statements of C. H. <strong>Boehringer</strong> Sohn the straight-line method of depreciation is used in the consolidated<br />
financial statements for the purpose of uniformity in group-wide measurement. Anticipated<br />
long-term losses in the value of investments were accounted for by unscheduled write-offs. Cost<br />
of direct material and production as well as appropriate portions of material and production overheads<br />
were taken into consideration for the determination of manufacturing costs. Fully amortised<br />
goodwill that is more than five years old, or is materially insignificant, is shown under disposals.<br />
All capitalised intangible assets have a limited useful life.<br />
The financial assets were valued at the lower of either purchase cost, present value or fair market<br />
value.<br />
2.2 Current assets<br />
Inventories are valued at purchase or manufacturing cost using the weighted average cost flow<br />
method as the group-wide uniform method of measurement, whereas C. H. <strong>Boehringer</strong> Sohn applies<br />
the LIFO Method in its individual financial statements. Appropriate portions of material and<br />
production overheads were taken into consideration for the determination of the manufacturing<br />
costs. Necessary reductions were made for inventory risks.<br />
Accounts receivable were stated at their nominal value net of any individual valuation allowances<br />
required. The general credit risk was covered by a general valuation allowance for bad debt.<br />
Other assets were stated at the lower of either purchase cost or fair market value.<br />
Foreign currency items were recorded at the year-end rate of exchange.<br />
Notes to the consolidated financial statements <strong>2006</strong> 125
126<br />
2.3 Group reserves<br />
Group reserves include the retained earnings of the consolidated subsidiaries from prior years,<br />
consolidation entries that affect earnings and credit balances arising from capital consolidation,<br />
where they respectively relate to prior years.<br />
2.4 Provisions<br />
The provisions include amounts necessary to cover any perceptible obligations and risks, including<br />
provisions for contingent losses from pending contracts. The valuation is made on the basis of<br />
reasonable commercial judgement. Provisions with an implied interest are shown on a discounted<br />
basis (e. g. certain personnel provisions).<br />
2.5 Liabilities<br />
Liabilities are shown in the balance sheet at the repayable amount. Liabilities in foreign currencies<br />
were recorded at the year-end rate of exchange.<br />
2.6 Deferred taxes<br />
The deferred tax assets and liabilities represent the tax deferral in accordance with section 274<br />
and 306 HGB, which arise because of temporary differences between the tax balance sheets of<br />
the individual companies and the consolidated balance sheet (including differences arising from<br />
adjustments for conformity in group-wide reporting and evaluation as well as consolidation<br />
measures). Quasi-permanent differences between the consolidated balance sheet and the tax<br />
balance sheet are treated as temporary differences in accordance with German Accounting Standard<br />
10 (GAS 10). Deferred tax assets and liabilities are offset in accordance with GAS 10.<br />
In the individual balance sheets (i.e. the financial statements II) the consolidated companies made<br />
use of their option to capitalise assets to the amount of probable tax relief in the following years in<br />
accordance with section 274, paragraph 2 HGB. The calculation of deferred taxes is based on the<br />
tax rates that are expected to be valid at the time of their realisation.<br />
The capitalisation of deferred tax assets on tax loss carry-forwards is carried out if it is sufficiently<br />
probable that the tax benefits can be realised.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> a n n u a l r e p o r t 2 0 0 6
3 Notes to the consolidated balance sheet<br />
3.1 Intangible assets<br />
(in millions of EUR)<br />
Procurement/manufacturing costs<br />
Concessions/<br />
Similar rights<br />
Goodwill Advance<br />
payments<br />
Balance as of 1. 1. 2005<br />
526 816 3 1,345<br />
Currency conversion difference 11 3 0 14<br />
Additions due to first consolidation 0 0 0 0<br />
Additions 50 0 7 57<br />
Disposals -18 -13 0 -31<br />
Reclassifications 4 0 -4 0<br />
Balance as of 31. 12. 2005 573 806 6 1,385<br />
Currency conversion difference -30 0 0 -30<br />
Additions due to first consolidation 0 0 0 0<br />
Additions 443 0 8 451<br />
Disposals -18 0 0 -18<br />
Reclassifications 7 0 -3 4<br />
Balance as of 31. 12. <strong>2006</strong> 975 806 11 1,792<br />
Accumulated depreciations<br />
Balance as of 1. 1. 2005 357<br />
721<br />
0 1,078<br />
Currency conversion difference 9 2 0 11<br />
Additions due to first consolidation 0 0 0 0<br />
Additions 44 48 0 92<br />
Write-ups 0 0 0 0<br />
Disposals -16 -13 0 -29<br />
Reclassifications 0 0 0 0<br />
Balance as of 31. 12. 2005 394 758 0 1,152<br />
Currency conversion difference -10 0 0 -10<br />
Additions due to first consolidation 0 0 0 0<br />
Additions 63 48 0 111<br />
Write-ups 0 0 0 0<br />
Disposals -15 0 0 -15<br />
Reclassifications 0 0 0 0<br />
Balance as of 31. 12. <strong>2006</strong> 432 806 0 1,238<br />
Book value as of 31. 12. 2005 179 48 6 233<br />
Book value as of 31. 12. <strong>2006</strong> 543 0 11 554<br />
Total<br />
Notes to the consolidated financial statements <strong>2006</strong> 127
128<br />
3.2 Tangible assets<br />
(in millions of EUR)<br />
Procurement/manufacturing costs<br />
Land and<br />
buildings<br />
Technical<br />
facilities and<br />
machines<br />
Other<br />
facilities/<br />
operating<br />
equipment<br />
Advance<br />
payments/<br />
construction<br />
in progress<br />
Balance as of 1. 1. 2005 2,022 1,982 1,312 270 5,586<br />
Currency conversion difference 96 82 61 15 254<br />
Additions due to first consolidation 3 2 2 0 7<br />
Additions 37 77 140 278 532<br />
Disposals -31 -42 -89 -8 -170<br />
Reclassifications 56 98 49 -203 0<br />
Balance as of 31. 12. 2005 2,183 2,199 1,475 352 6,209<br />
Currency conversion difference -115 -81 -56 -17 -269<br />
Additions due to first consolidation 0 0 0 0 0<br />
Additions 54 70 164 308 596<br />
Disposals -78 -57 -82 -2 -219<br />
Reclassifications 66 107 89 -266 -4<br />
Balance as of 31. 12. <strong>2006</strong> 2,110 2,238 1,590 375 6,313<br />
Accumulated depreciations<br />
Balance as of 1. 1. 2005 933 1,030 911 0 2,874<br />
Currency conversion difference 42 43 40 0 125<br />
Additions due to first consolidation 2 1 2 0 5<br />
Additions 125 163 151 0 439<br />
Write-ups 0 -2 0 0 -2<br />
Disposals -13 -37 -82 0 -132<br />
Reclassifications 0 0 0 0 0<br />
Balance as of 31. 12. 2005 1,089 1,198 1,022 0 3,309<br />
Currency conversion difference -58 -45 -38 0 -141<br />
Additions due to first consolidation 0 0 0 0 0<br />
Additions 83 172 164 0 419<br />
Write-ups -1 -1 -1 0 -3<br />
Disposals -36 -48 -73 0 -157<br />
Reclassifications -1 1 0 0 0<br />
Balance as of 31. 12. <strong>2006</strong> 1,076 1,277 1,074 0 3,427<br />
Book value as of 31. 12. 2005 1,094 1,001 453 352 2,900<br />
Book value as of 31. 12. <strong>2006</strong> 1,034 961 516 375 2,886<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> a n n u a l r e p o r t 2 0 0 6<br />
Total
3.3 Financial assets<br />
(in millions of EUR)<br />
Procurement/manufacturing costs<br />
Investments<br />
in affilated<br />
companies<br />
Loans<br />
to affiliated<br />
companies<br />
Investments<br />
in related<br />
companies<br />
Loans to<br />
related<br />
companies<br />
Investment<br />
securities<br />
Other loans<br />
Balance as of 1. 1. 2005 21 8 10 6 2,686 41 2,772<br />
Currency conversion difference 0 0 0 0 3 0 3<br />
Additions due to first consolidation 0 0 0 0 0 0 0<br />
Additions 0 1 0 0 674 5 680<br />
Disposals -1 0 0 0 -7 -21 -29<br />
Reclassifications 0 0 0 0 0 0 0<br />
Balance as of 31. 12. 2005 20 9 10 6 3,356 25 3,426<br />
Currency conversion difference -2 -1 -1 0 -9 0 -13<br />
Additions due to first consolidation 0 0 0 0 0 0 0<br />
Additions 0 0 7 0 603 4 614<br />
Disposals 0 0 -6 0 -911 -6 -923<br />
Reclassifications 0 0 0 0 0 0 0<br />
Balance as of 31. 12. <strong>2006</strong> 18 8 10 6 3,039 23 3,104<br />
Accumulated depreciations<br />
Balance as of 1. 1. 2005 3 0 3 3 4 3 16<br />
Currency conversion difference 0 0 0 0 0 0 0<br />
Additions due to first consolidation 0 0 0 0 0 0 0<br />
Additions 0 0 0 0 14 0 14<br />
Write-ups 0 0 0 0 0 0 0<br />
Disposals 0 0 0 0 0 0 0<br />
Reclassifications 0 0 0 0 0 0 0<br />
Balance as of 31. 12. 2005 3 0 3 3 18 3 30<br />
Currency conversion difference 0 0 -1 0 0 0 -1<br />
Additions due to first consolidation 0 0 0 0 0 0 0<br />
Additions 0 0 0 0 38 0 38<br />
Write-ups 0 0 0 0 -1 0 -1<br />
Disposals 0 0 0 0 -5 0 -5<br />
Reclassifications 0 0 0 0 0 0 0<br />
Balance as of 31. 12. <strong>2006</strong> 3 0 2 3 50 3 61<br />
Book value as of 31. 12. 2005 17 9 7 3 3,338 22 3,396<br />
Book value as of 31. 12. <strong>2006</strong> 15 8 8 3 2,989 20 3,043<br />
As in the previous year, the item “other loans” includes no loans to the shareholders.<br />
Total<br />
Notes to the consolidated financial statements <strong>2006</strong> 129
130<br />
3.4 Inventories<br />
(in millions of EUR) 31.12.<strong>2006</strong> 31.12.2005<br />
Raw materials and supplies 224 225<br />
Unfinished products 549 537<br />
Finished products and goods for resale 201 460<br />
Advance payments to suppliers 6 7<br />
3.5 Accounts receivable<br />
1,280 1,229<br />
Residual term<br />
Residual term<br />
(in millions of EUR) 31.12.<strong>2006</strong> over 1 year 31.12.2005 over 1 year<br />
Trade accounts receivable 1,937 2 1,854 71<br />
Receivables from affiliated companies 7 0 2 0<br />
Receivables from related companies 6 0 5 0<br />
Other assets 383 19 282 12<br />
2,333 21 2,143 83<br />
The item “other assets” contains receivables from the shareholders amounting to EUR 64 million<br />
(2005: EUR 0 million).<br />
3.6 Provisions<br />
(in millions of EUR) 31.12.<strong>2006</strong> 31.12.2005<br />
Pension provisions 2,062 2,035<br />
Tax provisions 382 548<br />
Other provisions 2,015 2,171<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> a n n u a l r e p o r t 2 0 0 6<br />
4,459 4,754
Pension provisions<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong>’s pension schemes are based on various defined contribution plans as well as<br />
defined benefit plans.<br />
Pension obligations arising from direct or indirect defined benefit plans are determined on the basis of<br />
the projected unit credit method, taking future salary and pension increases into consideration.<br />
The actuarial calculation of the pension obligation from defined benefit plans is based on country-<br />
specific biometric data (e. g. in Germany the “generation tables” issued in 2005 by Professor Klaus<br />
Heubeck) and actuarial assumptions. The main countries applied the following parameters:<br />
Germany USA Japan<br />
Parameter (in %) <strong>2006</strong> 2005 <strong>2006</strong> 2005 <strong>2006</strong> 2005<br />
Discount rate 4.5 4.1 5.8 5.5 1.5 1.5<br />
Expected return on plan assets 6.0 6.0 8.0 8.0 2.2-3.0 2.2–3.0<br />
Salary increase 3.5 2.5 5.5 5.5 2.4-3.0 2.4–4.7<br />
Pension increase 1.7 1.7 3.0 3.0 0.0 0.0<br />
At the balance sheet date, the present value of the expected pension obligation was netted with the fair<br />
value of the respective pension plan assets (funded status).<br />
Based on this, pension provisions are determined by deducting unrealised transition amounts as well<br />
as unrealised actuarial gains and losses from the funded status. Based on the “corridor approach”,<br />
unrealised gains and losses are amortised over the expected average service periods of the respective<br />
active employees. At balance sheet date, pension commitments (including total unrealised transition<br />
amounts and actuarial gains and losses) of EUR 498 million (2005: EUR 698 million) were not recognised<br />
as part of pension provisions.<br />
In conjunction with defined contribution plans, group companies paid contributions to state or<br />
private insurers on the basis of legal or contractual regulations. On payment of the contributions the<br />
companies no longer have any performance obligations. Contributions are recognised as personnel<br />
costs.<br />
Notes to the consolidated financial statements <strong>2006</strong> 131
132<br />
3.7 Accounts payable<br />
Residual term Residual term Residual term<br />
Residual term<br />
(in millions of EUR) less than 1 year 1–5 years over 5 years 31.12.<strong>2006</strong> 31.12.2005 less than 1 year<br />
Bank loans 225 116 25 366 480 216<br />
Other accounts payable 1,280 128 – 1,408 1,694 1,549<br />
of which:<br />
– Trade accounts payable 696 – – 696 775 775<br />
– Advance payments 56 – – 56 45 45<br />
– Notes payable 7 – – 7 14 14<br />
– Accounts payable to<br />
affiliated companies 9 – – 9 8 8<br />
– Accounts payable to<br />
related companies 1 – – 1 1 1<br />
– Other liabilities (*) 511 128 – 639 851 706<br />
(*) of which:<br />
1,505 244 25 1,774 2,174 1,765<br />
– taxes 68 24<br />
– social security contributions 13 22<br />
There were no liabilities secured by mortgages or similar rights on the balance sheet date consistent<br />
with the previous year.<br />
At year-end, there were no liabilities due to shareholders (2005: EUR 215 million).<br />
Payments received from the Asset-Backed-Security partners in conjunction with the ABS transaction<br />
are shown as short-term loans under “other liabilities” until the underlying accounts receivable are<br />
paid off.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> a n n u a l r e p o r t 2 0 0 6
4 Notes to the consolidated profit and loss statement<br />
The consolidated profit and loss statement is presented in line with the total cost method.<br />
4.1 Net sales<br />
by business and business segment (in millions of EUR) <strong>2006</strong> 2005<br />
Human Pharmaceuticals 10,200 9,174<br />
of which: Prescription Medicines 8,311 7,247<br />
Consumer Health Care 1,064 1,052<br />
Industrial Customer 809 847<br />
Other sales 16 28<br />
Animal Health 374 361<br />
10,574 9,535<br />
by geographic region (in millions of EUR) <strong>2006</strong> 2005<br />
Europe 3,295 3,177<br />
of which: Germany 822 816<br />
Americas 5,388 4,559<br />
of which: USA/Canada/Mexico 5,039 4,219<br />
Asia/Australasia/Africa 1,891 1,859<br />
of which: Japan 1,227 1,232<br />
4.2 Material costs<br />
10,574 9,535<br />
(in millions of EUR) <strong>2006</strong> 2005<br />
Costs of raw material, supplies and goods for resale 1,219 1,351<br />
Expenditure on services 265 262<br />
4.3 Personnel costs<br />
1,484 1,613<br />
(in millions of EUR) <strong>2006</strong> 2005<br />
Salaries and wages 2,217 2,087<br />
Social benefits and retirement benefits 619 584<br />
of which: retirement benefits 231 155<br />
2,836 2,671<br />
The interest component with respect to the increase in pensions and similar obligations is included in<br />
financial income rather than in personnel costs and is, therefore, not included in the operating result<br />
of the company.<br />
Notes to the consolidated financial statements <strong>2006</strong> 133
134<br />
Average headcount <strong>2006</strong> 2005<br />
Production 12,380 12,044<br />
Administration 4,972 4,742<br />
Marketing and Sales 14,368 14,257<br />
Research and Development 6,003 5,678<br />
Apprentices 705 685<br />
4.4 Amortisation of intangible and depreciation of tangible assets<br />
38,428 37,406<br />
The amortisation of intangible assets and depreciation of tangible assets includes unscheduled<br />
write-offs of EUR 21 million (2005: EUR 2 million).<br />
4.5 Other operating expenses<br />
Other operating expenses include third-party services in research, development, medicine, and<br />
marketing, further administration costs, fees, contributions, non-income-related taxes, commissions,<br />
rents, freight costs, and expenses for third-party repairs as well as expenses incurred by restructuring<br />
measures.<br />
4.6 Financial income<br />
(in millions of EUR) <strong>2006</strong> 2005<br />
Interest expense relating to pensions and similar obligations -100 -108<br />
Other interest expense and similar expenditure -53 -70<br />
Interest expense and similar expenditure -153 -178<br />
Amortisation of other financial assets and short-term investments -38 -14<br />
Income from other investment securities and from long-term loans 226 110<br />
Other interest income and similar proceeds 67 47<br />
102 -35<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> a n n u a l r e p o r t 2 0 0 6
4.7 Holding income<br />
(in millions of EUR) <strong>2006</strong> 2005<br />
Gains from the sale of investments 1 0<br />
4.8 Taxes<br />
(in millions of EUR) <strong>2006</strong> 2005<br />
Income taxes 501 504<br />
Deferred taxes 13 -154<br />
Other taxes – 24<br />
514 374<br />
As of the reporting year, other taxes are treated as operating expenses and have correspondingly<br />
reduced operating income.<br />
By concluding profit transfer agreements, significant German corporations have since 1 January 2004<br />
belonged to the trade and corporate taxation group of integrated companies of the parent company<br />
C. H. <strong>Boehringer</strong> Sohn. As income tax levied on taxable income allocated to the shareholders of<br />
C. H. <strong>Boehringer</strong> Sohn may not be shown in the consolidated profit and loss statement, only the trade<br />
tax of the relevant companies is shown as a tax expense.<br />
In the effective tax-rate reconciliation the expected tax expense for <strong>Boehringer</strong> <strong>Ingelheim</strong> is calculated<br />
on the profit tax rate for corporations (corporate tax, solidarity levy and trade tax). As in the profit and<br />
loss statement tax expenses related to the income tax for partnerships and integrated companies of<br />
C. H. <strong>Boehringer</strong> Sohn are limited to showing trade tax, the expected tax expense in the effective<br />
tax-rate reconciliation is in this respect adjusted for fictive current and deferred corporate tax expenses<br />
in order to link to the profit tax expense shown in the profit and loss statement. This elimination of<br />
fictive corporate tax (including the solidarity levy) is shown in the items Fictive Corporation.<br />
Notes to the consolidated financial statements <strong>2006</strong> 135
136<br />
The expected tax expense derived by using a fictive tax rate of 37.1 % (average tax rate for a German<br />
corporation at a municipal trade tax levy rate of 340 %; 2005: 360 %) can be related to the actual tax<br />
expense as follows:<br />
(in millions of EUR) <strong>2006</strong> 2005<br />
Income before taxes minus other taxes 2,243 1,864<br />
Expected tax expense (current and deferred) 832 37.1 % 701 37.6 %<br />
Decrease/increase in expected tax expense by<br />
– Fictive Corporation current taxes<br />
-284<br />
-12.7 % -378<br />
-20.3 %<br />
– Fictive Corporation deferred taxes -25 -1.1 % 49 2.6 %<br />
– Local tax rate divergences -28 -1.2 % -34 -1.8 %<br />
– Non-taxable income -26 -1.2 % -6 -0.3 %<br />
– Non-tax-deductible expenses 59 2.6 % 34 1.8 %<br />
– Taxes related to prior periods -10 -0.4 % -35 -1.9 %<br />
– Amortisation of goodwill 18 0.8 % 18 1.0 %<br />
– Changes in applicable tax rates -5 -0.2 % 7 0.4 %<br />
– Withholding taxes not subject to tax credits 5 0.2 % 20 1.1 %<br />
– Tax credits for research activities -39 -1.7 % -19 -1.0 %<br />
– Other effects 17 0.7 % -7 -0.4 %<br />
Actual tax expense (current and deferred) 514 22.9 % 350 18.8 %<br />
The deferred taxes can be attributed to the following balance sheet items:<br />
31.12.<strong>2006</strong> 31.12.2005<br />
(in millions of EUR) Assets Liabilities Assets Liabilities<br />
Intangible assets 9 2 7 2<br />
Tangible assets 32 122 32 132<br />
Financial assets 13 17 15 24<br />
Inventories 116 14 104 19<br />
Receivables 21 9 38 9<br />
Provisions 511 16 600 16<br />
Liabilities 17 2 14 2<br />
Tax loss carryforwards and tax credits 27 0 11 0<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> a n n u a l r e p o r t 2 0 0 6<br />
746 182 821 204
Other mandatory disclosures according to GAS 10.39:<br />
(in millions of EUR) <strong>2006</strong> 2005<br />
Deferred tax expense from changes in law -5 7<br />
Deferred tax expense relating to the write-off of deferred tax assets<br />
in fiscal year<br />
The absence of changes in accounting and evaluation methods results, as in the previous year,<br />
in no deferred tax income.<br />
The valuation allowances relating to deferred tax assets amount to EUR 10 million.<br />
Unused tax loss carryforwards, on which no deferred tax assets are recognized in the balance<br />
sheet, amount to EUR 29 million at year-end, EUR 24 million of which expire in five years and<br />
EUR 5 million expire in 10 years at the latest.<br />
4.9 Net income<br />
Net income for the year <strong>2006</strong> includes operating income unrelated to the accounting period<br />
(mainly the release of other provisions) amounting to EUR 136 million (2005: EUR 81 million).<br />
Operating expenditure unrelated to the accounting period amounted to EUR 17 million<br />
(2005: EUR 27 million).<br />
Notes to the consolidated financial statements <strong>2006</strong> 137<br />
5<br />
5
138<br />
5 Notes to the cash flow statement<br />
The cash flow statement shows how the total liquid funds (liquid assets and securities in fixed and<br />
current assets) of the <strong>Boehringer</strong> <strong>Ingelheim</strong> Group have changed during the reporting year through<br />
inflow and outflow of cash and cash equivalents. In accordance with German Accounting Standard<br />
No. 2 (GAS 2), Cash Flow Statements, cash flows are classified by operating, investing or financing<br />
activities.<br />
Changes reported by consolidated companies are converted at the average annual rate. Liquid funds<br />
are converted, as shown in the balance sheet, according to the year-end rate method. The influence<br />
of exchange rate changes on liquid funds is provided separately.<br />
6 Other information<br />
6.1 Derivative financial instruments<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> is, due to its extensive international structure, highly dependent on the<br />
development of the major world currencies and interest rates. In order to hedge against the risks,<br />
particularly those inherent in supplies and services and financial funding, use is generally made<br />
of foreign exchange forward contracts in the case of currency risks. Regarding interest rate risks,<br />
use is made of interest rate swaps and interest rate options.<br />
The use of derivative financial instruments and the organisational procedure are laid down in internal<br />
guidelines. Trade, processing, documentation, and control are kept strictly separate.<br />
The risk positions are recorded, analyzed and assessed regularly in a special consolidated financial<br />
report. The items are periodically re-evaluated and monitored. Derivative financial instruments are<br />
only agreed on with banks of sound financial standing.<br />
As of 31 December <strong>2006</strong>, the nominal value of all foreign currency and interest rate hedging<br />
transactions amounted to EUR 2,506 million (2005: 3,618 million). The corresponding market values<br />
amounted to EUR +103 million (2005: EUR -63 million).<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> a n n u a l r e p o r t 2 0 0 6
Derivative financial instruments at year-end were as follows:<br />
Nominal value Market value<br />
(in millions of EUR) 31.12.<strong>2006</strong> 31.12.2005 31.12.<strong>2006</strong> 31.12.2005<br />
Foreign exchange forward contracts 2,448 3,355 103 –62<br />
Interest instruments 58 263 0 –1<br />
The nominal value is the sum of all purchases and sales. The market value is calculated on the basis of<br />
quoted prices or derived values for derivative instruments.<br />
6.2 Contingent liabilities to the benefit of third parties<br />
(in millions of EUR) 31.12.<strong>2006</strong> 31.12.2005<br />
Liabilities from guarantees, guarantees for bills and cheques,<br />
warranties and provisions of collateral for third-party liabilities<br />
6.3 Other financial obligations<br />
(in millions of EUR) 31.12.<strong>2006</strong> 31.12.2005<br />
To third parties 967 741<br />
At year-end, other financial obligations included capital investments of EUR 665 million (2005:<br />
EUR 552 million). Furthermore, EUR 195 million (2005: EUR 182 million) from renting and leasing<br />
contracts are included, of which EUR 82 million concern long-term rent contracts with subsidiaries<br />
not included in the consolidation.<br />
6.4 Research and development expenses<br />
(in millions of EUR) <strong>2006</strong> 2005<br />
Expenditures for Research and Development 1,574 1,360<br />
12<br />
176<br />
Notes to the consolidated financial statements <strong>2006</strong> 139
140<br />
Auditor’s <strong>Report</strong><br />
We have audited the consolidated financial<br />
statements prepared by the C. H. <strong>Boehringer</strong><br />
Sohn, <strong>Ingelheim</strong> – comprising the balance sheet,<br />
the income statement, statement of changes in<br />
equity, cash flow statement and the notes to the<br />
consolidated financial statements – together<br />
with the group management report for the<br />
business year from 1 January to 31 December<br />
<strong>2006</strong>. The preparation of the consolidated financial<br />
statements and the group management<br />
report in accordance with German commercial<br />
law is the responsibility of the Management<br />
Board of the Managing Corporate Partnership-<br />
AG. Our responsibility is to express an opinion<br />
on the consolidated financial statements and the<br />
group management report based on our audit.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> a n n u a l r e p o r t 2 0 0 6<br />
We conducted our audit of the consolidated<br />
financial statements in accordance with § 317<br />
HGB (German Commercial Code) and German<br />
generally accepted standards for the audit of<br />
financial statements promulgated by the Institut<br />
der Wirtschaftsprüfer (Institute of Public<br />
Auditors in Germany) (IDW). Those standards<br />
require that we plan and perform the audit such<br />
that misstatements materially affecting the<br />
presentation of the net assets, financial position<br />
and results of operations in the consolidated<br />
financial statements in accordance with<br />
(German) principles of proper accounting and in<br />
the group management report are detected with<br />
reasonable assurance. Knowledge of the business<br />
activities and the economic and legal environment<br />
of the Group and expectations as to possible<br />
misstatements are taken into account in the<br />
determination of audit procedures. The effectiveness<br />
of the accounting-related internal control<br />
system and the evidence supporting the<br />
disclosures in the consolidated financial<br />
statements and the group management report<br />
are examined primarily on a test basis within<br />
the framework of the audit. The audit includes<br />
assessing the annual financial statements of the<br />
companies included in consolidation, the determination<br />
of the companies to be included in<br />
consolidation, the accounting and consolidation<br />
principles used and significant estimates made by<br />
the Management Board of the Managing Corporate<br />
Partnership-AG, as well as evaluating the<br />
overall presentation of the consolidated financial<br />
statements and the group management report.<br />
We believe that our audit provides a reasonable<br />
basis for our opinion.
With the following exception, our audit has not<br />
led to any reservations: Contrary to § 314 para-<br />
graph 1 number 6 HGB compensation of the<br />
members and the former members of the board<br />
of managing directors have not been disclosed.<br />
In our opinion based on the findings of our audit,<br />
the consolidated financial statements with the<br />
exception mentioned comply with the legal<br />
requirements. The consolidated financial state-<br />
ments give a true and fair view of the net assets,<br />
financial position and results of operations of<br />
the Group in accordance with German principles<br />
of proper accounting. The group management<br />
report is consistent with consolidated financial<br />
statements that comply with the legal require-<br />
ments and as a whole provides a suitable view<br />
of the Group’s position and suitably presents the<br />
opportunities and risks of future development.<br />
Frankfurt am Main, 16 February 2007<br />
PricewaterhouseCoopers<br />
Aktiengesellschaft<br />
Wirtschaftsprüfungsgesellschaft<br />
(E.-W. Frings) (P. Marshall)<br />
Wirtschaftsprüfer Wirtschaftsprüfer<br />
(German Certified (German Certified<br />
Public Accountant) Public Accountant)<br />
Auditor’s <strong>Report</strong><br />
141
142<br />
Glossary<br />
Human Pharmaceuticals<br />
Product name Active ingredient Indication<br />
actilyse® alteplase Fibrinolytic treatment of acute myocardial<br />
infarction, acute massive pulmonary embolism<br />
and ischaemic stroke.<br />
aggrenox®<br />
asasantin®<br />
persantin®<br />
persantine®<br />
persantina®<br />
alesion®<br />
flurinol®<br />
talerc®<br />
ASA / dipyridamole<br />
extended release<br />
epinastine Antiallergic agent<br />
antistax® quantified red wine leaf<br />
extract AS195 ®<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> AnnuA l RepoR t <strong>2006</strong><br />
Prevention of stroke following a first stroke<br />
or for transient ischaemic attacks.<br />
As above and adjunct to coumarin anti-coagulants<br />
in the prevention of postoperative thromboembolic<br />
complications of cardiac valve<br />
replacement.<br />
Prevention and treatment of symptoms of chronic<br />
venous insufficiency; varicosis veins, leg edema,<br />
painful swollen legs, tickling itching legs,<br />
tired and heavy legs.
Product name Active ingredient Indication<br />
aptivus® tipranavir Available as capsules for adults –<br />
used co-administered with 200 mg of ritonavir,<br />
is indicated for combination antiretroviral treatment<br />
of HIV-1-infected adult patients with<br />
evidence of viral replication, who are highly<br />
treatment-experienced or have HIV-1 strains<br />
resistant to multiple protease inhibitors.<br />
atrovent® ipratropium bromide Bronchodilator for maintenance treatment<br />
of bronchospasm associated with chronic<br />
obstructive pulmonary disease, including<br />
chronic bronchitis, emphysema and asthma.<br />
berotec®<br />
dosberotec®<br />
fenoterol a) Symptomatic treatment of acute asthma attacks<br />
b) Prophylaxis of exercise induced asthma<br />
c) Symptomatic treatment of bronchial asthma<br />
and other conditions with reversible airway<br />
narrowing e.g. chronic obstructive bronchitis.<br />
Concomitant anti-inflammatory therapy should be<br />
considered for patients with bronchial asthma and<br />
steroid responsive chronic obstructive pulmonary<br />
disease (COPD).<br />
bisolvon® bromhexine Mucolytic for the treatment of acute and chronic<br />
bronchopulmonary diseases associated with<br />
impaired formation and transport of mucus.<br />
Glossary 143
144<br />
Product name Active ingredient Indication<br />
buscopan®<br />
buscapina®<br />
catapresan®<br />
catapres®<br />
catapressan®<br />
atensina®<br />
combivent® ipratropium bromide /<br />
salbutamol<br />
cymbalta®<br />
xeristar®<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> AnnuA l RepoR t <strong>2006</strong><br />
butylscopolamine Treatment of abdominal discomfort and pain<br />
associated with intestinal cramps.<br />
clonidine All forms of high blood pressure,<br />
unless caused by phaeochromocytoma.<br />
Treatment of bronchospasms associated with<br />
reversible obstructive airway diseases in patients<br />
requiring more than one bronchodilator.<br />
duloxetine Major depressive disorder (MDD),<br />
diabetic peripheral neuropathic pain (DPNP)
Product name Active ingredient Indication<br />
dulcolax® bisacodyl (tablets,<br />
suppositories),<br />
sodium picosulphate<br />
(drops, pearls)<br />
duovent®<br />
bronchodual®<br />
berodual®<br />
flomax®<br />
alna®<br />
josir®<br />
pradif®<br />
secotex®<br />
urolosin®<br />
flomax® cr<br />
alna® ocas®<br />
pradif® t<br />
urolosin® ocas®<br />
fenoterol /<br />
ipratropium bromide<br />
Laxative for use in patients suffering from<br />
constipation. In preparation for diagnostic<br />
procedures, in pre- and postoperative treatment<br />
and in conditions, which require defecation<br />
to be facilitated.<br />
For prevention and treatment of symptoms in<br />
chronic obstructive airway disorders with<br />
reversible bronchospasm such as bronchial<br />
asthma and especially chronic bronchitis with<br />
or without emphysema.<br />
tamsulosin Lower urinary tract symptoms (LUTS) associated<br />
with benign prostatic hyperplasia (BPH).<br />
tamsulosin,<br />
orally controlled<br />
absorption system<br />
Lower urinary tract symptoms (LUTS) associated<br />
with benign prostatic hyperplasia (BPH).<br />
Glossary 145
146<br />
Product name Active ingredient Indication<br />
inflammide® budesonide Chronic control of symptoms and signs of<br />
bronchial asthma.<br />
laxoberal®<br />
laxoberon®<br />
dulcolax® pico<br />
lendormin®<br />
lendorm®<br />
lindormin®<br />
sintonal®<br />
sodium picosulphate<br />
(drops, pearls, tablets)<br />
Laxative for use in cases of constipation and<br />
in conditions which require defecation to<br />
be facilitated.<br />
brotizolam Short-term treatment of disorders of initiating and<br />
maintaining sleep.<br />
metalyse® tenecteplase Fibrinolytic treatment of acute myocardial<br />
infarction.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> AnnuA l RepoR t <strong>2006</strong>
Product name Active ingredient Indication<br />
mexitil®<br />
mexitilen®<br />
micardis®<br />
micardisplus®<br />
micardis® plus<br />
micardis® hct<br />
co-micardis®<br />
mobic®<br />
mobec®<br />
movalis®<br />
movatec®<br />
motens®<br />
caldine®<br />
tens®<br />
midotens®<br />
mexiletine Serious symptomatic ventricular tachycardic heart<br />
rhythm disturbances.<br />
telmisartan<br />
telmisartan / hydrochlorothiazide<br />
Treatment of essential hypertension.<br />
meloxicam Symptomatic treatment of rheumatic diseases.<br />
lacidipine Treatment of essential hypertension.<br />
Glossary 147
148<br />
Product name Active ingredient Indication<br />
mucoangin®<br />
frubizin® akut<br />
mucosolvan®<br />
motosol®<br />
mucosan®<br />
surbronc®<br />
vaksan®<br />
pharmaton®<br />
pharmaton® capsules<br />
geriavit pharmaton®<br />
pharmaton® caplets<br />
sifrol®<br />
mirapex®<br />
mirapexin®<br />
ambroxol (lozenges) Pain relief in acute sore throat.<br />
ambroxol Mucolytic treatment of acute and chronic<br />
bronchopulmonary diseases associated with<br />
impaired formation and transport of mucus.<br />
standardized ginseng<br />
extract G115®,<br />
vitamins, minerals,<br />
trace elements<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> AnnuA l RepoR t <strong>2006</strong><br />
To improve physical and mental performance<br />
and well-being.<br />
pramipexole Symptomatic treatment of idiophathic<br />
Parkinson’s disease,<br />
symptomatic treatment of idiophathic<br />
Restless Legs Syndrome.
Product name Active ingredient Indication<br />
silomat® clobutinol Symptomatic treatment of irritable,<br />
non-productive cough.<br />
spiriva® tiotropium bromide Maintenance treatment of patients with<br />
COPD (chronic obstructive pulmonary disease,<br />
including chronic bronchitis and emphysema),<br />
the maintenance treatment of associated<br />
dyspnoea and for prevention of exacerbations.<br />
thomapyrin® ASA, paracetamol,<br />
coffeine<br />
Mild to moderate pain.<br />
viramune® nevirapine Available as tablets for adults and suspension<br />
for children – for the combination therapy<br />
of HIV infection and for the prevention of<br />
mother-to-child transmission of HIV.<br />
Glossary<br />
149
150<br />
Animal Health<br />
Product name Active ingredient Indication<br />
enterisol® ileitis attenuated<br />
live vaccine (Lawsonia<br />
intracellularis)<br />
express® attenuated live vaccine<br />
(IBRV, BVDV, PI3V, BRSV)<br />
ingelvac® circoflex recombinant vaccine<br />
(Porcine Circovirus<br />
Type 2, PCV2)<br />
ingelvac® m.hyo inactivated vaccine<br />
(Mycoplasma<br />
hyopneumoniae)<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> AnnuA l RepoR t <strong>2006</strong><br />
For active immunisation of pigs to reduce intestinal<br />
lesions caused by Lawsonia intracellularis<br />
infection and to reduce growth variability and loss<br />
of weight gain associated with the disease.<br />
For prevention of reproductive and respiratory<br />
diseases in cattle.<br />
For the active immunisation of swine against<br />
porcine circovirus type 2.<br />
For the active immunisation of swine to reduce<br />
lung lesions following infection with Mycoplasma<br />
hyopneumoniae.
Product name Active ingredient Indication<br />
ingelvac® prrs mlv attenuated live vaccine<br />
(PRRS virus)<br />
mamyzin® penethamate<br />
hydroiodide<br />
For the active immunisation of clinically healthy<br />
swine against the respiratory and<br />
reproductive form of PRRS virus infection (porcine<br />
reproductive respiratory syndrome).<br />
For the treatment of mastitis caused by<br />
Gram-positive pathogens.<br />
metacam® meloxicam Dog, horse: alleviation of pain and inflammation<br />
associated with acute or chronic musculo-skeletal<br />
disorders<br />
Cat, dog: reduction of postoperative pain<br />
Cattle: respiratory infection, diarrhoea, mastitis<br />
Swine: non-infectious locomoter disorders,<br />
mastitis-metritis-agalactia-syndrome,<br />
Horse: for the alleviation of pain in the event of<br />
colic.<br />
ventipulmin® clenbuterol Bronchodilator for the treatment of acute and<br />
chronic obstructive airway disease in horses.<br />
vetmedin® pimobendan For the treatment of congestive heart failure<br />
in dogs.<br />
Glossary 151
If you have any queries or comments, please contact us:<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> GmbH<br />
Binger Strasse 173<br />
55216 <strong>Ingelheim</strong><br />
Germany<br />
Telephone + 49 / 6132 / 77-0<br />
Fax + 49 / 6132 / 77-3000<br />
Contacts<br />
CD Communications<br />
Telephone + 49 / 6132 / 77-2012<br />
Fax + 49 / 6132 / 77-6601<br />
Internet www.boehringer-ingelheim.com<br />
Issued by<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> GmbH<br />
Design and layout<br />
Neufrankfurt Corporate Design GmbH, Offenbach am Main<br />
info@neufrankfurt.net<br />
Printed by<br />
Süddeutsche Verlagsgesellschaft, Ulm<br />
Copyright<br />
© <strong>Boehringer</strong> <strong>Ingelheim</strong> GmbH, 2007<br />
All rights reserved. No part of this <strong>Annual</strong> <strong>Report</strong> <strong>2006</strong><br />
may be reproduced or transmitted in any form or<br />
by any means, electronic or photocopy, without permission<br />
in writing from <strong>Boehringer</strong> <strong>Ingelheim</strong> GmbH.<br />
Figures from third parties used in the annual report are based<br />
on data available at the time the financial statement was drawn up.
Comparison of Balance Sheets/<br />
Financial Data 1997—<strong>2006</strong> (in millions of EUR)<br />
Assets (as of 31.12.) 1997 1998 1999 * 2000 2001 2002 2003 2004 2005 <strong>2006</strong><br />
Intangible assets 508 452 400 344 322 302 242 267 233 554<br />
Tangible assets 1,612 1,739 1,992 2,217 2,467 2,840 2,767 2,712 2,900 2,886<br />
Financial assets 757 731 849 1,135 1,008 1,689 2,462 2,756 3,396 3,043<br />
Fixed assets 2,877 2,922 3,241 3,696 3,797 4,831 5,471 5,735 6,529 6,483<br />
Inventories 794 806 944 1,021 1,014 971 1,000 1,085 1,229 1,280<br />
Accounts receivable (incl. deferred charges and deferred taxes) 1,211 1,255 1,870 1,938 2,314 2,360 2,537 2,477 3,013 3,137<br />
Cash and cash equivalents (incl. securities) 134 299 459 477 1,002 1,055 1,134 1,333 1,247 945<br />
Current assets 2,139 2,360 3,273 3,436 4,330 4,386 4,671 4,895 5,489 5,362<br />
Total assets 5,016 5,282 6,514 7,132 8,127 9,217 10,142 10,630 12,018 11,845<br />
Liabilities and equity (as of 31.12.) 1997 1998 1999 * 2000 2001 2002 2003 2004 2005 <strong>2006</strong><br />
Shareholders’ capital 399 441 332 211 200 178 178 178 178 178<br />
Reserves (incl. currency conversion difference) 1,461 1,651 1,982 2,362 2,753 2,818 3,139 3,297 2,940 3,275<br />
Net income 212 229 320 379 401 537 529 888 1,491 1,722<br />
Total equity 2,072 2,321 2,634 2,952 3,354 3,533 3,846 4,363 4,609 5,175<br />
Minority interests 0 0 0 0 1 203 188 193 216 188<br />
Group equity 2,072 2,321 2,634 2,952 3,355 3,736 4,034 4,556 4,825 5,363<br />
Provisions (incl. deferred taxes) 1,982 2,012 2,631 2,932 3,150 3,568 3,963 4,172 4,958 4,641<br />
Liabilities (incl. deferred charges) 962 949 1,249 1,248 1,622 1,913 2,145 1,902 2,235 1,841<br />
Total liabilities 2,944 2,961 3,880 4,180 4,772 5,481 6,108 6,074 7,193 6,482<br />
Total liabilities and equity 5,016 5,282 6,514 7,132 8,127 9,217 10,142 10,630 12,018 11,845<br />
Summary of selected financial data 1997 1998 1999 * 2000 2001 2002 2003 2004 2005 <strong>2006</strong><br />
Net sales 4,201 4,474 5,086 6,188 6,694 7,580 7,382 8,157 9,535 10,574<br />
Operating income 350 336 655 800 980 1,082 901 1,372 1,923 2,140<br />
Operating income as % of sales 8.3 7.5 12.9 12.9 14.6 14.3 12.2 16.8 20.2 20.2<br />
Income after taxes 212 229 320 379 401 551 537 908 1,514 1,729<br />
Income after taxes as % of sales 5.0 5.1 6.3 6.1 6.0 7.3 7.3 11.1 15.9 16.4<br />
Return on equity (in %) 11.4 11.0 13.8 14.4 13.6 16.0 15.0 23.1 34.2 37.4<br />
Own capital resources (in %) 41.3 43.9 40.4 41.4 41.3 38.3 37.9 41.0 38.4 43.7<br />
Cash flow 561 595 737 791 1,117 1,049 1,059 1,430 2,069 2,317<br />
Financial funds 722 858 1,055 1,094 1,645 2,645 3,516 4,015 4,585 3,934<br />
Personnel expenditure 1,270 1,409 1,527 1,749 1,916 2,175 2,252 2,443 2,671 2,836<br />
Personnel expenditure as % of sales 30.2 31.5 30.0 28.3 28.6 28.7 30.5 29.9 28.0 26.8<br />
Average numbers of employees 24,860 25,927 26,448 27,325 27,980 31,843 34,221 35,529 37,406 38,428<br />
Research and development costs 771 812 826 968 1,019 1,304 1,176 1,232 1,360 1,574<br />
R&D as % of sales 18.4 18.1 16.2 15.6 15.2 17.2 15.9 15.1 14.3 14.9<br />
Investments in tangible assets 455 421 377 497 548 634 516 427 532 596<br />
Depreciation of tangible assets 189 211 256 288 305 340 354 377 439 419<br />
*As of the comparative financial statement<br />
1999, accounting and evaluation methods were<br />
brought closer into line with International<br />
Accounting Standards (IAS), particularly with<br />
regard to deferred taxes and provisions for<br />
pensions.
www.boehringer-ingelheim.com